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CHAPTER 1 
INTRODUCTION 
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Nevens D, Nuyts S. HPV-positive head and neck tumours, a distinct clinical entity. B-ENT 2015;11:81-
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radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer. Strahlenther 
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1.1. Epidemiology and etiology 
 
Head and neck cancer (HNC) is a broad term that encompasses a large number of tumour entities 
originating from different subsites, such as the nasal cavity, nasopharynx, oral cavity, oropharynx, 
larynx, hypopharynx and salivary glands. It is the sixth most common cancer worldwide [1]. In 
Belgium, in the year 2013, more than 2500 patients were diagnosed with head and neck cancer 
(latest data Belgian Cancer Registry). In the United States, for the year 2014,  there was an estimate 
of 55.070 new cases of HNC [2]. 
By far, head and neck squamous cell carcinoma (HNSCC) is the most common histological subtype 
(85% of diagnoses) [3]. Exposures to tobacco and/or alcohol are well-known, important risk 
factors for developing HNSCC [1-4]. With the decreasing prevalence of smoking in the Western 
world, the incidence of HNSCC at most subsites has stabilized, or even decreased, over recent 
years. On the other hand, the incidence of oropharyngeal cancer (particularly tonsillar cancer and 
base of tongue cancer) appears to be increasing [1, 4]. This trend has been attributed to an 
increase in oncogenic human papilloma virus (HPV) infections, another important risk factor for 
the development of HNSCC. HPV has long been known to be an important cause of cervical, penile, 
and anal cancer and of genital warts. In recent years, the importance of HPV in the development 
of oropharyngeal cancer has become elucidated. In particular, HPV 16 and 18 play important roles 
in oropharyngeal cancer [1, 4, 5]. In the United States, about 40-80% of oropharyngeal cancers are 
caused by HPV. In Europe, this proportion varies from around 90%, in Sweden, to less than 20% in 
communities with high rates of tobacco use [6]. In Belgium, 25% of oropharyngeal cancer cases 
are associated with HPV [6]. HPV-positive HNSCC has a distinct risk profile and clinical presentation, 
compared to HPV-negative tumours. The most important differences are summarized in Table 1. 
Furthermore, HPV-positive oropharyngeal cancer is recognized as a distinct subset of HNSCC, 
which has a relatively favorable prognosis [2-5]. Currently, less intense treatment strategies are 
under investigation for HPV-positive tumours. We have to wait for the results of these trials before 
we can change the current treatment paradigm for HPV-positive HNC. 
HNC is thus a heterogeneous disease with separate disease entities. Currently, however, patients 
are treated very homogeneously. Studies investigating the potential of more patient-tailored 
treatment are therefore in demand. 
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 HPV-positive tumours HPV-negative tumours 
Location Tonsil, base of tongue No specific location 
Age Younger Older 
TNM stage Higher N stage Every N stage 
Risk factors Large number of sexual 
partners 
Smoking, alcohol 
Incidence Increasing Decreasing 
Metastases Liver, brain 
Within the first 5 years after 
diagnosis 
Bone, lungs 
Within the first 2 years after 
diagnosis 
Socio-economic status Above average Below average 
Imaging characteristics Primary lesions with well-
defined borders 
Cystic nodal metastases 
Primary lesions with poorly 
defined borders 
Non cystic nodal metastases 
Table 1. The most important differences between both tumour types [3, 5-11]. 
 
1.2. Radiotherapy for head and neck cancer 
 
1.2.1. Introduction 
Approximately 60% to 80% of HNC patients present with loco-regionally advanced disease at time 
of diagnosis. The main treatment options for loco-regionally advanced HNSCC are (chemo-) 
radiotherapy (RT) and surgery. Treatment of HNSCC is highly complex because of the complicated 
anatomical relationship between the tumor and the surrounding functional structures. In the field 
of RT, however, much progress has been made. Over the last decades, the use of altered RT 
fractionation schedules and the addition of concurrent chemotherapy (ChT) to the management 
of this disease have significantly increased both locoregional control (LRC) and overall survival (OS) 
[12, 13]. However, outcome is still far from perfect, with 5-year OS rates in phase III trials ranging 
between 50 to 60%. Local and/or regional failure (LF, RF) is the most frequent form of therapy 
failure after RT, while failure due to metastases is much less common [14, 15]. 
1.2.2. Treatment of the neck in HNC  
 
Besides the treatment of the primary tumor itself, pathological lymph nodes and the lymph nodes 
of the neck that are not affected (the elective lymph nodes) are targeted. The necessity of elective 
lymph node irradiation in the eradication of subclinical disease has long been established in HNC 
RT [16]. Historically the dose suggested to achieve microscopic sterilization is 50 Gy in 2 Gy 
fractions [17, 18]. This is mainly based on empirical, nonrandomized data and the question arises 
whether this dose still applies in modern-day RT with better staging and improved treatment [19]. 
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Previously, this irradiation of the elective lymph nodes consisted of a treatment of all node levels 
in the neck. In recent years, international guidelines advocated a more selective treatment of the 
neck nodes [20]. If further volumetric-dose reduction of the elective neck can lead to less toxicity 
without jeopardizing tumor control, is still an important reseach question. 
 
Whether a neck dissection (ND) before RT  is beneficial in locally advanced head and neck cancer 
is a matter of debate [21-23]. Cervical nodal disease is an important prognostic factor and is 
generally less responsive to (chemo) RT than the primary tumor. This brings the need to perform 
an upfront ND into question [22]. Upfront ND gives good outcomes with acceptable toxicity rates 
and quality of life (QoL) in studies with small patient groups [23]. However, a concern about 
upfront ND is that this could delay the start of definitive R(C)T, with local tumor progression and 
worse prognosis as a result. Another concern is that the combination of surgery with RT might 
result in a higher incidence of acute and late toxicities. Literature on this subject is however not 
clear and scarce. Furthermore, most  studies date from before the concomitant ChT era and before 
HPV status was taken into account [23]. 
 
Management of the neck following RT or CRT has evolved over the past decades and has been a 
field of debate. Traditionally, patients with advanced neck disease underwent planned ND 
following RT [24]. In the 1990s, however, several institutes demonstrated low rates of neck failure 
in patients who had complete clinical response by physical examination and were not submitted 
to ND [25,26]. Nowadays considerable variability exists in the follow-up of HNSSC. Both Computed 
Tomography (CT) and Positron Emission Tomography (PET) studies are being used to evaluate if 
adjuvant ND is indicated [27-29].   
 
1.2.3. Recent technological innovations in RT for HNC 
To minimize toxicity following RT for HNSCC, there is a shift away from the more simple RT 
techniques towards more advanced RT in order to improve outcome and QoL for patients. 
Intensity-modulated radiotherapy (IMRT), Image guided adaptive radiotherapy (IGRT), and proton 
therapy are technological innovations in RT that try to improve the therapeutic ratio in HNC.  
1.2.3.1. IMRT 
Much progress has been made concerning the implementation of high-precision three-
dimensional conformal RT and IMRT in head and neck cancer. With the introduction of CT scans 
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and multileaf collimation, a more accurate 3 dimensional dose calculation and delivery becomes 
possible. Moreover, the steep dose gradients can be sculpted around the target volumes, allowing 
for more conformal target coverage and avoiding surrounding functional organs at risk [30].  This 
can result, for example, in sparing of the parotid glands, which ultimately results in less severe late 
xerostomia in HNSCC patients without compromising outcome [31,32]. Significantly less acute 
mucositis ≥ grade 3 and less late xerostomia ≥ grade 2 was observed using IMRT [33]. Randomized 
data are also available supporting the role of IMRT in the treatment of HNSCC. The PARSPORT and 
GORTEC trials showed that IMRT significantly reduces the incidence of xerostomia and improves 
QoL without jeopardizing local control and overall survival [34,35]. 
1.2.3.2. IGRT and Adaptive RT 
IGRT aims to improve the precision of RT by imaging the target and organs at risk just before or 
during treatment allowing the opportunity to optimize the original treatment plan when 
necessary. The classic method of RT using external markers gives rise to large geometrical 
uncertainties. To account for these uncertainties, relatively large margins around the target 
volume are used. Imaging of the target and organs at risk during treatment allows us to reduce 
these margins when shrinkage of the target or the organs at risk occurs. One of the unique aspects 
of RT to the head and neck region is that noticeable changes in the anatomy occur during 
treatment [36]. The reduction of the margins can lead to a reduction in the amount of normal 
tissue exposed to a high dose. In the head and neck region, there is a close relationship between 
the target volume and functionally important structures, such as the swallowing muscles and the 
parotid glands. Less irradiation of these functional structures could lead to an important decrease 
of side effects and an increase in the therapeutic ratio in patients treated with curative or palliative 
intent. IGRT could also be used to evaluate at what time point the target volume, organs at risk 
and dose distribution have changed in such a manner that replanning is essential [36]. This 
adaptive approach towards RT is still under investigation.  
1.2.3.3. Proton Therapy 
Proton therapy is a modality of external beam radiation therapy (EBRT) in which a particle 
accelerator is used to create a focused beam of protons. Like EBRT with photons, proton therapy 
acts by damaging the DNA of cells, ultimately leading to cell death. As protons travel through body 
tissues they interact in a different way compared to photons. Their heavier mass causes a smaller 
scattering angle, which leads to a sharper lateral dose distribution. In addition, the dose depth 
distribution for proton beam therapy is characterized by a sharp increase in dose deposited at the 
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end of the particle range, a phenomenon known as the Bragg peak. Because the proton particles 
stop in tissue immediately after the Bragg peak, they do not deposit any dose beyond the target 
[37].  
Proton therapy has been shown to be safe and effective for the treatment of head and neck tumors 
near the spinal cord, at the base of skull and in the paranasal region in the curative setting [37]. A 
comparison of two CRT strategies with proton therapy versus IMRT for stage III/IV squamous 
oropharyngeal tumors was recently opened at MD Anderson Cancer Center. 
1.3. Treatment induced late toxicity 
The intensification of treatment, by adding concomitant CT and by using altered fractionation 
schedules as described above, resulted in better outcome, but also in an increase in both acute 
and late toxicity [12,13]. Despite the technological advances, xerostomia, fibrosis and late 
dysphagia still severely compromise the patient’s QoL. 
1.3.1. Dysphagia 
Dysphagia has a strong negative impact on health-related QoL during and after treatment and can 
even lead to life-threatening events such as aspiration pneumonia [38]. 
In 2009, the total dysphagia risk score (TDRS), a risk model for assessing the risk to develop 
dysphagia after RT for HNSCC, was created [38]. The following independent prognostic factors for 
swallowing dysfunction at 6 months were found and incorporated into this model: (1) T3–T4, (2) 
bilateral neck irradiation, (3) weight loss prior to radiation, (4) oropharyngeal and nasopharyngeal 
tumours, (5) treatment modality: accelerated RT and concomitant chemoradiation (CRT). Other 
studies reported patient age and the presence of dysphagia pretreatment as predictive factors for 
dysphagia [38-43]. Furthermore, several studies have reported dose-volume correlations for the 
swallowing apparatus [39-41]. Lowering the dose to the swallowing apparatus as much as possible 
might help us in lowering the incidence of dysphagia. 
1.3.2. Xerostomia 
One of the most frequently reported side effects following RT in patients with HNC is 
hyposalivation and subsequent xerostomia due to co-irradiation of the salivary glands [44,45]. 
Xerostomia significantly impairs the patient's QoL due to the many secondary effects such as 
impairment of taste, swallowing, and speech [45-49]. Furthermore, the oral mucosa can become 
dry and atrophic, leading to frequent ulceration [49]. 
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Approximately 40% of patients with HNC will experience xerostomia to some degree after 
treatment with RT [50-54]. The introduction of new techniques such as parotid-sparing intensity-
modulated RT (IMRT) has resulted in less xerostomia; however, toxicity outcome is still far from 
perfect [55]. The Oncology and Radiotherapy Group for Head and Neck Cancer (GORTEC) proposed 
to evaluate prospectively acute and late toxicities, locoregional control, and overall survival for 
patients treated for head and neck cancer (HNC) with IMRT and bilateral neck irradiation in the 
GORTEC 2004–03 study. It was reported that 16.1% of patients treated with parotid-sparing IMRT 
experienced severe xerostomia 18 months after the completion of treatment [56]. 
Xerostomia can occur early during RT treatment. Depending on the localization of the tumor and 
the radiation portals, a rapid decrease of the salivary flow rate is observed during the first week of 
RT, after which there is a continuing gradual decrease to less than 10% of the initial flow rate. A 
review of published studies suggested that severe xerostomia can be avoided if either the mean 
dose to both parotid glands is less than 25 Gy or one parotid gland is spared to a mean dose of less 
than 20 Gy [56]. GORTEC 2004-03 showed that a mean dose administered to the spared parotid 
below 28 Gy led to significantly less severe xerostomia [56]. 
1.3.3. Fibrosis 
Neck fibrosis is another late complication following radio(chemo-)therapy (R(C)T) for HNC that 
negatively affects QoL [58-60]. Of patients with moderate to severe subcutaneous fibrosis, 4.2% 
to 15.6% have uncomfortable symptoms that impair their activities of ordinary life [59]. 
The mechanism behind fibrosis differs from normal wound healing by the aberrant growth of 
myofibroblasts and the excessive deposition of extracellular matrix proteins [58]. Several 
techniques have been used to treat fibrosis within the head and neck region, however without 
convincing results [61].  
A history of ND has been identified as risk factors for moderate to severe subcutaneous fibrosis 
after whole neck irradiation [59]. 
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CHAPTER 2 
OBJECTIVES AND SPECIFIC AIMS 
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1. General hypothesis 
The main focus of this PhD project was to investigate different approaches to improve the therapeutic 
ratio for HNC patients who are treated with (C)RT. We want to achieve this by: 
I. determining the best treatment and follow-up strategy for the neck (PART I of this project). 
The best treatment strategy for the neck is still a matter of debate in HNC.  Firstly, we want to 
assess if an upfront neck dissection prior to radiotherapy is beneficial in locoregionally 
advanced HNC in terms of oncological outcome and toxicity. Secondly, we want to investigate 
if dose de-escalation of the radiation dose to the elective neck can help us improve the 
therapeutic ratio for HNC. Furthermore, we want to assess the safety of a CT-based follow-up 
approach of the neck following radiotherapy for head and neck cancer. 
 
II. validating and creating predictive models for toxicity following RCT (PART II of this project).  
These models can give us more insights how to avoid treatment related toxicity and help us to 
further individualize the treatment of HNC patients. 
 
2. Specific aims 
 
I. To determine the best treatment and follow-up strategy for the neck in HNC 
(PART I of this project). 
 
-To evaluate the value of upfront neck dissection in locoregionally advanced HNC (chapter 
3). 
 
-To evaluate the effect of dose de-escalation to the elective neck (chapter 4). 
 
-To investigate the use of CT in the follow-up after CRT for HNC patients (chapter 5). 
 
II. Prediction of late toxicity in HNC with emphasis on fibrosis, dysphagia and 
xerostomia (PART II of this project). 
-To create a prediction model for late fibrosis (chapter 6). 
-To validate the total dysphagia risk score (TDRS) and to compare physician and patient 
reported dysphagia (chapter 7). 
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-To investigate if the dose to the superficial parotid lobe is predictive for late xerostomia 
(chapter 8). 
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Part I 
  OPTIMAL MANAGEMENT OF THE NECK  
IN HEAD AND NECK CANCER 
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Chapter 3 
PRIMARY HEAD AND NECK CANCER RADIO(CHEMO)THERAPY WITH 
OR WITHOUT UPFRONT NECK DISSECTION:  
DISEASE CONTROL AND LATE TOXICITY. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is submitted to Radiotherapy and Oncology as: 
Nevens D, Duprez F, Bonte K, Deron P, Huvenne W, Laenen A, De Neve W,  Nuyts S. Primary head and 
neck cancer radio(chemo)therapy with or without upfront neck dissection: disease control and late 
toxicity. 
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Primary head and neck cancer radio(chemo)therapy with or without upfront neck dissection: 
disease control and late toxicity. 
Purpose/objective 
The benefit of upfront neck dissection (ND) in locally advanced head and neck squamous cell carcinoma 
(HNSCC) treated with primary (chemo-) radiotherapy (R(C)T) is debated. Therefore, we retrospectively 
compared disease control and toxicity between patients who were treated with and without upfront 
ND followed by R(C)T.  
Material/methods 
Two-hundred sixty-four consecutive patients with HNSCC without distant metastases at diagnosis and 
with lymph node stage N2-N3 were included in 2 centers. Patients were all treated between January 
2002 and December 2012, and received definitive R(C)T in center 1 and upfront ND followed by R(C)T 
in center 2. Clinical data and outcome were assessed retrospectively. Toxicity was scored using the 
LENT-SOMA scale at 6, 12, 18 and 24 months following the end of treatment. 
Results 
We included 150 patients in the group without ND (center 1) and 114 patients in the group with 
upfront ND (center 2). Mean follow up was 5.68 years in the group without ND and 5.83 years in the 
group with upfront ND. Local, regional and distant control after 2 years were 91.07% and 85.96% (p = 
0.09), 89.22% and 83.27% (p=0.12) and 76.74% and 75.13% (p=0.92) in the group with and without 
upfront ND, respectively. We did not find a significant difference between both groups regarding 
edema and atrophy at 6, 12, 18 and 24 months. We found a trend at all time-points towards worse 
outcome in the ND group at all time-points (p=0.06). A significantly higher proportion of moderate to 
severe fibrosis (grade ≥2) was present in the ND group (p=0.01) at all time points. 
Conclusion 
There was no significant difference in local, regional or distant control and disease-free survival 
between both patient populations. Fibrosis, specifically fibrosis grade ≥2 is more prominent following 
upfront ND and R(C)T when compared to R(C)T alone.  
 
 
   
 
29 
 
Introduction 
Radiation therapy (RT) with or without concurrent chemotherapy R(C)T has emerged as the treatment 
of choice for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Over 
the last decades, the use of altered RT fractionation schedules and the addition of concurrent 
chemotherapy to the management of this disease have significantly increased both locoregional 
control and overall survival (OS) [1-3]. Whether upfront neck dissection (ND) is beneficial in locally 
advanced head and neck cancer treated with R(C)T is debated [4-22]. Cervical nodal disease is an 
important prognostic factor and is generally less responsive to R(C)T than the primary tumor [5]. This 
brings the need to perform an upfront ND into question. Upfront ND  gives good outcomes with 
acceptable toxicity rates and quality of life in studies with small patient groups [6]. However, a concern 
about upfront ND is that this could delay the start of definitive R(C)T, with local tumor progression and 
worse prognosis as a result. Another concern is that the combination of surgery with RT might result 
in more frequent and more severe acute and late toxicity. Comparative literature reporting toxicity in 
both treatment modalities is not clear and scarce. Furthermore, most  studies include small patient 
groups, date from before the concomitant chemotherapy era and before HPV status was taken into 
account [6].  
In this study we compare the outcome in 2 centers that use different approaches. In center 1, patients 
with locally advanced HNSCC were treated with definitive R(C)T; in center 2, an upfront ND followed 
by R(C)T was performed in locally advanced HNSCC with a cN2-3 neck. 
Material/methods 
Endpoints and inclusion criteria 
The primary endpoint of this study was disease-free survival (DFS).  Secondary endpoints are local (LC) 
and regional control (RC) after 2 years of follow up, distant control (DC), OS and late edema, atrophy 
and fibrosis of the neck. 
This is a comparative multi-center retrospective analysis between two centers that used a different 
approach for the cN2-3 neck in HNSCC. All patients with invasive squamous cell carcinoma of the oral 
cavity, larynx, oro- and hypopharynx without distant metastasis (DM) at time of diagnosis and with 
lymph node stage cN2-N3, treated with R(C)T between January 2002 and December 2012 were taken 
into account for this study. In center 1, definitive R(C)T was given while in center 2, upfront ND 
proceeded R(C)T in case of cN2-N3 disease that was estimated to be operable. Patients with clinically 
pathological retropharyngeal lymph nodes were not eligible to undergo upfront ND. 
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Exclusion criteria of the current study are: no proof of invasive HNSCC, DM at diagnosis, cancer of 
unknown primary, nasopharyngeal cancer, sinonasal ancer, N0/N1 disease and patients who did not 
receive an upfront ND in center 2. 
Two-hundred sixty-four consecutive patients with HNSCC were included. Clinical data and outcome 
were assessed retrospectively. Toxicity was scored using the LENT-SOMA scale at 6, 12, 18 and 24 
months after the end of treatment. 
Radio(chemo)therapy 
All patients had pathologically proven HNSCC and underwent chest radiography or CT, head and neck 
CT, and, in some cases, MRI or PET-CT.  
All macroscopically affected tumor sites were treated up to a normalized iso-effective dose in 2 Gy 
fractions (NID2Gy) of 70 Gy. The elective nodal volumes were treated up to a NID2Gy of 50 Gy. In center 2, 
following upfront ND, lymph node regions with resected pathological lymph nodes and no capsular 
rupture were treated up to a NID2Gy of 60.9Gy and lymph node regions with resected pathologic lymph 
nodes and capsular rupture were treated up to a NID2Gy of 67.2Gy [23] until Q4 2006 (n=56); from Q1, 
2007 all patients received an NID2Gy of 50Gy (n=58). 
Patients were immobilized in supine treatment position using a custom-made head and neck mask. CT 
scanning simulation was performed in all patients. When chemotherapy was indicated, 2 cycles of 
cisplatin were given (100 mg on days 1 and 22 of radiotherapy).  
Follow-up was performed in center 1, every 2 months for the first 2 years, every 3 months for the 3th 
year, every 4 months for the 4th, every 6 months the 5th year and then yearly. In center 2, follow-up 
was performed 1, 3, 6, 9, 12, 16, 20 and 24 months after the end of treatment and biannually 
thereafter.  
Neck dissection 
Upfront ND in center 2 was done by radical or modified radical ND. Via a Schobinger incision and after 
developing platysmacutaneous flaps radical ND was performed, always including the 
sternocleidomastoid muscle. When oncologically sound, modifications could be preservation of the 
spinal accessory nerve and/or the internal jugular vein. 
Statistical analysis 
Both patient groups are compared on patient- or tumor characteristics using Chi-square test for 
categorical variables or Mann-Whitney U test for continuous variables. Descriptive statistics on OS are 
based on Kaplan Meier estimates. For all other time-to-event outcomes cumulative incidence function 
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(CIF) estimates are given, where death is considered as a competing event. The difference between 
both groups with respect to the different outcomes is analyzed using multivariable models, including 
group and all prognostic patient- or tumor characteristics on which the groups are different. OS is 
defined as the time between start of treatment and death, or last visit for patients alive. LC and RC was 
defined as the time between start of treatment and first relapse (event), death without local or 
regional relapse (competing event), or last visit (censored observation). The analysis of a group 
difference for OS is based on Cox proportional hazards regression, for all other time-to-event outcomes 
we performed proportional hazards regression within a competing risk framework [24] where death is 
considered as competing event.  
Side effects were scored in both groups unless patients were lost to follow-up or had a local, regional 
or distant recurrence that warranted salvage treatment. The analysis of a group difference is based on 
proportional odds models for side effects measured on ordinal scales, or on logistic regression models 
for severe fibrosis (score > 1). All analyses are performed with estimation based on generalized 
estimating equations (GEE) to account for clustering by repeated measures. All tests are two-sided, a 
5% significance level is assumed for all tests. Analyses have been performed using SAS software 
(version 9.4 of the SAS System for Windows). 
Results 
We included 150 patients in the group without ND (center 1) and 114 patients in the group with 
upfront ND (center 2). The group comparison is given in Table 1. 
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Variable Statistic 
Center 1 
No dissection 
(n=150) 
Center 2 
Neck dissection 
(n=114) p-value 
Gender  
Male n/N (%) 126 (84.00%) 103 (90.35%) 0.132 
Female n/N (%) 24 (16.00%) 11 (9.65%) 
Age at diagnosis Mean 58.9 59.0 0.794 
Std 8.78 8.67 
Median 58.0 58.9 
IQR (52.0; 65.0) (52.4; 65.4) 
Range (38.0; 81.0) (40.1; 86.8) 
 
T stage  0.001 
1 n/N (%) 7 (4.67%) 14 (12.28%) 
2 n/N (%) 36 (24.00%) 39 (34.21%) 
3 n/N (%) 39 (26.00%) 37 (32.46%) 
4 n/N (%) 68 (45.33%) 25 (21.93%) 
N stage  
2A n/N (%) 8 (5.33%) 6 (5.26%) 0.182 
2B n/N (%) 63 (42.00%) 59 (51.75%)  
2C n/N (%) 73 (48.67%) 41 (35.96%)  
3 n/N (%) 6 (4.00%) 8 (7.02%)  
Subsite  
Oral cavity n/N (%) 13 (8.67%) 6 (5.26%) 0.526 
Oropharynx n/N (%) 66 (44.00%) 46 (40.35%) 
Hypopharynx n/N (%) 53 (35.33%) 49 (42.98%) 
Larynx n/N (%) 18 (12.00%) 13 (11.40%) 
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Variable Statistic 
Center 1 
No dissection 
(n=150) 
Center 2 
Neck dissection 
(n=114) p-value 
IMRT  
No n/N (%) 64 (42.67%) 42 (36.84%) 0.339 
Yes n/N (%) 86 (57.33%) 72 (63.16%) 
Concomitant 
treatment 
 
No n/N (%) 22 (14.67%) 26 (22.81%) 0.089 
Yes n/N (%) 128 (85.33%) 88 (77.19%) 
Type 
concomitant 
treatment 
 
Cisplatinum n/N (%) 109 (85.16%) 84 (73.68%) 0.017 
Cetuximab n/N (%) 19 (14.84%) 4 (3.50%) 
HPV status 
Oropharyngeal 
tumors 
 
 
Positive 
Negative 
Unknown 
n/N (%) 
n/N (%) 
n/N (%) 
13 (19.70%) 
44 (66.67%) 
9 (13.64%) 
10 (21.74%) 
31 (67.40%) 
5 (10.87%) 
0.752 
Table 1. Group comparison on patient/tumor characteristics. 
The patients groups differed significantly in T stage and type of concomitant treatment. Based on this 
result, we decided to account for the differences in T stage and concomitant treatment for the 
statistical analysis of outcome and toxicity.  
Of all patients who received upfront ND, 50 patients underwent bilateral ND and 64 unilateral ND. 
Mean follow up was 5.68 years in the group without ND and 5.83 years in the group with upfront ND; 
median follow up was 5.13 years (quartile range 3.21-7.53) and 5.54 years (quartile range 3.59-7.89) 
respectively. Local control, RC, distant control and DFS after 2 years were 91.07% versus 85.96%, 
89.22% versus 83.27%, 76.74% versus 75.13% and 62.48% versus 63.32% in the group with and without 
upfront ND, respectively (Table 2). None of these outcomes were statistically significant when we took 
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the group differences into account (Table 2). We observed worse OS after 2 years  in the subgroup 
with upfront ND (48.01% vs. 70.79%, p = 0.01). The difference in OS can be explained by more 
secondary primaries in this subgroup with upfront ND and more non-disease related deaths. In the ND 
group 16 patients (14%) experienced a second primary, in the definitive R(C)T group 13 patients (8.6%). 
Non-disease related death occurred in 10 patients (8.7%) in the ND arm and 8 patients (5.3%) in the 
definitive R(C)T group. 
Regarding late fibrosis, we found an overall trend towards worse outcome in the upfront ND group at 
all time-points (p=0.06). A significantly higher proportion of severe fibrosis (grade ≥2) was present in 
the ND group (p=0.01) at all time points (Table 3). This was also the case when we looked at the group 
with unilateral and bilateral ND separately (p=0.01 for both arms). 
In the group without upfront ND, 9 patients (6%) underwent a salvage ND. Two of these nine salvage 
ND, were performed for a combined locoregional recurrence (4 years following RT, n=1; and 1 year 
following RT, n=1). In 4 of the 9 patients, a salvage ND was performed because of a persistent lymph 
node (6 months following RT, n=1; 10 months following RT, n=1; 1 year following RT, n=1; and 2 years 
following RT; n=1). Three ND were performed when a locoregional recurrence was suspected, however 
only one local recurrence was found after pathological examination. In these 9 patients, no severe side 
effects like  carotid blow out, necrosis or fistula were reported following the salvage ND. 
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Time point No neck dissection group 
(95% CI) 
Neck dissection group 
(95% CI) 
Local control 
p=0.06 
2 years 85.96 (79.89-90.95) 91.07 (84.91-95.43) 
3 years 84.43 (78.11-89.74) 90.13 (83.75-94.77) 
5 years 82.61 (75.93-88.33) 90.13 (83.75-94.77) 
Regional control 
p=0.12 
2 years 83.27 (76.86-88.74) 89.22 (82.66-94.11) 
3 years 80.99 (74.26-86.87) 89.22 (82.66-94.11) 
5 years 80.99 (74.26-86.87) 88.06 (81.17-93.31) 
Distant control 
p=0.92 
2 years 75.13 (67.96-81.75) 76.74 (68.57-84.07) 
3 years 73.57 (66.25-80.41) 72.72 (64.16-80.68) 
5 years 72.37 (64.82-79.48) 72.72 (64.16-80.68) 
Disease-free survival 
p=0.71 
2 years 62.48 (54.78-70.71) 63.32 (54.47-72.17) 
3 years 60.16 (53.36-68.09) 59.30 (50.29-68.52) 
5 years 57.08 (49.03-65.42) 59.30 (50.29-68.52) 
Overall survival 
p<0.01 
2 years 70.79 (62.71-77.44) 48.01 (38.48-56.91) 
3 years 62.13 (53.54-69.60) 38.94 (29.73-48.03) 
5 years 49.65 (40.49-58.15) 29.36 (20.67-38.55) 
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Table 2. Per outcome, the effect of group (Neck dissection versus No neck dissection) by means of 
hazard ratios (HR) with 95% confidence intervals. Results are obtained based on multivariable 
proportional hazard models, including group, T, overall treatment time and concomitant treatment. 
Clinical variables were included to correct for imbalances between the groups. 
 
Outcome OR (95% CI) P-value 
Fibrosis 1.558 (0.982;2.470) 0.06 
Severe fibrosis (grade ≥2) 2.811 (1.384;5.710) 0.01 
Edema 1.251 (0.758;2.063) 0.38 
Atrophy 1.652 (0.644;4.242) 0.30 
OR: Odds ratio, CI: Confidence interval 
OR >(<) 1 means higher (lower) level on scale for Neck dissection group. 
Table 3. The table presents for every toxicity, the effect of group (Neck dissection versus No neck 
dissection) by means of odds ratios (OR) with 95% confidence intervals at all time-points (6, 12, 18 
and 24 months). 
Discussion 
The aim of this study was to compare outcome and late toxicity for patients with a locoregionally 
advanced HNSCC that were treated by either an upfront ND before R(C)T or definitive R(C)T. Recently, 
a systematic review on this subject was published [6]. The authors of this review pose the question if 
we would see a difference in oncological outcome at 3 and 5 years of follow-up. Furthermore, the 
authors of this review state that most studies on this subject date from before the concomitant 
chemotherapy era and before HPV status was taken into account. With the current study, we tried to 
answer these questions. We proposed a comparative study with a mean and median follow-up of more 
than 5 years. Furthermore, in our study most patients were treated with concomitant RCT and HPV 
status was assessed. 
We observed no statistically significant differences between both treatment groups regarding LC, RC, 
DC and DFS. More local failures in the definitive R(C)T group (not statistically significant) were 
observed. This can be explained by the difference in patient characteristics between both treatment 
groups, with statistically significant more  advanced T stages in the definitive R(C)T group. The need 
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for a salvage ND was low in the definitive R(C)T group (6% of patients). Only in 4 patients (2.7%), the 
indication of this ND was a persistent pathological lymph node. DFS was similar in both groups; around 
60% in both treatment arms after 3 years of follow up. We observed worse OS in the ND group. This 
can be partially explained by the difference in second primaries and none-disease related deaths 
between both groups. With a similar DFS, the value of OS can be discussed in a patient group with a 
lot of comorbidities and high chances of second primaries. 
Comparison of our results with literature is difficult since most patient cohorts are small and do not 
use IMRT or 3DCRT nor chemotherapy. In total 6 retrospective studies compared the outcome 
between upfront ND and definitive R(C)T so far. Three studies reported no statistically significant 
differences regarding oncological outcome [10,12,22]. Two studies showed a significant impact on RC 
[8,19], however one of these studies was published in 1991 [8] and the question arises if these results 
still stand after the many advances in RT and the addition of concomitant systemic treatment for 
HNSCC of the last decade [1-3]. The study by Liu et al dates from 2012, however RT was performed 
using 2D techniques and none of the patients received chemotherapy [19]. Comparison with today’s 
R(C)T is therefore difficult. One study used 3-DCRT and IMRT and reported better OS and DFS following 
upfront ND when compared to RCT alone. However, this was a relatively small study, in which only 32 
patients of the study population of 135 patients received an upfront ND and only 9 patients were 
treated with R(C)T [7]. Furthermore, the reason why patients received upfront ND was not explained. 
Toxicity was often not reported in past studies [8, 14-16, 18, 19]. A comparison regarding toxicity 
between patient groups treated with upfront ND versus definitive RT was performed in 3 studies 
[7,12,22]; in one study for acute toxicity only [22] and in two studies for acute and late toxicity [7,12]. 
Two studies found no difference for both late and acute toxicity [7,12], one study found a significant 
difference in acute toxicity with less acute pain and mucositis in the upfront ND group [22]. No 
differences regarding acute dermatitis and dysphagia were found [22].  For the purpose of this study, 
late fibrosis was studies  since ND had been identified as an important risk factor for moderate to 
severe late fibrosis [7,25]. We could confirm these results in our present study. We also found more 
moderate to severe late fibrosis following upfront ND.  
This is a retrospective study with its inherent limitations. However, we present the largest patient 
population on this subject and with the longest follow-up period. In our study, we chose to compare 
patients of 2 different centers to minimize the effect of selection bias. Therefore, we chose not to 
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include patients of center 2 who did not receive an upfront ND, but were treated with definitive R(C)T 
since these patients either refused surgery, were unfit for surgery or had positive retropharyngeal 
lymph nodes. Including these patients in the definite R(C)T group would bring a selection bias into the 
study. Whether this was the case in previous comparative studies regarding upfront ND is not clear 
but is expected since none of the studies were multicentric and the institutional guidelines for when 
an upfront ND was given were not clearly reported in the studies. Elicin et al. recently published a 
comparative study with a large patient population, however this study was monocentric  and only 
stated that definitive R(C)T and upfront ND followed by R(C)T are two strategies that are used without 
giving insights why certain patients were treated with an upfront ND and other patients were not [22]. 
Al-Mangani et al, on the other hand, stated that in their study upfront ND was performed if the waiting 
time before R(C)T was too long or in case of bulky nodal disease [7]. This might introduce bias in the 
results of the study.  
A prospective randomized trial regarding the need for upfront ND could clarify whether upfront ND is 
beneficial in locally advanced HNSCC [6]. However the question remains if such a study should be 
undertaken when evidence of any benefit in terms of oncological outcome following ND is so scarce 
and when we observe a good regional control and low need for salvage ND following definitive R(C)T 
as was confirmed in the current study.  
Conclusion 
We found no significant differences regarding LC, RC, distant control and DFS. Fibrosis and more 
specifically fibrosis grade ≥2 is more prominent following upfront ND and R(C)T when compared to 
R(C)T alone.  
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Chapter 4 
DOSE DE-ESCALATION TO THE ELECTIVE NODAL SITES FOR HNC. 
 
 
 
 
 
 
 
 
 
Elements in this chapter are published as: 
Nevens D, Duprez F, Daisne JF, Dok R, Belmans A, Voordeckers M, Van den Weyngaert D, De Neve W, 
Nuyts S. Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell 
carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiother Oncol. 2016 
Aug 12. [Epub ahead of print]. 
Elements in this chapter are submitted to Head and Neck as: 
Nevens D, Duprez F, Daisne JF, Dok R, Belmans A, Voordeckers M, Van den Weyngaert D, De Neve W, 
Nuyts S. A multicenter, randomized clinical trial with dose-reduction to the elective nodal sites in head 
and neck cancer: results on the quality of life.  
Elements in this chapter are resubmitted to Radiotherapy and Oncology after major revision: 
Nevens D, Duprez F, Daisne JF, Schatteman J, Van der Vorst A, De Neve W, Nuyts S. Patterns of nodal 
failure following dose-de-escalation to the electively irradiated lymph node regions in  head and neck 
cancer. 
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Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell 
carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. 
Background and purpose 
A multi-center prospective randomized clinical trial has been performed investigating whether a 
reduction of the dose to the elective nodal sites in head and neck cancer delivered by intensity 
modulated radiotherapy (IMRT) would result in a reduction of late side effects without compromising 
tumor control. 
Materials and Methods 
Two hundred patients were included. The prescription dose to the elective nodal volumes  was a 
normalized iso-effective dose in 2 Gy fractions (NID2Gy) of 50 Gy in the standard arm and of 40 Gy in 
the experimental arm.  Late toxicity was scored at 6, 12, 18 and 24 months using the RTOG scoring 
system.  
Results 
We observed a trend towards less dysphagia at 6 months in the experimental arm, however this was 
not confirmed after longitudinal analysis. Regarding moderate salivary gland toxicity we observed 
lower incidence of salivary gland toxicity ≥ grade 1, at 6 (p=0.01) and 18 months (p=0.03).   
After two years of follow up, we did not observe significant differences in estimated local failure rate 
(14.1 %  in the 40Gy arm vs 14.4% in the 50 Gy arm), estimated regional failure rate (13.0 % vs 5.5% in 
the 40 and the 50 Gy arm respectively), estimated metastatic recurrence (13.4% vs 18.5% in the 40 
and the 50 Gy arm respectively), estimated disease-free survival (57.9% vs 65.3% in the 40 and the 50 
Gy arm respectively) nor estimated overall survival (72.0% vs 73.2% in the 40 and the 50 Gy arm 
respectively).  
Conclusions 
In our study population there was no statistically significant difference regarding survival and 
estimated recurrence rates between both arms of this study. We found a trend towards less dysphagia 
at 6 months (however not significant after longitudinal analysis) and found a significant reduction of 
any salivary gland toxicity at 6 and 18 months in the 40 Gy arm.  
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Introduction 
Radiotherapy (RT) with curative intent for head and neck cancer (HNC) results in a significant amount 
of side effects due to unwanted doses in normal tissues surrounding the target volume [1, 2].  One of 
the most important late side effects limiting quality of life is swallowing dysfunction (dysphagia). 
Following the introduction of more aggressive treatment strategies for HNC in the last decades, more 
attention has been addressed to late dysphagia [3-5]. Both concurrent chemotherapy and accelerated 
fractionation have been identified as significant predictive factors to develop dysphagia [3-5,6]. The 
dose delivered to the pharyngeal constrictor muscles plays a crucial role in the development of severe 
late dysphagia [7-11]. Our research group demonstrated in a previous paper that a dose de-escalation 
to the elective lymph nodes in HNC results in significantly less dose to these functionally important 
structures and less severe dysphagia at 3 months following treatment [12].  
In this paper we report the results of a multi-center prospective randomized clinical trial that 
investigated whether a reduction of the dose to the elective nodal sites would result in a reduction of 
late dysphagia without compromising regional control.  
Material and methods 
A prospective randomized multicenter non-inferiority phase III study was set up between 6 centers. 
Inclusion criteria were previously untreated, histologically proven squamous cell carcinoma of the oral 
cavity, oropharynx, hypopharynx, larynx or cervical lymph node metastases of unknown primary 
cancer (CUP). Patient work-up was done according to institutional guidelines. T1–T2N0 were allowed, 
if prophylactic neck irradiation was performed. Patients were older than 18 years with a Karnofsky 
performance status ⩾70%. The decision for primary (chemo-)RT with curative intent had to be made 
after a multidisciplinary meeting at each participating center. Concurrent chemotherapy was allowed, 
as well as pretreatment lymph node dissection. Local ethics committee approval was obtained before 
start of the study and all patients gave written informed consent. Patients were randomized to two 
treatment arms (experimental arm A and standard arm B). A total of 200 patients were included in the 
study (100 for each arm). To minimize the influence of center-specific parameters randomization was 
performed per center. 
All macroscopically affected tumor sites were treated up to a normalized iso-effective dose in 2 Gy 
fractions (NID2Gy) of 70 Gy. Fractionation schedule and total dose delivered to the primary tumor and 
affected lymph nodes were left to the discretion of each individual center. An overview of the different 
fractionation schedules and CTV-PTV margins can be found in the preliminary analysis of this study 
   
 
45 
 
[12]. For the elective nodal volumes, patients randomized in arm A (experimental arm) were treated 
up to a NID2Gy of 40 Gy. For arm B (control arm) the elective nodal volumes were treated up to a 
NID2Gy of 50 Gy (Figure 1) [12].  
 
Figure 1. Consort diagram of the study. * xInformation of 1 participating center (7 patients) could not 
be retrieved before close-out date of this analysis, yielding 193 patients for analysis. 
 
All patients were treated with IMRT using either an in-house developed extension of the GRATIS-
software by Sherouse coupled to dose calculation using Pinnacle version 6.2b or the commercially 
available treatment planning systems (Eclipse®, Palo Alto; Tomotherapy High-art®, Madison) and 
delivered using 6 or 10 MV photons using either a step-and-shoot, a sliding window or rotational 
technique. Patient set-up and position verification was performed according to each center’s 
discretion. 
Late toxicity was scored at 6, 12, 18 and 24 months using the RTOG scoring system. 
Assessment of HPV status 
Since HPV status was not considered in the first paper, this was currently assessed [12]. For all patients 
with oropharyngeal tumors, formalin-fixed, paraffin-embedded (FFPE) tissue was centralized 
(University Hospital of Leuven) for HPV-status determination. HPV testing was performed using a 
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previously validated algorithm using p16 immunohistochemistry (IHC) followed by HPV-polymerase 
chain reaction (PCR) [13-15]. A tumor was regarded as HPV related when both p16 IHC as well as HPV-
PCR were positive. 
For p16 IHC a purified mouse anti-human p16 antibody (G175-405, BD Pharmigen) was used. Sections 
were scored as p16 positive when clear p16 immunoreactivity was seen in at least 50% of cells [14]. 
DNA was extracted from PPFE sections using the QIAamp DNA FFPE Tissue kit. Concentration and 
purity where then defined with spectrophotometry. HPV status was determined with a PCR reaction 
using the GP5+/6+ primer set. 
Endpoints of the study 
The primary endpoint of the study was the rate of dysphagia at 6 months of follow-up.  
Secondary endpoints of the study were: local, regional and distant control;  recurrence and site of 
recurrence; overall, disease-free and disease-specific survival; stiffness of the neck; skin toxicity; 
salivary gland toxicity and mucosal integrity. 
General considerations of the statistical analysis 
Assuming a 70% rate of late dysphagia ≥ grade 1 will be unacceptable and a 50% rate will be expected 
(α = 0.05, P = 0.8, two-tailed test) the power calculation of the study resulted in 200 eligible patients 
(100 patients per arm). 
All tests were 2-sided and assessed at a significance level of 5%. Due to the exploratory nature of the 
study, no adjustments were made to the significance level to account for multiple testing.  All analyses 
have been performed using SAS System for Windows (version 9.4). 
Statistical analysis of the late toxicity endpoints 
The following toxicity endpoints were assessed: dysphagia, stiffness of the neck, skin toxicity, salivary 
gland toxicity and mucosal integrity.  
A chi-square test for trend was performed at each time-point to assess whether there was a statistically 
significant difference between the two randomized groups. Because these tests are susceptible to bias 
due to missing data, early withdrawals and/or early mortality, a longitudinal analyses using 
Generalized Estimating Equations (GEE) was also performed since it has been documented that GEE 
models can provide unbiased estimates even in such circumstances if the condition of Missingness at 
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Random (MAR) holds.  The above toxicity endpoints were analysed using a GEE proportional odds 
model with an independent correlation matrix to account for the clustering of the data.  
Primarily, the longitudinal proportional odds model includes a factor for randomized treatment, visit 
and their interaction. The inclusion of the interaction allows for the treatment effect to vary between 
visits. The effect of randomized treatment was estimated from the GEE model at each visit.  
In addition, analyses were done for the probability of having severe (≥ grade 3) and moderate ( ≥ grade 
1) toxicity. Since these are binary endpoints, the longitudinal analyses were done by means of a GEE 
logistic regression model. 
Statistical analysis of outcome 
Overall and disease-free survival were estimated using Kaplan-Meier methodology. Differences 
between treatments were assessed by means of a log-rank test.  
Competing risk methodology was used for local, regional or distant failure, whereby death was 
considered to be a competing risk, to take the fact into account that patients who died cannot have a 
recurrence in the future. Event rates were estimated using cumulative incidence functions (CIF) and 
comparisons were made using Gray’s test. 
Location of recurrences 
In case of a regional recurrence, the recurrence was contoured on the CT study and rigidly co-
registrated with the initial pretreatment CT study. Co-registration was done automatically using 
Eclipse® Treatment Planning system. If this was not accurate, manual registration was performed. To 
determine the exact location of recurrence the method described by Dawson et al. was used [13]. The 
recurrences were classified as 1) “in-field,” in which 95% or more of the recurrence volume (Vrecur) 
was within the 95% isodose; 2) “marginal,” in which 20% to 95% of Vrecur was within the 95% isodose; 
or 3) “outside,” in which less than 20% of Vrecur was within the 95% isodose. 
Results 
Patients 
Between May 2008 and May 2011, 200 patients were included and randomized. Treatment 
characteristics of 7 patients could not be retrieved before close-out date of this analysis, yielding 193 
patients for analysis (96 in the experimental arm and 97 in control arm). Patient characteristics are 
depicted in Table 1. The study included 83 patients with an oropharyngeal tumor; 41 in the 40 Gy and 
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42 in the 50 Gy arm. 17 patients (20,5 %) of these 83 patients had an HPV positive tumor; 60 patients 
(72,5 %) had an HPV negative tumor and 6 patients (7%) had an unknown HPV status. The summary of 
the result of the HPV assessment can be found in Table 1.  
 
Study arm 
(n = 96) 
 
Control arm 
(n = 97) 
 
p-
Value 
 
(%) 
 
(%) 
 
Social status Single 27 28 27 28 0.9 
Partner 52 54 57 59 
Unknown 17 18 13 13 
Age <70 80 83 85 88 0.4 
>70 16 17 12 12 
Gender M 75 78 84 87 0.13 
F 21 22 13 13 
KI performance status >80 70 73 67 69 0.75 
<80 26 27 28 29 
Unknown 1 1 2 2 
Tumor site CUP 4 4 5 5 1 
Larynx 18 19 18 19 
Oral cavity 11 11 9 9 
Hypopharynx 22 23 23 24 
Oropharynx 41 43 42 43 
HPV + 
HPV - 
Unknown 
7 
31 
3 
 10 
29 
3 
 
      0.35 
AJCC stage I 1 1 0 0 1 
II 10 10 12 12 
III 19 20 25 26 
IV 66 69 60 62 
T-stage X 4 4 5 5 0.1 
1 1 1 4 4 
2 32 33 40 41 
3 34 35 30 31 
4 25 26 18 19 
N-stage X 1 1 0 0 1 
0 22 23 26 27 
1 16 17 14 14 
   
 
49 
 
 
Study arm 
(n = 96) 
 
Control arm 
(n = 97) 
 
p-
Value 
 
(%) 
 
(%) 
 
2 54 56 56 58 
3 3 3 1 1 
Pretreatment dysphagia Grade 0 52 54 54 56 0.16 
Grade 1 26 27 32 33 
Grade 2 17 18 10 10 
Grade 3 1 1 1 1 
Neo-adjuvant chemotherapy No 91 95 95 98 0.28 
Yes 5 5 2 2 
Pretreatment lymph node 
dissection 
No 79 82 78 80 0.85 
Yes 17 18 19 20 
Prescribed dose (in Gy) for 
PTVther 
Mean 70 
 
70 
 
0.37 
SD 1.6 
 
1.9 
 
OTT (days) Mean 45 
 
45 
 
0.2 
SD 2.3 
 
2.6 
 
Planned dose reached Yes 94 98 93 96 0.68 
No 2 2 4 4 
Concurrent systemic 
treatment 
Platinum based 56 58 61 63 0.44 
Targeted 
therapy 
5 5 7 7 
Other 1 1 0 0 
No 34 35 29 3 
 
Table 1. Patient and treatment characteristics. KI, Karnofsky index; OTT, overall treatment time; 
AJCC, American Joint Committee on Cancer. 
Toxicity 
Following a chi square test, we observed a trend towards less dysphagia at 6 months (p=0.02) and at 
24 months (p=0.07) in the 40 Gy group. The difference in grade 2 dysphagia at 6 months stands out 
with 3.8% in the 40 Gy arm versus 20.8% in the 50 Gy arm.  However, when accounting for early drop-
outs and deaths using longitudinal analyses, no statistically significant differences regarding dysphagia 
between both treatment groups could be observed (Table 2).  The interaction between visit and 
treatment was found to be not significant (p=0.80) and when removing the interaction from the model, 
the odds ratio between 40 Gy and 50 Gy for observing a lower grade of dysphagia was in favor of the 
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40 Gy group, however clearly not significant; 1.40 (95% confidence interval 0.93 to 2.10, p= 0.11).  
Furthermore, regarding moderate dysphagia (≥grade1) or severe dysphagia (≥grade 3), we did not 
observe significant differences between both groups.  
Dysphagia 
 randomisation G 0 G 1 G2 G3 Total P(GEE) 
Month 
6 
40 Gy 48 
(61.5%) 
27 
(34.6%) 
3 
(3.8%) 
0 78 0.06 
50 Gy 37 
(51.4%) 
20 
(27.8%) 
15 
(20.8%) 
0 72 
Month 
12 
40 Gy 45 
(67.2%) 
14 
(20.9%) 
7 
(10.4%) 
1 
(1.5%) 
67 0.21 
50 Gy 37 
(56.9%) 
18 
(27.7%) 
6 
(9.2%) 
4 
(6.1%) 
65 
Month 
18 
40 Gy 39 
(68.4%) 
12 
(21.0%) 
6 
(10.5%) 
0 57 0.16 
50 Gy 33 
(55.0%) 
19 
(31.7%) 
8 
(13.3%) 
0 60 
Month 
24 
40 Gy 39 
(73.6%) 
12 
(22.6%) 
2 
(3.8%) 
0 53 0.15 
50 Gy 34 
(63.0%) 
12 
(22.2%) 
6 
(11.1%) 
2 
(3.7%) 
54 
Using a GEE proportional odds model including treatment, visit and their interaction, the 
interaction was found not significant (p=0.8332).  When dropped from the model, the odds ratio 
between 40 Gy and 50 Gy for observing a lower grade toxicity was 1.40 (95% confidence interval 
0.93 to 2.10, p-value = 0.1088). 
Table 2. Prevalence of dysphagia at each time-point. 
 
We observed a lower incidence of any salivary gland toxicity (≥grade1), at 6 and 18 months (p=0.01 
and p=0.04, respectively) in the 40 Gy arm (Table 3). This was confirmed by the longitudinal analyses 
(p=0.01 and 0.03, respectively).  The interaction between treatment and visit was found to be not 
significant (p=0.14) and when removing the interaction from the model, the odds ratio between the 
40 Gy group versus the 50 Gy group for having no salivary gland toxicity was in favor of the 40 Gy arm; 
1.88 (95% CI 1.07 to 3.31, p=0.03).  
No significant difference between both groups was detected regarding stiffness of the neck, salivary 
gland toxicity ≥ grade 3, skin problems and mucosal integrity. Using a GEE logistic regression model 
including treatment, visit and their interaction, the interaction was found not significant (p=0.1442).  
When dropped from the model, the odds ratio between 40 Gy and 50 Gy for having no salivary gland 
toxicity was 1.88 (95% confidence interval 1.07 to 3.31, p-value = 0.0281). 
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 ≥grade1 
salivary 
gland 
toxicity 
Total P(GEE) ≥grade3 
salivary 
gland 
toxicity 
Total P(GEE) 
Month 
6 
40 
Gy 
55 
(68.7%) 
80 0.01 2 
(2.5%) 
80 0.7 
50 
Gy 
63 
(86.3%) 
73 3 
(4.1%) 
73 
Month 
12 
40 
Gy 
47 
(71.2%) 
66 0.23 3 
(4.5%) 
66 1.0 
50 
Gy 
53 
(80.3%) 
66 2 
(3.0%) 
66 
Month 
18 
40 
Gy 
37 
(63.8%) 
58 0.03 2 
(3.4%) 
58 1.0 
50 
Gy 
49 
(81.7%) 
60 2 
(3.3%) 
60 
Month 
24 
40 
Gy 
34 
(63.0%) 
54 0.84 1 
(1.8%) 
54 1.0 
50 
Gy 
35 
(64.2%) 
54 0 
(0.0%) 
54 
 
Table 3. Prevalence of salivary gland toxicity ≥ grade 1 and salivary gland toxicity ≥ grade 3 at each 
time-point. 
 
Outcome 
Median follow-up was 34.2 months (range 2.2-79.0). We did not observe significant differences in 
outcome and survival between both groups at 6, 12, 18 and 24 months (Table 4).  
After 2 years, estimated overall survival was similar in both groups (72% and 73% in the 40 Gy and 50 
Gy group, respectively (p=0.73)). Furthermore no statistically significant difference was found in the 
estimated disease free survival at 2 years (p=0.41), although a lower rate was observed in the 40Gy 
group (58%) in comparison with the rate in the 50 Gy group (65%). 
We did not observe statistically significant differences in estimated locoregional recurrence rates 
between both groups at 6, 12 and 24 months. However, after 2 years of follow-up, the cumulative 
incidence of locoregional recurrence was higher (24 %) in the 40 Gy arm when compared to the 50 Gy 
arm (15%) (p=0.14). The estimated local recurrence rate was 14% in both groups. 
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 6 months 12 months 24 months p 
value 40 Gy arm 50 Gy arm 40 Gy arm 50 Gy arm 40 Gy arm 50 Gy arm 
OS 92.6% 
(85-96.4) 
95.7% 
(88.9-98.4) 
82.7% 
(73.3-89.0) 
85.7% 
(76.6-91.4) 
72.0% 
(61.4-80.2) 
73.2% 
(62.3-81.4) 
0.73 
DFS 83.0% 
(73.7-89.2) 
85.0% 
(76.0-90.8) 
70.0% 
(59.6-78.2) 
69.9% 
(59.5-78.1) 
57.9% 
(47.1-67.2) 
65.3% 
(54.6-74.1) 
0.41 
LFR 4.3% 
(1.4-9.8) 
3.2% 
(0.9-8.4) 
10.7% 
(5.5-18.0) 
8.7% 
(4.0-15.5) 
14.1% 
(7.9-22.1) 
14.4% 
(8.1-22.5) 
0.99 
RFR 7.4% 
(3.3-13.9) 
2.2% 
(0.4-7.0) 
11.8% 
(6.2-19.3) 
5.5% 
(2.0-11.6) 
13.0% 
(7.1-20.8) 
5.5% 
(2.0-11.6) 
0.08 
LRFR 10.6% 
(5.4-17.8) 
5.4% 
(2.0-11.3) 
20.3% 
(12.8-29.1) 
10.8% 
(5.5-18.2) 
23.7% 
(15.6-32.8) 
15.4 
(8.9-23.7) 
0.14 
MR 4.3% 
(1.4-9.8) 
9.8% 
(4.8-16.9) 
6.4% 
(2.6-12.6) 
17.4% 
(10.4-25.8) 
13.4% 
(7.3-21.3) 
18.5% 
(11.3-27.1) 
0.25 
For OS and DF, differences were assessed using a log-rank test.  For LFR, RFR, LRFR and MR, 
differences between groups were assessed using Gray’s testing, considering death as a competing 
risk. 
Table 4. Overview of the estimated outcome of the study and 95% confidence interval and 
corresponding p values. 
 
Regarding regional recurrences, we see a difference in estimated risk between both groups, however 
not significant (p=0.08): 13% vs. 6%  in the 40 Gy arm and 50 Gy arm at 2 years, respectively (figure 2). 
In total, 17 regional recurrences have been observed during follow-up (Table 5). Three of seventeen 
(18%) occurred in the PTV elective (2 in the 40 Gy arm and 1 in the 50 Gy arm) whereas  12 regional 
recurrences were located in the high dose volume (11 in the GTV, 1 in the PTV). Two regional 
recurrences occurred outside the planning volume in the 40 Gy arm. 
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Figure 2. Cumulative Incidence Curves for regional Recurrence. 
Of the 17 patients with regional recurrence, 6 underwent salvage neck dissection. Palliative 
chemotherapy was started in 4 patients, as salvage neck dissection was not considered to be 
advantageous because of synchronous metastases (n=3) or an irresectable relapse (n=1). No further 
therapy was provided in 7 patients because these patients opted not to be treated. 
RECURRENCE 40 Gy ARM 50 Gy ARM 
GTV lymph node 6 5 
PTV lymph node 1 0 
Outside planning volume 2 0 
PTV elective 2 1 
 
Table 5. Site of the regional recurrences. 
PTV: Planning Target Volume; GTV: Gross Tumor Volume 
Regarding estimated metastatic risk, we observed no significant differences; however we observed a 
lower incidence (13.4%) in the 40 Gy arm when compared to the  50 Gy arm (18.5%) after 2 years of 
follow up (p=0.25) (figure 3). 
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Figure 3. Cumulative Incidence Curves for metastatic risk. 
Discussion 
In this paper we describe the late toxicity and outcome of a multicenter randomized controlled trial 
reducing the dose to the elective lymph nodes in patients treated for head and neck cancer.  
The primary endpoint of this study was late dysphagia as this is the most important quality of life 
compromising toxicity after curative treatment of HNC [2]. Altered fractionation schedules, 
concomitant chemotherapy and oropharyngeal tumor location are associated with more dysphagia 
[6]. With the incidence of oropharyngeal carcinoma in the western world on the rise, the widespread 
use of concomitant chemoRT and the use of altered fractionation schedules, prevention of late 
dysphagia will be of upmost importance in optimizing the quality of life in these patients [16-19].  
Our preliminary analysis demonstrated that a dose de-escalation to the elective lymph nodes, 
significantly reduced the volume of the swallowing apparatus irradiated up to a high dose without 
compromising target coverage and dose homogeneity. Clinically this dose reduction resulted into 
significantly less grade ⩾3 dysphagia in the de-escalated arm 3 months after treatment with similar 
LRC and DFS rates [12]. We also observed a better quality of life in the 40 Gy arm (unpublished data, 
recently submitted to Radiotherapy and Oncology). 
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The current updated results show a trend towards less late dysphagia, however not confirmed after 
longitudinal analysis. Furthermore, we observed significantly less moderate salivary gland toxicity in 
the 40 Gy arm at 6 and 18 months, confirmed after longitudinal analysis.  This is a somewhat 
unexpected finding, since there was no significant difference between doses tot the parotid glands in 
both treatment arms, as published in our first paper.  
No significant difference between both groups was detected regarding stiffness of the neck, severe 
salivary gland toxicity, skin problems and mucosal integrity. A possible explanation for this is the fact 
that the high doses given to the PTV of the primary tumor were identical in both groups. 
Outcome in terms of local, regional and distant control and survival did not differ significantly between 
the groups after two years of follow up. In the 40 Gy arm however, we observed a higher absolute 
number of all regional recurrences (i.e. in the elective neck as well as in pre-existing pathological lymph 
nodes). It was reassuring that there were only 2 regional recurrences in the elective neck outside the 
high-dose PTV in the 40 Gy arm and 1 in the 50 Gy arm. Obviously, these numbers are too small to 
conclude that more elective neck recurrences would occur when lowering the dose in the elective neck 
from 50 to 40 Gy NID2Gy.  
It could be hypothesized that lowering the dose for subclinical disease could result in less control and 
thereby in higher numbers of distant metastases [20]. We did not observe more distant metastases in 
the de-escalated group; on the contrary, a higher absolute number of patients had distant metastases 
in the 50 Gy group (not significant). This finding is reassuring with respect to the possibility to enhance 
occurrence of distant metastases when lowering the dose to the elective neck.  
So far, no randomized data on dose de-escalation to the elective nodal volume in head and neck cancer 
were published. Therefore the choice of 40 Gy for our de-escalation arm was quite arbitrarily chosen, 
although supported by two non-randomized analyses [21,22].  
We hereby present the first study that demonstrates the non-inferiority of dose de-escalation in the 
elective neck to 40 Gy in terms of regional control in the elective neck.  Meanwhile, a follow-up 
multicentre trial has been conducted comparing dose de-escalation in the elective neck using adaptive 
RT in reduced volumes of the elective neck  in an attempt to further diminish treatment-induced 
toxicity. Combining data of both studies can give us more information on the safety of dose-reduction 
to the elective nodal volume. 
Although the main purpose of the trial was to study the effect of a dose-reduction to 40 Gy-equivalent 
dose in the elective neck, a large heterogeneity remains between the treating centres in terms of 
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fractionation schedules, dose prescription to the high-dose PTV, expansion margins from CTV to PTV, 
patient positioning protocols and the use of concurrent chemotherapy. In order to avoid confounding 
effects of this centre-dependent heterogeneity,  the trial randomization was performed per center. 
Conclusions 
Dose de-escalation to the elective nodal volume in HNC from a 50  to a 40 Gy-equivalent dose results 
in a trend towards less dysphagia at 6 months and less moderate salivary gland toxicity without 
significant differences in disease control or survival.  
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A multicenter, randomized clinical trial with dose-reduction to the elective nodal sites in head and 
neck cancer: results on the quality of life. 
Background and purpose 
A randomized trial was initiated to investigate whether a reduction of the dose to the elective nodal 
sites would result in less side effects and better Quality of Life (QoL) without compromising tumor 
control. The aim of this paper was to compare QoL in both treatment arms. 
Materials and methods 
Two-hundred patients were randomized. The elective nodal volumes of patients randomized in the 
experimental arm were treated up to a 40 Gy-equivalent dose. In the control arm, the elective nodal 
volumes were treated up to a 50 Gy-equivalent dose. The QoL data were collected using The European 
Organization for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and the 
EORTC Head and Neck cancer module (H&N35).  
Results 
We see statistically significant differences for global health status, physical functioning, emotional 
functioning, speech problems and trouble with social eating in favor of the 40 Gy arm. Clinically 
relevant better outcome in the 40 Gy arm was found for physical functioning, emotional functioning 
and speech problems.  
 
Conclusions 
QoL following RT for head and neck cancer is less impaired when a 40 Gy-equivalent dose is given to 
the elective lymph nodes. For physical functioning, emotional functioning and speech problems we 
observed statistically significant and clinically relevant differences between both treatment arms in 
favor of the 40 Gy-equivalent dose arm. 
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Introduction 
Radiotherapy (RT) for head and neck cancer (HNC) has significantly changed over the past decades. 
Treatment intensification improved clinical outcome, but also increased both acute and late toxicity, 
heavily compromising Quality of Life (QoL) of the surviving HNC patients [1-5]. Late swallowing 
disorders are particularly of concern [6]. From a dosimetrical point of view the dose delivered to the 
pharyngeal constrictor muscles plays a crucial role in the development of severe late 
dysphagia/aspiration [7-10]. A possible way to limit the dose to these organs at risk is by delivering a 
lower RT dose to the elective nodal volume. Historically the dose suggested to achieve microscopic 
sterilization is 45-50 Gy in 1.8 to 2 Gy fractions [11].  Therefore a multicenter, randomized clinical trial 
was initiated with the aim to investigate whether a dose-reduction to the elective nodal sites and off-
target regions of the swallowing apparatus using Intensity Modulated Radiotherapy (IMRT) would 
result in a reduction of both acute and late side effects and an improvement in QoL without 
compromising tumor control [12].  In a previous paper we demonstrated that a dose de-escalation to 
the elective lymph nodes in HNC results in significantly less dose to the pharyngeal constrictor muscles 
and less severe dysphagia at 3 months following treatment [12]. Furthermore, dose de-escalation to 
the elective nodal volume in HNC from a 50 to a 40 Gy-equivalent dose results in a trend towards less 
dysphagia at 6 months and less moderate late salivary gland toxicity without significant differences in 
disease control or survival [13: paper resubmitted (after minor revision) for publication in 
Radiotherapy and Oncology].  
The purpose of this paper was to longitudinally compare patient-reported QoL of both treatment arms 
in this study. 
Material & methods 
Study design and patients 
A prospective randomized multicenter phase III study was set up between 6 centers. Inclusion criteria 
were previously untreated, histologically proven squamous cell carcinoma of the oral cavity, 
oropharynx, hypopharynx, larynx or cervical lymph node metastases with unknown primary cancer 
(CUP). Patients were older than 18 years with a Karnofsky performance status ≥70%. Concurrent 
chemotherapy was allowed, as well as pretreatment lymph node dissection. Local ethics committee 
approval was obtained before start of the study and all patients gave written informed consent. 
Patients were randomized to two treatment arms (experimental arm A and standard arm B). A total of 
200 patients were included in the study (100 for each arm). To minimize the influence of center-specific 
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parameters randomization was performed per center. The patient and disease characteristics can be 
found in the original paper on acute toxicity and dosimetry [12]. The primary endpoint of the original 
study is dysphagia at 6 months of follow-up; secondary endpoints are clinical outcome, acute and late 
toxicities and QoL [12]. This paper addresses thus one of the secondary endpoints of this trial. 
Treatment 
After randomization, a planning computed tomography study was performed. The primary tumor and 
enlarged lymph nodes were contoured separately and defined as gross tumor volume. All 
macroscopically affected tumor sites were treated up to a normalized iso-effective dose in 2 Gy 
fractions (NID2Gy) of 70 Gy. For the elective nodal volumes, patients randomized in arm A 
(experimental arm) were treated up to a NID2Gy of 40 Gy. For arm B (control arm) the elective nodal 
volumes were treated up to a NID2Gy of 50 Gy. The definition and contouring of the elective nodal 
volume are described in the paper on acute toxicity [12]. 
QoL 
The QoL data were collected using The European Organization for Research and Treatment of Cancer 
(EORTC) core questionnaire QLQ-C30 and the EORTC Head and Neck cancer module (QLQ-H&N35) [14]. 
Both instruments were available in Dutch and French. Both tools have robust psychometric properties 
resulting from rigorous testing and external validity.  
The cancer-specific QLQ-C30 questionnaire includes 30 questions organized into 5 functional scales 
(physical, role, emotional, cognitive, and social) and 3 symptom scales (nausea/vomiting, pain, and 
fatigue). It also includes a global health/QoL scale and 6 single additional symptom items (constipation, 
diarrhea, loss of appetite, insomnia, dyspnea, and financial difficulties). Higher scores on functional 
and global health/QoL scales indicate a higher level of functioning, while a higher score on the 
symptom scales or single items indicate greater symptoms or problems.  
The QLQ-H&N35 questionnaire was used to measure symptoms and problems specific for head and 
neck cancer and treatment side effects. The questionnaire includes 35 questions organized into 7 
symptom scales (local pain, swallowing, senses, speech, social eating, social contact, sexuality), 6 single 
symptom items (problems with: teeth, opening the mouth, dry mouth, sticky saliva, coughing and 
feeling ill), and 5 yes/no questions (use of painkillers, nutritional supplements, feeding tube, losing or 
gaining weight). Higher scores indicate more or more serious symptoms/problems. For the yes/no 
questions the scores indicate the percentage of yes answers. QLQ-C30 and QLQ-H&N35 questionnaires 
were assessed at baseline and at the end of treatment and at 1, 2, 3, 6, 12, 18 and 24 months following 
the end of treatment.  
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Statistical analysis 
Compliance levels were calculated following a standard EORTC procedure (number of forms received 
divided by the number expected) at each assessment point.  
The questions on both QoL measures were scaled and scored using the recommended EORTC Quality 
of Life Group procedures. Raw scores were transformed to a linear scale ranging from 0 to 100. 
All tests were 2-sided and assessed at a significance level of 5%. Due to the exploratory nature of the 
study, no adjustments were made to the significance level to account for multiple testing.  All analyses 
have been performed using SAS System for Windows. 
A longitudinal analysis was performed to assess differences between the two groups over time. For 
this analysis a Generalized Estimating Equations (GEE) proportional odds model was used, with an 
independent correlation matrix to account for the clustering of the data. Primarily, the longitudinal 
proportional odds model includes a factor for randomized treatment, visit and their interaction. The 
inclusion of the interaction allows for the treatment effect to differ between visits. The effect of 
randomized treatment was estimated at each visit.  
To interpret clinical relevance, differences of at least 10 points (on a scale of 0-100) were classified as 
the minimum clinically meaningful change in the mean value of a QoL parameter. No grouping 
according to survival, site, gender, age or other clinical parameters was done, since both groups were 
well balanced at baseline [12]. The frequency of surgery and upfront neck dissections was not 
significantly different between both groups at baseline and randomization was done per center [12]. 
This assures that the differences found in the QoL between both groups are related to the different RT 
dose to the elective nodal volumes. 
All available questionnaires filled in by included patients were included in the analysis. 
Results 
Compliance 
The compliance at every time-point is given in Table 1. Compliance was 92% at baseline, 80% at 3 
months of follow-up, 85% at 6 months and 1 year of follow-up and 80% at 2 years of follow-up. 
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Time-point 40 Gy arm (n) 50 Gy arm (n) Total for 
both arms 
Expected n 
for both arms 
compliance 
Baseline 88 89 177 193x 92% 
End of RT 77 82 159 193 82% 
Month 1 77 80 157 193 81% 
Month 2 80 80 160 193 83% 
Month 3 80 75 155 193 80% 
Month 6 69 66 135 159 85% 
Month 12 57 54 111 131 85% 
Month 18 49 50 99 116 85% 
Month 24 42 48 90 112 80% 
Table 1. Compliance for both study arms at every time point for QLQ-C30 and QLQ-H&N35. 
xInformation of 1 participating center (7 patients) could not be retrieved before close-out date of this 
analysis, yielding 193 patients for analysis (96 in the experimental arm and 97 in control arm)  
QLQ-C30 
An overview of the baseline mean QLQ-C30 scores and comparison with reference data is given in 
Table 2. We did not observe clinically relevant (>10 points of difference between the mean values) 
differences between our results and the reference data [14]. Furthermore, no clinically relevant 
differences were seen between both treatment arms at baseline. 
 
40 Gy arm 
(N=100), 
Mean (SD) 
50 Gy arm 
(N=100), 
Mean (SD) 
Reference Data: Head 
and Neck Cancer at All 
Stages (N=2929), Mean 
(SD) 
Reference Data: Head 
and Neck Cancer Stage 
III-IV (N=1722), Mean 
(SD) 
QLQ-C30 
Global health 
status 
56.4(20.2) 62.6 (19.1) 64.1 (22.7) 63.1 (22.4) 
Physical 
Functioning 
86.1 (16.7) 84.1 (19.9) 81.2 (20.4) 81.2 (20.2) 
Role 
Functioning 
76.8 (26.7) 80.3 (26.1) 78.9 (28.1) 78.8 (27.9) 
Emotional 
Functioning 
71.2 (22.3) 73.2 (24.3) 72.5 (24.1) 71.2 (24.1) 
Cognitive 
Functioning 
88.4 (19.2) 88.0 (19.4) 85.9 (19.7) 86.4 (19.1) 
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40 Gy arm 
(N=100), 
Mean (SD) 
50 Gy arm 
(N=100), 
Mean (SD) 
Reference Data: Head 
and Neck Cancer at All 
Stages (N=2929), Mean 
(SD) 
Reference Data: Head 
and Neck Cancer Stage 
III-IV (N=1722), Mean 
(SD) 
Social 
Functioning 
87.1 (20.8) 85.9 (24.6) 82.6 (24.7) 82.2 (24.7) 
Fatigue 30.5 (26.2) 24.0 (23.7) 26.9 (24.9) 27.6 (25) 
Nausea and 
Vomiting 
6.4 (14.1) 4.1 (11.1) 5.3 (13.7) 5.2 (13.3) 
Pain 23.6 (25.8) 20.3 (25.4) 23.2 (26.1) 24.9 (26.3) 
Dyspnea 20.6 (25.4) 14.6 (25.1) 18.2 (26.9) 18.0 (26.6) 
Insomnia 31.4 (31.5) 29.2 (31.7) 27.3 (31.8) 28.5 (32.4) 
Appetite Loss 21.6 (32.0) 18.3 (31.8) 17.7 (28.2) 19.4 (29.3) 
Constipation 13.1 (25.4) 10.1 (22.3) 11.1 (22.6) 11.7 (23.2) 
Diarrhea 4.5 (16.6) 3.9 (12.9) 6.1 (16.9) 6.1 (16.7) 
Financial 
Difficulties 
15.1 (26.2) 13.67 (25.9) 18.2 (29.6) 18.8 (30.2) 
Table 2. Baseline score of QLQ-C30 for both treatment arms compared to the reference data [15]. 
Abbreviations: QLQ-C30: Quality of Life Questionnaire C30; SD, standard deviation. 
Regarding global health status (Figure 1), the interaction between treatment and visit was found to 
be significant (p0.01), indicating that the treatment effect differs at the different time-points.  
An overall effect towards a better global health status was observed in the 40 Gy arm (p0.01). 
Furthermore, at month 6 (p=0.04; 95% CI 0.42 to 13.04) and month 18 (p0.01; 95% CI 6.85 to 21.42), 
the odd ratios for global health status are in favor of the  40 Gy arm (Table 3). Differences are however 
never more than 10 points between both treatment arms. In both treatment arms, the mean global 
health status rises to baseline levels at 2 months following the end of treatment (Fig. 1). At 2 years of 
follow up, we observe a clinically relevant increase (>10 points) in the mean values of global health 
status (73.3 in both treatment arms) when compared to baseline levels (56.4 in the 40 Gy arm and 62.6 
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in the 50 Gy arm). We see thus after 2 years of follow-up a clinically relevant increase in global health 
status when compared to pre-treatment values.  
Figure 1. Global health status in the 2 treatment arms. Lines connect median values at each visit. Top 
and bottom of boxes are Q1 and Q3, respectively. Whiskers indicate P5 and P95. Higher scores on the 
scale indicate a higher level of functioning. 
 
Regarding physical functioning (Figure 2), the interaction between treatment and visit was found to 
be significant (p=0.03) (Fig. 2). Furthermore we observe an overall effect towards better physical 
functioning in the 40 Gy arm (p=0.01). At the end of therapy (p<0.01; 95%CI 3.08 to 15.99) and month 
1 (p=0.02; 95% CI 0.90 to 12.64), the odd ratios are in favor of the 40 Gy group (Table 3). Furthermore, 
at the end of therapy, the difference between the mean values in both groups is more than 10 points 
(73.2 vs 62.2) in favor of the 40 Gy arm, thus there is not only a statistically significant difference but 
also a clinically relevant difference (Table 3). After 1 month of follow-up, this difference between both 
treatment arms becomes less than 10 points but is still in favor of the 40 Gy arm (76.1 vs 71.2). Until 2 
months of follow-up, there is a clinically relevant decrease in physical functioning in both arms (75.6 
in the 40 Gy arm and 73.5 in the 50 Gy arm) when compared to baseline values (86.1 in the 40 Gy arm 
and 84.1 in the 50 Gy arm); from that time-point on, we see an increase in physical functioning to 
baseline levels after 2 years of follow-up. 
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Figure 2. Physical functioning in the 2 treatment arms. Lines connect median values at each visit. Top 
and bottom of boxes are Q1 and Q3, respectively. Whiskers indicate P5 and P95. Higher scores on the 
scale indicate a higher level of functioning. 
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 Time-point 40 Gy arm 
Mean value 
(SD) 
50 Gy arm 
Mean value 
(SD) 
Odds ratio 
Odds ratio 
(95% CI) 
p-value 
QLQ-C30 
Global 
health status 
Interaction 
Overall effect 
Month 6 
Month 18 
 
 
65.1 (20.3) 
75.0 (17.6) 
 
 
62.4 (17.9) 
68.0 (22.7) 
 
 
6.73 (0.42 to 13.04) 
14.14 (6.85 to 21.42) 
p<0.01 
p<0.01 
p=0.04 
p<0.01 
Physical 
functioning 
Interaction 
Overall effect 
End of RT 
Month 1 
 
 
73.2 (22.9) 
76.1 (22.4) 
 
 
62.2 (26.4) 
71.2 (22.2) 
 p=0.03 
p=0.01 
p<0.01 
p=0.01 
Emotional 
functioning 
Interaction 
Without 
interaction 
 
 
 
 
 
 
5.21 (1.06 to 9.37) 
p=0.24 
 
p=0.01 
QLQ-H&N35 
Speech 
problems 
Interaction 
Overall 
End of RT 
Month 24 
 
45.0 (28.6) 
9.4 (14.4) 
 
55.1 (31.3) 
11.6 (16.2) 
 p=0.05 
p=0.03 
p=0.21 
p=0.02 
Trouble with 
social eating 
Interaction 
Without 
interaction 
 
 
 
 
 p=0.53 
p=0.01 
Sticky saliva Overall 
Month 18 
 
28.7 (26.8) 
 
36.9 (30.5) 
 p=0.08 
p=0.03 
 
Table 3. Statistically significant and clinically relevant differences (in bold) between both groups for 
QLQ-C30 and QLQ-H&N35. 
The interaction between treatment and visit was found to be not significant regarding emotional 
functioning (p=0.24). This means the treatment effect is similar at all time-points. When we remove 
the interaction from the model, the odds ratio between the 40 Gy group versus the 50 Gy group was 
in favor of the 40 Gy arm for all time-points; 5.21 (95% CI 1.1 to 9.4, p=0.01). Furthermore, at the end 
of therapy, the score in the 40 Gy arm is 10 points higher (74.4) than in the 50 Gy arm (64.0) and thus 
not only statistically significant but also clinically relevant. At other time-points we do not observe 
clinically relevant differences. 
We do not observe significant differences between both groups regarding nausea and vomiting, role 
functioning, cognitive functioning, social functioning, fatigue, pain, dyspnea, insomnia, appetite loss, 
constipation, diarrhea and financial difficulties.  
All the different parameters of the QLQ-C30 return to baseline levels or are better than baseline levels 
after 2 years of follow-up. 
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QLQ-H&N35 
An overview of the baseline mean QLQ-H&N35 scores and comparison with reference data [15] is given 
in Table 4. We observe clinically relevant (>10 points) differences between the mean results of the 
current study and the reference data regarding teeth problems, dry mouth, sticky saliva, the use of 
painkillers and nutritional supplements, the use of a feeding tube, weight loss and weight gain. 
Furthermore, no clinically relevant differences were seen between both treatment arms at baseline. 
 
40 Gy arm 
(N=100), 
Mean (SD) 
50 Gy arm 
(N=100), 
Mean (SD) 
Reference Data: Head 
and Neck Cancer at All 
Stages (N=2929), 
Mean (SD) 
Reference Data: Head 
and Neck Cancer Stage 
III-IV (N=1722), Mean 
(SD) 
QLQ-H&N35 
Pain 30.4 (25.1) 26.0 (25.4) 27.1 (24) 29.9 (25.1) 
Swallowing 29.3 (27.9) 27.0 (25.9) 23.9 (25.3) 27.5 (26.1) 
Senses 11.6 (19.6) 10.7 (20.3) 19.3 (28.8) 20.0 (30.0) 
aSpeech 21.8 (25.2) 19.9  (26.5) 28.0 (27.6) 27.1 (27.2) 
Social Eating 24.2 (26.7) 20.9 (24.1) 20.9 (25.1) 23.9 (26.7) 
Social Contact 10.7 (15.2) 10.3 (20.0) 13.0 (18.9) 13.2 (19.1) 
Sexuality 33.8 (34.5) 27.8 (35.0) 31.3 (35.2) 32.3 (36.1) 
Teeth 17.3  (31.4) 13.9  (27.5) 25.5 (33.2) 27.8 (35.0) 
Opening mouth 22.6 (32.3) 18.8 (30.8) 19.5 (29.5) 22.4 (31.9) 
Dry mouth 20.4 (27.9) 19.2 (27.2) 30.7 (33.4) 31.1 (34.2) 
Sticky Saliva 21.2 (29.5) 19.4 (27.2) 30.5 (33.9) 32.4 (35.4) 
Coughing 31.1 (29.4) 28.7 (31.4) 33.9 (32.2) 34.9 (32.1) 
Felt ill 16.1 (26.4) 16.9 (26.3) 21.6 (28.9) 21.7 (29.2) 
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Painkillers 21.8 (16.7) 16.9 (16.8) 49.5 (50) 52.8 (49.9) 
Nutritional 
supplementation 
6.1 (12.9) 7.1 (13.7) 26.7 (44.2) 27.0 (44.4) 
Feeding tube 1.9 (7.8) 2.4 (8.6) 19.7 (39.8) 18.3 (38.7) 
Weight loss 17.2 (16.8) 13.2 (16.4) 38.9 (48.8) 41.3 (49.2) 
Weight gain 4.3 (11.2) 4.5 (11.4) 27.3 (44.6) 25.9 (43.8) 
 
Table 4. Baseline score for QLQ-H&N35 in both treatment arms and reference data [15]. 
Abbreviations: H&N35, European Organization for Research and Treatment of Cancer Quality of Life 
Head and Neck cancer-specific questionnaire; SD, standard deviation. Bold type indicates clinically 
relevant difference between trial data and reference data (>10 points) 
 
Regarding swallowing problems, the interaction between treatment and visit was found to be not 
significant (p=0.09). When we remove the interaction from the model, we only observe a trend 
towards less swallowing problems in the 40 Gy group (p=0.08; 95%  CI -9.95 to 0.70). We never observe 
a clinically relevant difference between both groups (Table 3). At the end of therapy, the mean values 
in both groups are twice the baseline values (29.3 vs 60.9 in the 40 Gy arm; 27.0 vs 67.4 in the 50 Gy 
arm). However, at 2 years of follow-up the mean values of both groups are significantly better when 
compared to pretreatment values. 
We observe a significant interaction effect between treatment and visit regarding speech problems 
(p=0.05). Furthermore we observe a statistically significant overall effect towards less speech problems 
in the 40 Gy arm (p=0.03). At 24 months of follow-up, we see e significant difference between both 
groups (p=0.02). Moreover, at the end of therapy, the difference between both groups was more than 
10 points, however this failed to reach a statistical significant difference (p=0.21) (Table 3). 
For trouble with social eating the interaction between treatment and visit was found to be not 
significant (p=0.53). When we removed interaction from the model we found a statistically significant 
effect towards less problems with social eating in the 40Gy arm for all time points (p<0.01; 95% CI -
14.22 to 2;83). Differences between both groups never exceed 10 points. 
Some symptoms never show any significant differences between both study arms at any time-point 
(sticky saliva, pain, senses problems, trouble with social contact, sexuality, teeth problems, opening of 
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the mouth, dry mouth, coughing, ill feeling, use of pain killers, feeding tube, weight gain/loss and use 
of nutritional supplements).  
For senses problems, speech problems, trouble with social eating, less sexuality, nutritional 
supplements and feeding tube use, we observe clinically relevant worse outcome at the end of therapy 
till 2 months of follow up in both treatment arms with an increase afterwards to baseline levels. For 
pain, swallowing, trouble with social contact, opening of the mouth, coughing and ill feeling, we see a 
decrease until 1 month of follow-up, with an increase afterwards to baseline values. For dry mouth 
and sticky saliva, we observe clinically relevant worse outcome at all time-points till 2 years of follow-
up when compared to baseline values. 
Discussion 
This paper reports on QoL in head and neck cancer patients treated with RT; and compares a RT dose 
equivalent to 40 Gy in the elective neck with 50 Gy. The primary endpoint of this randomized, phase 3 
clinical trial study was to detect a difference in dysphagia at 6 months. Oncological outcome and QoL 
were secondary endpoints. We demonstrated in a previous paper that a dose de-escalation to the 
elective lymph nodes in HNC results in significantly less dose to the swallowing structures and less 
severe dysphagia at 3 months following treatment [12]. Furthermore, we observed a trend towards 
less dysphagia at 6 months and less moderate salivary gland toxicity without significant differences in 
disease control or survival [13].To our knowledge, there is no earlier report on QoL on this subject.  
The results of the current study are presented in accordance with guidelines for the reporting of QoL 
studies [16]. Compliance in our study is high when compared to other studies and reached at least 80% 
at every time point [17, 18]. 
Baseline QoL scores are similar in both treatment arms, and comparable to the reference values in 
patients with head and neck cancer. However, some differences are observed between the treatment 
scores and reference data in the QLQ-H&N35 questionnaire. The differences observed between the 
reference and current data can be attributed to the large differences in sample size between our study 
population and the reference data and were also observed in a previous study [18]. 
 
The results of the present study are in favor of the 40 Gy arm. We see overall a better result in the 40 
Gy arm, with statistically significant differences for global health status, physical functioning, 
emotional functioning, speech problems and trouble with social eating in favor of the 40 Gy arm. 
Clinically relevant differences are found for physical functioning, emotional functioning and speech 
problems, all in favor of the 40 Gy arm.  
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The better emotional and physical functioning in the 40 Gy arm might be related to less side effects in 
the 40 Gy arm, as was demonstrated in the initial paper and the paper on late outcome [13]. In the 
late outcome paper [13], we found less late salivary gland toxicity in the 40 Gy arm. This could explain 
why we see less patient reported speech problems and problems with social eating in the 40 Gy arm. 
 
We find differences in both the early and late phase following the end of RT, implying that the RT dose 
to the elective nodal volume has short- and long-term implications on QoL. There is a similar pattern 
for both treatment groups: almost all of the scales, symptoms and functions, returned to baseline 
levels very early after the end of treatment; at 2-3 months of follow-up. For senses problems this was 
the case at 6 months of follow-up. This point is important and also partially supported by other 
literature [19-21] in whom initial treatment can have short-term negative effects on QoL. For dry 
mouth and sticky saliva, however, the mean results in our patient population never returned to 
baseline levels, and after 2 years of follow up stayed clinically relevant worse when compared to 
baseline in both groups. On the other hand, global health status and speech problems were 
significantly better after 2 years of follow-up when compared to baseline. 
 
Conclusions 
In this study, we compared QoL in 2 arms of a randomized trial in head and neck cancer, 40 Gy vs 50 
Gy to the elective lymph nodes in head and neck cancer. The results of the present study are in favor 
of the 40 Gy arm. We observe statistically significant differences for global health status, physical 
functioning, emotional functioning, nausea and vomiting, pain, swallowing problems, speech 
problems, trouble with social eating and sticky saliva in favor of the 40 Gy arm. Clinically relevant 
differences are found for physical functioning, emotional functioning and speech problems, all in favor 
of the 40 Gy arm.  
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Recurrence patterns after a decreased dose of 40 Gy to the elective treated neck in head and neck 
cancer. 
Purpose 
To investigate the patterns of regional recurrences with emphasis on recurrences in the electively 
irradiated lymph node regions after dose de-escalation to 40 Gy (EQD2Gy) in head and neck cancer.  
Methods and materials 
Two hundred thirty-three patients treated with radio(chemo)therapy using 40 Gy (EQD2Gy) to the 
elective lymph node regions were included. All regional recurrences were reconstructed and projected 
on the initial radiotherapy planning Computed Tomography studies to identify the localization of 
recurrence. Furthermore, patient and treatment characteristics were correlated with the regional 
recurrences to identify risk factors. 
Results 
The median follow-up in our study was 26 months. Overall- and disease-specific survival at 2 years 
were 71.2% (95% CI 65.3-77.1) and 64.2 % (95% CI 59.2-69.3), respectively. Local, regional and distant 
control at 2 years was 84.1% (95% CI 79.1-89.2), 89.2% (95% CI 84.3-94.1) and 83.2% (95% CI 76.3-
90.1), respectively.  
The actuarial rate of recurrence in the electively irradiated lymph node regions was 3.9% (95% CI 1.8-
6.0)  at 2 years. No significant associations could be observed between recurrence in electively 
irradiated lymph node regions and age, gender, tumor site, stage, or the presence of human 
papillomavirus in oropharyngeal cancers. 
Conclusions 
The actuarial rate of recurrence in the electively irradiated lymph node regions was 3.9% (95% CI 1.8-
6.0) at 2 years. This incidence is comparable to recurrence rates after standard dose of 50 Gy, 
suggesting that lower doses to the elective neck do not result in higher regional recurrences. 
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Introduction 
Radiotherapy (RT) for head and neck cancer (HNC) has significantly changed over the past decades. 
Treatment intensification improved clinical outcome, but also increased both acute and late toxicity 
[1-5]. Late swallowing disorders are particularly of concern [6]. From a dosimetrical point of view the 
dose delivered to the pharyngeal constrictor muscles plays a crucial role in the development of severe 
late dysphagia/aspiration [7-10]. A possible way to limit the dose to these organs at risk is by delivering 
a lower RT dose to the elective nodal volume. Historically the dose suggested to achieve microscopic 
sterilization is 45-50 Gy in 1.8 to 2 Gy fractions [11]. In a previous paper we demonstrated that a dose 
de-escalation to the elective lymph nodes in HNC results in significantly less dose to the pharyngeal 
constrictor muscles and less severe dysphagia at 3 months following treatment [12]. Furthermore, 
dose de-escalation to the elective nodal volume in HNC from a 50 to a 40 Gy-equivalent dose results 
in a trend towards less dysphagia at 6 months and less moderate late salivary gland toxicity without 
significant differences in disease control or survival [13]. Concerning quality of life, significant better 
outcome for global health status, physical functioning, emotional functioning, nausea and vomiting, 
pain, swallowing problems, speech problems, trouble with social eating and sticky saliva following dose 
de-escalation was observed [14]. 
The purpose of this study was to further investigate the safety of a dose de-escalation by analyzing the 
patterns of regional recurrence in electively irradiated lymph node regions after dose-de-escalation to 
an EQD2Gy of 40Gy in head and neck cancer. Furthermore we correlated patient and treatment 
characteristics with the recurrences in the elective lymph node regions to identify risk factors for a 
recurrence in the elective lymph nodes following dose de-escalation. 
Methods and materials: 
Two hundred thirty-three patients that were included in 3 prospective randomized studies, were 
analysed in the current study. All patients were treated with definitive radiotherapy or 
chemoradiotherapy for head and neck cancer between 2009 and 2015. The dose to the elective nodal 
volume was  40Gy (EQD2Gy) in all patients.  
Ninety-six patients from this paper, were originally included in a randomized dose de-escalation study 
to the elective lymph node regions [12, 13]. In the standard arm, the elective nodal volumes were 
irradiated up to an EQD2Gy of 50 Gy. In the experimental arm an EQD2Gy of 40 Gy was prescribed. For 
the current analysis, we only included the patients of the experimental arm. The inclusion criteria of 
this study were previously untreated, histologically proven squamous cell carcinoma of the oral cavity, 
oropharynx, hypopharynx, larynx or cervical lymph node metastases of unknown primary cancer 
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(CUP). All macroscopically affected tumor sites were treated up to an EQD2Gy of 70 Gy. The elective 
lymph nodes were delineated according to the guidelines of Grégoire et al [15, 16]. 
Furthermore, one hundred patients of the current study were included in a randomized trial comparing 
a 3-phase adaptive intensity-modulated radiotherapy (IMRT) with reduced volumes of elective neck 
compared with standard non-adaptive IMRT in head and neck cancer [ClinicalTrials.gov Identifier: 
NCT01287390]. Inclusion criteria of this study were patients with histologically proven non-resected 
squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx. All stages were 
allowed, except for cT1-2 N0 M0 glottic carcinoma or patients with distant metastases. One hundred 
patients were randomized to two treatment arms: adaptive de-escalation vs standard radiotherapy 
(50 patients per arm). The dose to the high-risk volume (primary tumor and metastatic lymph nodes) 
was not reduced in any of the patients. The elective neck received 40 Gy in 2 Gy fractions in both arms. 
The elective lymph nodes were delineated according to study specific guidelines which can be found 
in the supplementary material.  
A third group of thirty-seven patients, that were analysed in this paper, were included in a still ongoing 
three-phase adaptive dose-painting-by-numbers (DPBN) study for head-and-neck cancer patients [17, 
ClinicalTrials.gov Identifier: NCT01341535]. This study includes patients with non-metastatic, non-
resected histologically confirmed squamous cell carcinoma of head and neck. The patients in the 
experimental arm are treated by adaptive dose-painting-by-numbers, while patients in the control arm 
receive standard treatment. The elective neck in the adaptive dose-painting-by-numbers group was 
irradiated to 40 Gy (EQD2Gy). The elective lymph nodes were delineated according to the guidelines 
of Grégoire et al [15, 16]. 
Follow-up in all patients of these 3 studies was performed every 2 to 3 months in the first years and 
every 4 months in the second year after treatment, and bi-annually thereafter. Evaluation of 
recurrence included physical examination and nasopharyngeal laryngoscopy. Furthermore a CT study 
was performed 3 to 4 months following the end of treatment. Only if failure was suspected in the 
further follow-up, additional diagnostic imaging was performed.  
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Table 1. Cox regression analysis of patient characteristics for recurrence in electively irradiated nodal 
regions. 
Patient characteristics Number of events 
(regional recurrences in elective lymph nodes) 
Age In years 
(range) 
61 
(38-86) 
≤60         4 
60-70     3 
≥70         2 
p=0.41 
Gender Male 
Female 
190 
43 
7 
2 
p=0.84 
Site 
 
Oral cavity 
Oropharynx 
Hypopharynx 
Larynx 
CUP 
16 
115 
51 
47 
4 
2 
5 
2 
0 
0 
p=0.63 
HPV-status 
oropharynx 
 
Positive 
Negative 
Unknown 
21 
85 
9 
 
0 
4 
1 
p=0.16 
Stage 
grouping 
I 
II 
III 
IV 
4 
20 
47 
162 
0 
1 
1 
7 
P=0.09 
T-staging 
 
T1 
T2 
T3 
T4 
x 
11 
74 
78 
66 
4 
0 
3 
4 
2 
0 
p=0.62 
N-staging 
 
N0 
N1 
N2a 
N2b 
N2c 
N3 
 
53 
30 
7 
74 
59 
6 
 
1 
1 
0 
5 
2 
0 
 
p=0.47 
Pre-IMRT 
neck 
dissection 
Yes 
No 
34 
199 
2 
7 
P=0.32 
Concomitant 
systemic 
therapy 
 
Cisplatin-based 
Cetuximab 
Other 
No 
133 
8 
1 
91 
4 
1 
0 
4 
p=0.29 
Neo adjuvant 
chemotherapy 
Yes 
No 
5 
228 
0 
9 
p=0.30 
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Recurrence information was obtained from prospectively gathered patient information from the 3 
different studies. Each recurrence was categorized as local, regional, distant or a combination. In case 
of a regional recurrence, the regional recurrence was reconstructed and projected on the initial RT 
planning CT scan by performing rigid or deformable coregistration. Subsequently, regional recurrences 
were classified into 3 subtypes: (1) recurrent disease within the high dose volume: if located in initially 
pathologic lymph nodes located within the high dose volume; (2) recurrence in the elective volume; 
(3) recurrence outside the target volume: if located entirely outside the elective and high dose volume. 
All statistical analyses were performed using STATISTICA version 10 for Windows. Actuarial rates on 
recurrence and survival were calculated using the Kaplan-Meier method and were measured as the 
time from the end of treatment until the day of an event. Univariate Cox regression analysis was 
performed to identify predictors of recurrence in electively irradiated lymph nodes treated with dose 
de-escalation. 
Results: 
The patient characteristics can be found in Table 1. All 233 patients received IMRT, of which 142 
received concomitant systemic therapy (61%), of which 134 received Cisplatinum (94%). Eight patients 
were treated with Cetuximab. Only a small minority of patients underwent induction chemotherapy 
(2%). Thirty-four patients underwent neck dissection prior to IMRT. Patients with various tumor stages 
were included (cT1-4 N0-2 M0), of which a majority of 69% had a stage IVA-B tumor. Stage I (2%), stage 
II (9%) and stage III (20%) patients were also present in this study.  
The median follow-up in our patient cohort was 26 months (range 0.5 - 87 months). Overall- and 
disease-free survival at 2 years were 71,2% (95% CI 65.3-77.1) and 64.2 % (95% CI 59.2-69.3), 
respectively. Local, regional and distant control rates at 2 years were 84,1% (95% CI 79.1-89.2), 89.2% 
(95% CI 84.3-94.1) and 83.2% (95% CI 76.3-90.1), respectively.  
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Figure 1. Patterns of failure (first failure only) in the patient cohort of the study 
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Table 2. Demographics of patients with regional recurrence inside elective field. 
Seventy-one patients developed a recurrence. Twenty-eight were regional recurrences (of which 12 
isolated regional recurrences), 9 locoregional recurrences, 5 regional and distant recurrences and 2 
patients had a combined regional/local/distant recurrence (Figure 1). All regional recurrences could be 
reconstructed and projected on the initial RT planning CT scans. Fourteen of these patients had a 
recurrence within the high dose volume (14 of 28). Nine had a recurrence in the electively irradiated 
lymph node regions (9 of 28). The demographics of these 9 patients are listed in Table 2. Only one of 
these 9 had an isolated regional recurrence. Two recurrences in the elective nodal volume, occurred 
in patients who underwent an upfront neck dissection. Both recurrences occurred in the contralateral 
neck. 
 
 
 Sex, age, 
location, p16 
status 
Stage Failure 
type 
Initial 
pathological 
lymph nodes 
Regional 
recurrence 
Treatment 
1 Male, 53 years 
old, hypopharynx 
T4aN2b T + N II, III, IV 
ipsilateral 
II, III 
contralateral 
No treatment 
2 Male, 68 years 
old, oral cavity 
T3N2c N + M III, IV 
ipsilateral; 
II contralateral 
II 
contralateral 
Palliative 
chemotherapy 
3 
 
Female, 71 years 
old, oropharynx, 
unknown HPV 
status 
T3N2b T + N II ipsilateral Retropharyn
geal node 
ipsilateral 
Surgical ressection 
4 
 
Male, 43 years 
old, oropharynx, 
HPV negative 
T2N2b N II ipsilateral II, III 
contralateral 
Lymph node dissection 
 
5 Male, 86 years 
old, oral cavity 
T2N1 N + M I ipsilateral I, III 
ipsilateral 
No treatment 
6 Male, 55 years 
old, oropharynx, 
HPV negative 
T4aN2c T + N + 
M 
II-III bilateral II, IV 
ipsilateral 
Palliative 
chemotherapy 
7 
 
Male, 67 years 
old, hypopharynx 
T3N2b N + M II, III, IV, V 
ipsilateral 
 
III 
contralateral 
Palliative 
chemotherapy 
8 
 
Female, 59 years 
old, oropharynx, 
HPV negative 
T3N2c T + N Ib, II, III, IV 
ipsilateral; 
Ib, II, III, IV 
contralateral 
II, III, IV 
ipsilateral 
Palliative 
chemotherapy 
9 
 
Male, 62 years 
old, oropharynx, 
HPV negative 
T2N0 T + N None II, III 
ipsilateral 
Lymph node dissection 
 
   
 
82 
 
Five recurrences occurred outside the target volume (5 of 28). The characteristics of these 5 patients 
are listed in Table 3. We observed 1 recurrence in level VI, 2 intraparotid recurrences, 1 in level I and 
1 retropharyngeal lymph node recurrence.  One of these 5 patients with a regional recurrence outside 
the target volume was included in the AD-arm in a region of the neck that would have been irradiated 
in the C-arm; salvage neck dissection was successfully performed in this patient 
Table 3. Demographics of patients with regional recurrence outside elective field. 
 
The actuarial rate of recurrence in the electively irradiated lymph node regions was 3.9% (95% CI 1.8-
6.0) at 2 years. No significant associations could be observed between recurrence in electively 
irradiated lymph node regions and age, gender, tumor site, stage, or the presence of human 
papillomavirus in oropharyngeal cancers (Table 1). 
Discussion 
RT for HNC has significantly changed over the past decades. We hypothesize that, thanks to more 
accurate nodal staging, more precise treatment planning and delivery and the improved outcome using 
both concurrent chemotherapy and altered fractionation schedules, lower doses may be sufficient. 
The purpose of this study was therefore to investigate the patterns of regional recurrence, and more 
specifically recurrences in the elective regions, following dose de-escalation to an EQD2Gy of 40Gy to 
 Sex, age, 
location, p16 
status 
Stage Failure 
type 
Initial 
pathological 
lymph nodes 
Regional 
recurrence 
Treatment 
1 Female, 46 
years old, 
oropharynx, 
HPV negative 
T4aN2b N II-III 
ipsilateral 
VI 
 
Lymph 
node 
dissection 
2 Female, 60 
years old, 
hypopharynx 
T2N2b T + N II ipsilateral Intraparotid 
lymph node 
ipsilateral 
No 
treatment 
3 
 
Male, 59 years 
old, larynx 
T2N2c T + N II, III, IV, V 
ipsilateral 
II 
contralateral 
Intraparotid 
lymph node 
ipsilateral 
No 
treatment 
4 
 
Female, 76 
years old, 
hypopharynx 
T2N2b N + M II, IV 
ipsilateral 
Retropharyn
geal node 
ipsilateral 
Surgical 
ressection 
5 Female, 63 
years old, 
oropharynx, 
HPV negative 
T2N0 N None IB ipsilateral Lymph 
node 
dissection 
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the elective lymph nodes in head and neck cancer. Unlike other studies [18, 19] our focus was not 
whether the recurrence was in-field, marginal or out-field, but to decide whether the nodal recurrence 
was in the elective field. A patient cohort of 233 patients was analysed; this number of patients is 
comparable to a recent publication that analysed the pattern of nodal recurrence in head and neck 
cancer patients following a dose of 50Gy to the elective nodal volume (n=264)  [20].  
The exact sites of all regional recurrences were projected on the initial RT planning CT scan by 
performing rigid or deformable coregistration with the CT scan acquired to diagnose the recurrence. 
The actuarial rate of recurrence in the electively irradiated lymph node regions in our patient 
population was 3.9% (95% CI 1.8-6.0) at 2 years. There is extensive data on the rate of recurrences in 
the elective nodal volume following a dose of 50Gy (EQD2Gy) [20-28]. Observed rates of recurrence in 
electively irradiated lymph node regions varied from 2% to 11%. Our results are thus comparable to 
literature following 50Gy (EQD2Gy), and more importantly are in line with the latest studies [20, 28]. 
Two recurrences in the elective nodal volume occurred in patients who underwent an upfront neck 
dissection. Both recurrences occurred in the contralateral neck. 
Additionally we looked if we could find patient or treatment factors related to recurrences in the 
elective nodal volume, however we were not able to find significant correlations. This is in line with 
the study of van den Bosch et al, where age, gender, tumor site, stage, T classification, N classification 
and HPV status were not significantly associated with recurrences in the elective nodal field following 
irradiation of 50Gy (EQD2Gy) to the elective lymph nodes [20].  
We only found 5 recurrences outside the elective volume: 2 recurrences were located in an ipsilateral 
intraparotid lymph node. Furthermore, we found 1 recurrence in level VI, 1 in level IB and 1 in the 
retropharyngeal lymph nodes. These results confirm previous observations that recurrences in the 
retropharyngeal lymph nodes and in level IB are rare [28].  
It could be hypothesized that lowering the dose for subclinical disease could result in less control and 
thereby in higher numbers of distant metastases [29]. In this study we observed a 2 year distant control 
of 83.2% (95% CI 76.3-90.1). This is comparable to recent literature following a dose of 50 Gy [20, 28]. 
This is reassuring with respect to the possibility to enhance occurrence of distant metastases when 
lowering the dose to the elective neck. The rate of distant metastases is thereby in the range of 
locoregional failure.  
The present study has limitations. Although we had a relatively large patient population, the number 
of recurrences in the elective nodal volume was very small. Therefore we might have not been able to 
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identify predictors of recurrence in the present study. Furthermore, 34 patients underwent pre-IMRT 
neck dissection.   
However, this is the first paper that analyses regional recurrences following 40 Gy (EQD2Gy) based on 
data gathered prospectively in multicentric trials. We hereby demonstrate that dose de-escalation in 
elective lymph node regions to 40 Gy (EQD2Gy) results in recurrence rates that seem to be similar to 
the 50 Gy treated neck.  
In conclusion, we want to advocate the further use of 40 Gy (EQD2Gy) to the elective lymph nodes in 
future clinical study protocols, since we demonstrated that this is a safe treatment approach that 
deserves further exploration. In previous studies we demonstrated the benefit of dose de-escalation 
in terms of quality of life and acute and late toxicity. With this paper we demonstrated the safety in 
terms of oncological outcome in a larger patient population and demonstrated that these results are 
comparable to the results in literature following 50Gy (EQD2Gy). 
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Supplementary material. Guidelines for elective neck treatment for head and neck cancer in the 
experimental- and control- arm based on theoretical risk of lymph node metastases. 
 
Level N-stage experimental-arm control-arm 
Oral cavity 
I  Bilateral Bilateral 
II  Bilateral Bilateral 
III N0 Not included in CTV Not included in CTV (Ghent) vs. bilateral 
(Leuven) 
 N+ Ipsilateral if N+ in II or lip cancer Ipsilateral (Ghent) vs. bilateral (Leuven) 
IV N0 Not included in CTV Not included in CTV (Ghent) vs. bilateral 
(Leuven) 
 N+ Ipsilateral if N+ in III Ipsilateral (Ghent) vs. bilateral (Leuven) 
V  Not included in CTV Not included in CTV 
Rt  Not included in CTV Not included in CTV 
Oropharynx 
Ib N0 Not included in CTV Not included in CTV 
 N+ Ipsilateral Ipsilateral 
Ia  Not included in CTV Included if N+ in Ib (Ghent) vs. not 
included (Leuven) 
II  Bilateral Bilateral 
III  Bilateral Bilateral 
IV N0 Not included in CTV Ipsilateral (Ghent) vs. bilateral (Leuven) 
 N+ Ipsilateral or bilateral if cancer of the posterior 
pharyngeal wall 
Bilateral 
V N0 Not included in CTV Not included in CTV 
 N+ Not included in CTV Ipsilateral 
Rt N0 Included if cancer of the posterior pharyngeal wall Included if cancer of the posterior 
pharyngeal wall 
 N+ Included if cancer of the posterior pharyngeal wall 
or soft palate 
Included 
Hypopharynx 
Ib N0 Not included in CTV Not included in CTV 
 N+ Not included in CTV Ipsilateral 
Ia  Not included in CTV Included if N+ in Ib (Ghent) vs. not 
included (Leuven) 
II  Bilateral Bilateral 
III  Bilateral Bilateral 
IV N0 Not included in CTV Ipsilateral (Ghent) vs. bilateral (Leuven) 
 N+ Ipsilateral Bilateral 
V N0 Not included in CTV Not included in CTV 
 N+ Ipsilateral Ipsilateral 
VI  Not included in CTV Not included (Ghent) vs. included if 
esophageal extension (Leuven) 
Rt N0 Not included in CTV Not included in CTV 
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 N+ Not included in CTV Included 
Larynx 
Ib N0 Not included in CTV Not included in CTV 
 N+ Not included in CTV Ipsilateral if N+ in II or III 
Ia  Not included in CTV Included if N+ in Ib (Ghent) vs. not 
included (Leuven) 
II  Bilateral Bilateral 
III  Bilateral Bilateral 
IV  Bilateral Bilateral 
V N0 Not included in CTV Not included in CTV 
 N+ Not included in CTV Ipsilateral 
VI  Included if cancer of the subglottis Included if trans/subglottic cancer or T4 
Rt N0 Not included in CTV Not included in CTV 
 N+ Not included in CTV Included if supraglottic cancer 
Abbreviations 
CTV = clinical target volume of the elective neck 
N+ = metastatic lymph node(s) found at another level than the one under consideration 
Rt = bilateral retropharyngeal lymph nodes 
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Chapter 5 
CT-BASED FOLLOW-UP OF THE NECK AFTER RADIOTHERAPY FOR 
HEAD AND NECK CANCER. 
 
 
 
 
 
 
 
 
 
 
 
 
Elements in this chapter are published as: 
Nevens D, Vantomme O, Laenen A,  Hermans R, Nuyts S. A CT-based prognostic model after 
radiotherapy for locoregionally advanced head and neck cancer. Br J Radiol. 2016 
Dec;89(1068):20160492. 
 
Elements in this chapter are resubmitted to Cancer Imaging after minor revision: 
Nevens D, Vantomme O, Laenen A,  Hermans R, Nuyts S. The prognostic value of location and size 
change of pathological lymph nodes evaluated on CT-scan following radiotherapy in head and neck 
cancer. 
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A CT-based prognostic model after radiotherapy for locoregionally advanced head and neck cancer. 
 
Objective(s) 
The purpose of this study is to make a prognostic model for regional relapse in head and neck cancer 
using clinical and Computed Tomography (CT) parameters.  
Methods 
183 patients with lymph node-positive head and neck cancer were treated between 2002 and 2012 
with radiotherapy or concurrent chemoradiotherapy. CT studies pre- and post-treatment were 
reviewed for lymph node size and presence of necrosis, extracapsular spread and calcifications. For 
every patient, correlations with 3 year regional control (RC), metastasis free survival (MFS), disease 
free survival (DFS) and overall survival (OS) were made.  
Results  
3-year outcome rates were as follows: LC of 84%, RC of 80%, MFS of 74%, DFS of 61%, OS of 63%. Pre-
treatment nodal size and presence of necrosis were associated with a poorer outcome.  This was also 
the case for post-treatment lymph node size, the presence of necrosis and extracapsular spread. We 
developed a CT-based prognostic model for regional control with an area under the curve of 0.78 (95% 
Confidence Interval 0.63;0.85). 
Conclusions  
We reached a good outcome in our patient cohort using a CT-based follow-up approach.  A CT-based 
model was developed which can aid in predicting regional control. 
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Introduction 
Head and neck cancer encompasses a large number of tumor entities originating from subsites such as 
the nasal cavity, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx and salivary glands. The 
majority of these tumors are squamous cell carcinoma [1]. Head and neck cancer is the fifth most 
common cancer worldwide. In the United States about 55070 new cases were estimated for the year 
2014  [2].  
Approximately 60 to 80% of patients present with locoregionally advanced disease at the time of 
diagnosis.  Radio(chemo)therapy has become the standard of care for this subset of patients [3,4]. 
Overall survival (OS) after radio(chemo)therapy ranges between 50 to 60% after 5 years of follow up. 
Local and/or regional recurrence (LR, RR) is the most frequent form of therapy failure after 
radio(chemo)therapy, while failure due to metastasis is much less common. [5,6] Close follow-up of 
the neck after radio(chemo)therapy in this patient group is therefore very important. At our center the 
need for neck dissection after radiotherapy is determined based on the nodal response on the post-
radiotherapy Computed Tomography (CT) study 4 months after radiotherapy.  Only patients who show 
suspicion of residual disease undergo a subsequent salvage neck dissection.  Due to the increased risk 
of potentially severe postoperative complications such as wound infection, fistulae, skin flap necrosis, 
pneumonia and pulmonary embolism, we aim to limit the amount of unnecessary neck dissection [7,8].  
Moreover, surgery exacerbates chronic effects of radiation such as subdermal fibrosis, neck stiffness 
and shoulder dysfunction [9]. 
Management of the neck following radiotherapy or radio(chemo)therapy has evolved over the past 
decades and has been a field of debate. Traditionally, patients with advanced neck disease underwent 
planned neck dissection after radiotherapy [7]. In the 1990s, however several institutes demonstrated 
low rates of neck failure in patients who had complete clinical response by physical examination and 
were not submitted to neck dissection [10,11]. Nowadays considerable variability exists in the follow-
up of head and neck cancer. Both CT and PET studies are being used for response evaluation [12,13, 
14]. Data on the use of CT are however scarce. The aim of this study is to report the outcome of a CT-
based follow-up of the neck after radiotherapy or radiochemotherapy  for head and neck cancer and 
to investigate whether a prognostic model can be made to determine the risk of RR for every individual 
patient.  
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Methods and Materials 
 
Table 1. Patient and Treatment Characteristics. 
Between January 2002 and December 2012, 183 consecutive patients with nodal positive squamous 
cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx were treated with 
radio(chemo)therapy or radiotherapy. In- and exclusion criteria are specified in fig. 1. Patients were 
included by review of patient files. The patients were assessed clinically weekly during and after 
treatment until acute side-effects regressed and every 2 months for the first 2 years, every 3 months 
for the 3th year, every 4 months for the 4th, every 6 months the 5th year and then yearly. 
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Follow-up with CT study was carried out 4 months after completion of radiotherapy in all patients. 
Only those with suspicion of residual neck disease underwent subsequent neck dissection. In equivocal 
cases follow up CT studies were carried out, omitting a neck dissection in non-evolving situations. 
The primary endpoint of this study is 3 year RR. Secondary endpoints are 3 year local control (LC), 
metastasis-free survival (MFS), OS and disease-free survival (DFS). 
CT-studies prior and after radio(chemo)therapy were reviewed for all included patients. All CT studies 
were performed using multidetector spiral CT. An iodinated contrast agent was injected in most 
patients; 100 ml at a rate of 1-1.5 ml/sec. Scanning was started 80-100 sec after the start of the 
contrast agent injection. The native CT-images were acquired with a slice thickness of 0.6-0.75 mm, 
and reformatted for display with a slice thickness of 3 mm. 
All CT studies were analyzed by a single observer under the supervision of both a radiologist and 
radiation oncologist specialized in head and neck cancer. Volumes and diameters of the the lymph 
nodes were calculated using the Impax Volume Viewing 3D software from Agfa Healthcare.  
We scored nodal volume, largest axial diameter, necrosis, extracapsular spread (ECS) and the presence 
of calcifications in all pathological lymph nodes in our patient population both, on the pre- and post-
treatment CT study. The scoring of the CT images was done blinded to patient outcome and blinded to 
follow-up imaging. 
Description of the time-to-event outcomes (LC, MFS, DFS, OS) of the patient cohort was based on 
Kaplan-Meier estimates. Predictors for time-to-event outcomes were analyzed by Cox regression 
models, and results presented as hazard ratios (HR) with 95% confidence intervals. Predictors for 
binary outcomes (RR) were analyzed by logistic regression models, and results presented as odds ratios 
(OR) with 95% confidence intervals. Analyses have been performed using SAS software (version 9.4 of 
the SAS System for Windows). 
We correlated age, gender, tumor (T) and nodal (N) stage, HPV status and localization of the tumor 
with the different outcome parameters. For every patient, the total nodal volume of all lymph nodes, 
the largest axial diameter, the presence of necrosis and extracapsular spread was correlated with 
clinical outcome.  
In order to further investigate the prognostic significance of the presence of necrosis before or after 
treatment, patients were assigned to 4 groups: 1. no necrosis on the pre- and post- CT study  , 2. 
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necrosis on the pre-treatment study only, 3. necrosis post-treatment only, 4. necrosis on both the pre- 
and post-treatment study. Pairwise comparisons between these groups were made. 
A stepwise selection procedure was followed to construct a multivariable prediction model for regional 
relapse within 3 years.  The area under the ROC curve (AUC) was determined for the selected model. 
Additionally a bootstrap-corrected AUC value was calculated. This AUC value corrects for over 
optimism resulting from the fact that model construction and model validation were performed on the 
same data set.  
For all patients with oropharyngeal tumors; Formalin-Fixed, Paraffin-Embedded (FFPE) tissue was 
obtained for HPV-status determination. HPV testing was performed using p16 immunohistochemistry 
(IHC) followed by HPV-Polymerase Chain reaction (PCR). A tumor was regarded as HPV related when 
both p16 IHC as well as HPV-PCR were positive. Sections were scored as p16 positive when clear p16 
immunoreactivity was seen in at least 50% of cells.  
Results 
I. Patient/treatment characteristics and outcome 
We included 183 head and neck cancer patients (fig. 1). Patient and treatment characteristics are 
presented in table 1. Median follow-up was 5.04 years. 
We report the following 3-year outcome rates: LC of 84% (95% CI 77-88%), RC of 80% (95% CI 73-86%) 
MFS of 74% (95% CI 66-80%), DFS of 61% (95% CI 53-67%), OS of 63% (95% CI 56-70%).  
A higher T stage was statistically significant associated with a poorer LC (HR 1.570, p = 0.0316), RC at 2 
years (Odds Ratio (OR) 1.725, p = 0.0346), DFS (HR 1.543, p = 0.0016) and OS (HR 1.364, p = 0.0111). 
This was borderline significant for MFS (HR 1.402, p = 0.0523). Higher N stage was associated with a 
higher risk for local relapse (HR 1.438, p = 0.0355). Age, gender, HPV status and localization of primary 
tumor site could not be withheld as useful predictors for outcome. 
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 N 
n=183 
% 
Primary tumor site 
Oral cavity 30 16 
Oropharynx 
HPV + 
HPV – 
Unknown 
122 
20 
92 
10 
67 
 
Hypopharynx 25 14 
Larynx 6 3 
T classification* 
T1 8 4 
T2 47 26 
T3 51 28 
T4 76 42 
N classification 
1 32 17 
2 142 78 
2a 7 4 
2b 63 34 
2c 72 39 
3 9 5 
Radiation therapy 
3D CRT 84 46 
IMRT 99 54 
Systemic therapy 
None 35 19 
Cisplatin 118 64 
carboplatin/5-FU 2 1 
Cetuximab 11 6 
Panitumumab 8 4 
Cisplatin + 
tirapazamine 
8 4 
Cisplatin 
+zalutumumab 
1 1 
Abbreviations: 3D CRT = three-dimensional conformal radiation therapy; IMRT =  intensity-modulated 
radiation therapy; 5-FU = 5-fluoro-uracil; CT study = computed tomography study. * 1 patient had 4 
synchronous head and neck malignancies and was not included in the T-classification statistics. 
Table 1. Patient and Treatment Characteristics. 
 
II. Results of the analysis of CT data  
a. Pre-treatment CT study 
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On the pre-treatment CT study 37 patients had ECS (20.2%), 123 patients had necrosis (67.2%) and 
3 patients had calcifications (1.6%).  A trend was observed towards more RR when lymph node 
necrosis was present pretreatment (Odds Ratio (OR) 2.4, p=0.08). The pre-treatment presence of 
necrosis was furthermore significantly associated with a higher risk for distant metastasis (HR 2.29, 
p = 0.03). On the other hand, a higher total sum of nodal volume was associated with a poorer DFS 
(HR 1.01, p = 0.01). There was no impact of maximal nodal axial diameter, nor the presence of 
calcifications or ECS on outcome. Sensitivity, specificity, PPV and NPV of the presence of necrosis 
and ECS for RR are presented in table 2. This was not conducted for the presence of calcifications 
because there was only 1 case in the analyzed subset of patients with calcifications present 
pretreatment. 
b. Post-treatment CT study 
On the post-treatment CT study 18 patients had ECS (10.7%), 53 patients had necrosis (31.6%) and 
21 patients had calcifications (12.5%). Post-treatment all pre-defined characteristics (ECS, necrosis, 
larger diameter and larger volume) except the presence of calcifications were significantly 
associated with poor outcome (table 3).  Calcifications post-treatment are thus correlated with 
better outcome. Sensitivity, specificity, PPV and NPV for the influence of necrosis, ECS and 
calcifications on RR are presented in table 2.  
 RR pre CRT RR post CRT 
Sensitivity (%) 
Necrosis 81 65 
ECS 16 23 
Absence of calcifications  90 
Specificity (%) 
Necrosis 36 77 
ECS 81 92 
Absence of calcifications  14 
PPV (%) 
Necrosis 33 53 
ECS 24 54 
Absence of calcifications  30 
NPV (%) 
Necrosis 83 84 
ECS 72 75 
Absence of calcifications  79 
Abbreviations: CT = computed tomography; RR = regional recurrence;; CRT = chemoradiation; ECS = 
extracapsular spread; PPV = positive predictive value; NPV = negative predictive value. 
Table 2. Predictive value of CT characteristics for RR 
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Figure 2 
a. Nonlinear trend of sum of nodal volume in relation with risk of distant metastasis. The dots 
represent predictions for individual patients.  
b. Nonlinear trend of largest nodal diameter in relation with overall survival. A best cut-off for 
largest axial diameter of 31.8 mm was selected. The dots represent predictions for individual 
patients. 
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CT 
characteristic 
Outcome OR/HR (95% CI)  p-value 
∑ nodal volume  
RR  OR 1.262 (1.072;1.486) 0.0051 
MFS nonlinear trend  
DFS HR 1.051 (1.028;1.074) <0.0001 
OS HR 1.056 (1.035;1.078) <0.0001 
∑ nodal volume 
2cm³ vs 1cm³ 
MFS HR 1.152 (1.054;1.259) 0.0018 
Largest 
diameter 
 
RR  OR 1.108 (1.047;1.172) 0,0004 
MFS HR 1.043 (1.014;1.072) 0.0036 
DFS HR 1.059 (1.035;1.083) <0.0001 
OS nonlinear trend <0.0001 
Largest 
diameter > 31.8 
mm 
OS HR 5.764 
(2.851;11.651) 
<0.0001 
Necrosis  
RR  OR 5.960 
(2.410;14.738) 
0.0001 
MFS HR 2.203 (1.186;4.092) 0.0124 
DFS HR 2.668 (1.671;4.262) <0.0001 
OS HR 2.406 (1.529;3.785) 0.0001 
Calcifications  
RR  OR 0.643 (0.167;2.483) 0.5189 
MFS HR 0.950 (0.373;2.421) 0.9143 
DFS HR 0.843 (0.404;1.759) 0.6494 
OS HR 0.863 (0.430;1.729) 0.6772 
ECS  
RR OR 3.451 
(1.056;11.283) 
0.0404 
MFS HR 2.482 (1.144;5.385) 0.0214 
DFS HR 2.343 (1.275;4.303) 0.0061 
OS HR 1.800 (0.971;3.337) 0.0620 
Abbreviations: CT = computed tomography; OR = odds ratio; HR = hazard ratio; CI = confidence 
interval; ∑ = sum; RR = regional recurrence; MFS = metastasis-free survival; DFS = disease-free 
survival; OS = overall survival; ECS = extracapsular spread. 
Table 3. Predictive value of post-treatment CT characteristics for outcome 
 
c. Presence of necrosis pre- versus post-treatment  
The sum of nodal volumes showed a nonlinear trend in relation to the risk for distant metastasis (fig. 
2a). Concerning OS, a nonlinear trend was observed for maximal nodal diameter (fig. 2b). Among all 
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possible cut-off values for dichotomizing maximal nodal diameter, the value of 31.88 mm provided the 
best model fit. 
The risk for RR significantly increased in patients with post-treatment necrosis only compared to 
patients without necrosis (OR 13.50, p=0.01), and for patients with pre- and post-treatment necrosis 
compared to those with pre-treatment necrosis only (OR 7.52, p=0.01). 
d. Development of a model to predict regional recurrence 
Based on our results we developed a multivariable model for RR prediction. After performing a 
stepwise selection procedure pre-treatment T stage (p=0.02), post-treatment necrosis (p=0.03) and 
largest diameter (p=0.01) were included in the model. The AUC of this model was 0.78 (95% CI 
0.633;0.845); the bootstrap-corrected AUC was 0.74 (95% CI 0.667; 0.889). The risk for RR within three 
years can be calculated using following formula: 
𝑅𝑅 (%) =  
𝑒𝜇
1 + 𝑒𝜇
 
𝜇 =  0.085 ∗ 𝑙𝑎𝑟𝑔𝑒𝑠𝑡 𝑎𝑥𝑖𝑎𝑙 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 (𝑚𝑚) + 0.6749 ∗ (𝑇 𝑠𝑡𝑎𝑔𝑒)  −  4.8482 
+ (𝑜𝑛𝑙𝑦 𝑤ℎ𝑒𝑛 𝑛𝑒𝑐𝑟𝑜𝑠𝑖𝑠) 1.1384  
Discussion 
The role of planned neck dissection after radio(chemo)therapy for locoregionally advanced head and 
neck cancer has weakened over the past decade but is still a matter of debate. Data from mostly 
retrospective series support a conservative approach with ND only carried out in those patients with 
residual disease on a clinical or radiological basis [12, 15-20]. Some centers still perform planned neck 
dissection in all patients with N2 or N3 disease, irrespective of their response to initial treatment [21]. 
Robust data from randomized trials addressing this issue are lacking. In our center we advocate a 
conservative approach, thereby avoiding neck dissection and its complications in a large amount of 
patients. Outcome in our patient cohort is comparable to that described by other authors. Liauw et al. 
described a 5 year RC and OS of 84% and 45% respectively in a group of 209 patients treated by 
radio(chemo)therapy without neck dissection. Clavel et al. reported a 3 year RC and OS of 91% and 
83% respectively in 369 patients treated with radio(chemo)therapy and subsequent neck dissection in 
96 patients [17,18]. 
The value of the pre-radiotherapy CT parameters is disputable. In our dataset we could only confirm a 
negative relation between the presence of necrosis and MFS, and between total nodal volume and 
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DFS. Moreover we correlated clinical parameters with outcome. A higher T stage was statistically 
significant associated with a poorer outcome.   
In the post-treatment setting, scoring nodal CT characteristics does have prognostic significance. We 
confirmed the value of necrosis and ECS, as well as measuring lymph node diameter and total nodal 
volume on CT studies after radio(chemo)therapy. Within the range of the majority of the observations, 
a higher lymph node volume leads to a higher risk for all outcome parameters.  Due to a striking non-
linear trend of largest nodal axial diameter for OS, the variable was dichotomized leading to a cut-off 
at 31.88 mm, above which OS is compromised more importantly. A linear trend was observed for the 
relation between nodal diameter and the other outcome parameters. Regarding MFS, a nonlinear 
trend was observed for the sum of nodal volumes in relation with the occurrence of distant metastasis. 
This nonlinear trend was induced by a small number of outlying values though. In the lower range, 
were the majority of observations lie, a linear relationship was seen.   
We investigated the presence of pre- and post-treatment necrosis further to see at which moment this 
parameter was the most predictive for RR. Patients with newly formed necrosis have a higher risk for 
RR than patients without or with pre-existing necrosis. The  presence of the necrosis might suggest 
more hypoxic nodal disease and might prevent delivery of chemotherapy and reduce the effectiveness 
of radiotherapy. 
Using the results of our study, a model was constructed to estimate the risk for RR in a given patient. 
This model reached a good AUC of 0.78. Because creation and validation of the model was done in the 
same data set, we also calculated a corrected AUC; this was 0.74. This corrected value gives an honest 
estimate of the predictive accuracy of the model when applied to an independent patient. For 
example, using our model, a patient with a T4 tumor without necrotic pathological lymph nodes and 
largest nodal axial diameter 12,1 mm would have a risk of 24.61% for developing a RR within 3 years. 
To our knowledge, no other model using clinical parameters and parameters obtained from a CT study 
or other imaging modalities was proposed in other papers so far. 
An extensive discussion of the role of other imaging modalities of the neck after radio(chemo)therapy 
such as ultrasound, PET-CT, and MRI is beyond the scope of this article, but each of those are believed 
to be useful in assessing response and the need for salvage neck dissection. Ultrasound (US), in 
combination with fine-needle aspiration cytology (FNAC), is an inexpensive and readily available tool. 
Yom et al. described a NPV of 95% for US-FNAC [22,23]. Data on the role of post-treatment PET-CT are 
emerging rapidly, and results are promising. Loo et al. described a NPV of 100 % for PET-CT obtained 3 
months after completion of radiotherapy [15]. This was further investigated in a multi-center study 
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(PET-NECK), which recruited 564 patients with N2 or N3 head and neck cancer treated with 
radio(chemo)therapy and randomized between routine neck dissection and a wait and see approach 
if PET-CT 9-13 weeks after treatment shows no abnormal FDG-uptake in the neck [13]. This study 
reports similar results in patients who underwent PET-CT-guided surveillance and those who 
underwent planned neck dissection but surveillance resulted in fewer operations and was more cost-
effective. In the last few years advances in MRI, with development of diffusion-weighted MR (DW-MRI) 
and dynamic contrast-enhanced MRI, have provided additional information. Recently, Vandecaveye et 
al. evaluated response after radiotherapy in 29 patients with DW-MRI at three weeks after completion 
of treatment. He reported a NPV of 96% for adenopathies per neck side, and a sensitivity of 78% of 
DW-MRI versus 67% for conventional MRI for detecting subcentimeter lymph node metastasis [24]. 
We can conclude that CT is at least of equivalent value in the assessment of the neck after 
radio(chemo)therapy. Moreover, CT is more accessible than PET-CT and DW-MRI, and has been widely 
used for many years in this setting.    
This was a monocentric retrospective study, with its inherent limitations. However, we made sure to 
have sufficient follow-up of every patient in order have firm reliable data. The strength of this study 
lies in the large number of analyzed data and the fact that all measurements were performed by the 
same observer, with cooperation of both a radiation oncologist and radiologist specialized in head and 
neck cancer. This study can therefore be a first step in designing a prospective trial addressing the 
management of the neck post radio(chemo)therapy and validating the proposed model for RR 
prediction. 
Conclusions 
Our data confirm that in a group of patients with locoregionally advanced head and neck cancer, good 
disease control in the neck can be obtained with radio(chemo)therapy without subsequent planned 
neck dissection. Furthermore, we propose a multivariable model to calculate the risk of a regional 
relapse with an AUC of 0.78 based on T stage before therapy and post-treatment presence of necrosis 
and largest nodal diameter. 
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The prognostic value of location and size change of pathological lymph nodes evaluated on CT-scan 
following radiotherapy in head and neck cancer. 
Background 
 Overall survival after chemo-radiotherapy ( CRT ) for head and neck cancer ranges between 50 to 60% 
after 5 year of follow-up. Local and/or regional recurrence is the most frequent form of therapy failure. 
The aim of this study is to investigate whether the initial location and size change of pathological lymph 
nodes as evaluated on Computed Tomography ( CT ) studies can help predict outcome. 
Methods 
183 patients with lymph node-positive head and neck cancer were treated with radiotherapy ( RT ) or 
CRT. CT studies pre- and post-treatment were reviewed for lymph node size and location. Data were 
correlated with local control, regional control, metastasis free survival, disease free survival and overall 
survival. 
Results  
Regarding the risk for distant metastasis, a significant influence was seen for the location of the 
pathological lymph nodes. The metastatic risk increases when levels IV-V are affected rather than 
levels I-III. A similar observation is seen for levels VI-VII. Regional control improves with decreasing 
lymph node diameter and volume as evaluated on CT. 
Conclusion 
Both location and size change of pathological lymph nodes are of prognostic value after CRT for head 
and neck cancer.  
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Introduction 
Head and neck cancer encompasses a large number of tumor entities originating from subsites such as 
the nasal cavity, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx and salivary glands. The 
majority of these tumors are squamous cell carcinoma [1]. Head and neck cancer is the fifth most 
common cancer worldwide. In the United States about 55070 new cases were estimated for the year 
2014  [2].  
Approximately 60 to 80% of patients present with locoregionally advanced disease at time of diagnosis. 
Concurrent radiation therapy ( RT ) and chemotherapy has become the standard of care for this subset 
of patients [3,4]. Overall survival after chemo-radiotherapy ( CRT ) ranges between 50 to 60% after 5 
year of follow up. Local and/or regional recurrence is the most frequent form of therapy failure after 
CRT, while failure due to metastasis is much less common [5,6]. Close follow-up of the neck after CRT 
in this patient group is therefore very important. There is a wide variability regarding the decision for 
salvage neck dissection as well as post-treatment surveillance imaging. 
The aim of this study is to investigate whether the initial location of the pathological lymph nodes and 
size changes after treatment evaluated using CT studies can help predict outcome and can help us in 
selecting patients who might benefit from a closer follow-up with more frequent radiological 
examinations.  
 
 
 
 
 
 
 
 
 
 
   
 
107 
 
Materials and methods 
Patients 
 N 
n=183 
% 
Primary tumor site 
Oral cavity 30 16 
Oropharynx 
HPV + 
HPV – 
Unknown 
122 
20 
92 
10 
67 
 
Hypopharynx 25 14 
Larynx 6 3 
T classification* 
T1 8 4 
T2 47 26 
T3 51 28 
T4 76 42 
N classification 
1 32 17 
2 142 78 
2a 7 4 
2b 63 34 
2c 72 39 
3 9 5 
Radiation therapy 
3D CRT 84 46 
IMRT 99 54 
Systemic therapy 
None 35 19 
Cisplatin 118 64 
Carboplatin/5-FU 2 1 
Cetuximab 11 6 
Panitumumab 8 4 
Cisplatin + 
tirapazamine 
8 4 
Cisplatin 
+zalutumumab 
1 1 
 
Table 1. Patient and Treatment Characteristics 
Abbreviations: 3D CRT = three-dimensional conformal radiation therapy; IMRT =  intensity-modulated 
radiation therapy; 5-FU = 5-fluoro-uracil; HPV=Human papilloma virus. 
* 1 patient had 4 synchronous head and neck malignancies and was not included in the T-
classification statistics. 
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Between January 2002 and December 2012, 539 patients with invasive head and neck squamous cell 
carcinoma were treated with (C)RT at our centre. After the exclusion of patients with in situ cancer, 
metastasized disease or N0 disease at time of diagnosis, unknown primary tumors, nasopharyngeal or 
sinonasal primaries, RT at another centre and neoadjuvant chemotherapy or upfront surgery before 
RT, we had a cohort of 183 patients for further analysis. 
All patients received external beam radiotherapy and were CT planned. The primary tumor and 
pathological lymph nodes were irradiated to doses ranging from 69.96 to 72 Gy. Mean overall 
treatment time was 43.4 days (range, 37-58 days). Most patients received concurrent cisplatin. A 
smaller group was treated with cetuximab or carboplatin/5-fluoro-uracil, or was included in a clinical 
trial and received alternative or additional therapeutic regimens. Patient and treatment characteristics 
are presented into more detail in table 1. For all patients with oropharyngeal tumors, formalin-fixed, 
paraffin-embedded tissue was centralized ( University Hospital of Leuven ) for Human papilloma virus 
( HPV )-status determination. HPV testing was performed using a previously validated algorithm using 
p16 immunohistochemistry followed by HPV-polymerase chain reaction ( PCR ). A tumor was regarded 
as HPV related when both p16 immunohistochemistry as well as HPV-PCR were positive. For p16 
immunohistochemistry a purified mouse anti-human p16 antibody (G175-405, BD Pharmigen) was 
used. Sections were scored as p16 positive when clear p16 immunoreactivity was seen in at least 50% 
of cells . 
CT studies were carried out before treatment and 4 months after the completion of treatment. If the 
CT scan was negative at 4 months, further follow-up was done by clinical examination. 
Analysis of the CT imaging data 
CT-scans prior and following CRT were reviewed for all included patients. All CT studies were 
performed using multidetector spiral CT. An iodinated contrast agent was injected in most patients; 
100 ml at a rate of 1-1.5 ml/sec. Scanning was started 80-100 sec after the start of the contrast agent 
injection. The native CT-images were acquired with a slice thickness of 0.6-0.75 mm, and reformatted 
for display with a slice thickness of 3 mm. 
All CT scans were analyzed by a single observer under the supervision of both a radiologist and a 
radiation oncologist specialized in head and neck cancer.  
To obtain volumes and diameters of the lymph nodes, every lymph node was contoured on each slide. 
Consecutively, volumes and diameters were calculated using the Impax Volume Viewing 3D software 
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from Agfa Healthcare. At patient level volumes were obtained by considering the sum of all 
pathological lymph nodes volumes in one patient. At nodal level individual pathological lymph nodes 
volumes were used. Lymph node levels were clustered (level I-III, IV-V and VI-VII) and compared 
pairwise. Furthermore, necrosis, calcifications and ECS was evaluated on all the CT studies. 
Statistical Analysis 
Description of the time-to-event outcome (LC ( local control ), RC ( regional control ), MFS ( metastasis 
free survival ), DFS ( disease free survival ), OS ( overall survival )) of the patient cohort was based on 
Kaplan-Meier estimates. The predictive power of localization and volume changes were analyzed by 
Cox regression models, and results presented as hazard ratios ( HR ) with 95% confidence intervals. 
Predictors for binary outcome were analyzed by logistic regression models, and results presented as 
odds ratios ( OR ) with 95% confidence intervals. Furthermore, a multivariate analysis was done to 
correct for T stage, N stage, pre-RT diameter, the presence of necrosis or calcifications within the 
pathological lymph nodes, HPV and ECS. 
Analyses at lymph node-level were based on generalized estimating equations ( GEE ) to account for 
clustering of lymph nodes within patients. Size changes of pathological lymph nodes are presented as 
percentage of change. A negative % indicates decrease, a positive % increase. Disappearing 
pathological lymph nodes after treatment were considered as a 100 % decrease of volume and 
diameter.  Analyses have been performed using SAS software (version 9.4 of the SAS System for 
Windows). 
Volume change was analyzed at patient level as well at individual nodal level. Data at patient level 
were correlated with RC, MFS, DFS and OS, with inclusion of disappearing pathological lymph nodes 
(100 % decrease of volume) after treatment. At individual nodal level data were correlated with 
individual lymph node relapse (LNR), and analyzed both with in- and exclusion of disappearing 
pathological lymph nodes. 
Change of largest axial diameter was analyzed on individual nodal level only, both with and without 
disappearing pathological lymph nodes after treatment. 
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Results 
I. Survival, disease control, CT characteristics 
We report the following 2-year outcome rates: LC 86% (95% Confidence Interval: 80-90%), RC 83% 
(95% Confidence Interval: 77-88%), MFS 77% (95% Confidence Interval: 70-83%), DFS 65% (95% 
Confidence Interval: 57-71%) and OS 70% (95% Confidence Interval: 63-77%). Median observed follow-
up was 5.04 years (Q1 3.48 years; Q3 7.04 years). For 116 patients we had at least 2 years of follow-
up.  
The pre- and post-CT study characteristics are presented in Table 2 a and b. 
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Variable Statistic All 
Sum-volume N 183 
Mean 18.4 
Std 31.21 
Median 9.7 
IQR (3.9; 19.9) 
Range (0.3; 257.3) 
Largest diameter N 183 
Mean 26.0 
Std 14.46 
Median 23.0 
IQR (17.0; 32.8) 
Range (2.6; 123.0) 
ECS 
No n/N (%) 146/183 ( 79.78%) 
Yes n/N (%) 37/183 ( 20.22%) 
Necrosis 
No n/N (%) 60/183 ( 32.79%) 
Yes n/N (%) 123/183 ( 67.21%) 
Calcifications 
No n/N (%) 180/183 ( 98.36%) 
Yes n/N (%) 3/183 (  1.64%) 
 
Table 2a. 
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Variable Statistic All 
Sum-volume N 168 
Mean 3.8 
Std 8.02 
Median 1.3 
IQR (0.7; 3.1) 
Range (0.1; 56.7) 
Largest diameter N 168 
Mean 15.2 
Std 9.19 
Median 12.5 
IQR (9.6; 16.8) 
Range (5.5; 55.8) 
ECS 
No n/N (%) 150/168 ( 89.29%) 
Yes n/N (%) 18/168 ( 10.71%) 
Necrosis 
No n/N (%) 115/168 ( 68.45%) 
Yes n/N (%) 53/168 ( 31.55%) 
Calcifications   
No n/N (%) 147/168 ( 87.50%) 
Yes n/N (%) 21/168 ( 12.50%) 
 
Table 2b. 
Table 2a and 2b. CT parameters on pre and post RT CT study. 
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II. Location 
The distribution of affected lymph node levels in our patient cohort is presented in fig. 1. Level II was 
most frequently affected. Regarding the risk for distant metastasis, a significant influence was seen for 
the location of the pathological lymph nodes. The metastatic risk increases when levels IV-V are 
affected rather than levels I-III. A similar observation is seen for levels VI-VII (table 3). On the other 
hand, no significant differences were found for RC or DFS. 
 
Table 3:  Impact of PLN localization on metastatic risk. 
levels levels Hazard Ratio (95 % CI) p-value 
univariate 
analysis 
p-value 
multivariate 
analysis* 
I-III IV-V 0.325 (0.165;0.639) 0.0011 0.0002 
IV-V VI-VII 0.461 (0.127;0.745) 0.0852 0.0302 
 
Hazard Ratio <1 (>1) means lower (higher) risk for lower levels.  
Abbreviations: CI = confidence interval; PLN = pathological lymph node. 
*Corrected for T stage, N stage, pre-radiotherapy diameter, necrosis, calcifications, extra-capsular 
spread and HPV. 
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Figure 1. Distribution of affected lymph node levels. 
III. Size change 
VOLUME 
At a patient level, following multivariate analysis, less decrease of total lymph node volume on a CT 
study was significantly associated with a higher risk for regional relapse (OR 1.039, p=0.003), distant 
metastasis (HR 1.006, p=0.0277) and poorer DFS (HR 1.01, p=<0.001) and OS (HR 1.006, p=0.0037). At 
nodal level, less decrease of volume of an individual lymph node was associated with a higher risk for 
LNR, both with in- (OR 1.015, p=0.0126) and exclusion (OR 1.009, p=0.033) of completely resoluting 
pathological lymph nodes.  
 
 
   
 
115 
 
LARGEST AXIAL DIAMETER 
 
 
Less decrease of largest axial diameter or an increase of diameter was correlated with a higher risk for 
LNR. Both with and without considering completely resoluting pathological lymph nodes, a nonlinear 
trend was observed for this relation (fig. 2 and 3). Hence, the OR associated with a 1% increase in 
diameter around the median value was conducted (table 4). 
 
 
 
 
 
 
 
 
 
OR > (<1) means higher (lower) risk for higher % of change. 
Abbreviations: LNR = lymph node relapse; CR PLN = completely resoluting pathological lymph node; 
ΔDmax = change in largest axial diameter ; CI = confidence interval.  *Corrected for , pre-
radiotherapy diameter, necrosis, calcifications and extra-capsular spread. 
Table 4. Predictive value of diameter change for lymph node relapse. 
 
 
Dmax Odds Ratio (95% CI) p-value* 
with CR PLN 
   
 
ΔDmax (nonlinear trend) 
 
<0.001 
 
ΔDmax (+1% ~ median) 1.012 (1.006;1.017) <0.001 
without CR PLN 
   
 
ΔDmax (nonlinear trend) 
 
0.0167 
 
ΔDmax (+1% ~ median) 1.009 (1.003;1.015) 0.0062 
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Figure 2. Nonlinear trend of diameter change in relation with risk of Lymph Node Relapse (LN 
Relapse) with inclusion of completely responding LN’s. The dots represent predictions for individual 
LN’s. 
 
 
Figure 3. Nonlinear trend of diameter change of diameter change in relation with risk of Lymph Node 
Relapse (LN Relapse) with exclusion of completely responding LN’s. The dots represent predictions 
for individual LN’s. 
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Discussion 
In an era where the role of planned neck dissection after CRT for locoregionally advanced head and 
neck cancer is diminishing [8,9,10], using prognostic information derived from the clinic and 
radiological examinations which can help predict treatment outcome and thereby the necessity of neck 
dissection, is gaining importance. The goal of this study is to situate the prognostic value of the location 
of pathological lymph nodes, as well as size change of pathological lymph nodes as evaluated on CT 
studies in the follow up after (C)RT. Data were conducted from a large patient cohort treated at our 
institute with (C)RT but without adjuvant neck dissection. As a result of this, data were correlated with 
clinical outcome, and not with pathology results from neck dissection. Therefore, we made sure to 
have sufficient follow-up for every patient. Multivariate analysis were done to correct for T stage, N 
stage, pre-RT diameter, necrosis, calcifications, HPV and ECS, since these factors are known to impact 
outcome [11-16]. 
To investigate the prognostic impact of the location of pathological lymph nodes, we analyzed the 
distribution of affected lymph node levels in our patient cohort, clustered adjacent levels and 
compared them to each other. As described for overall survival by Jones et al. in a large cohort of 947 
patients, one would expect a worse prognosis with pathological involvement of the lower neck [11]. 
We could establish a significant correlation between location and metastatic risk, without significant 
impact on the DFS. Involvement of level IV-V entails a higher risk to develop metastasis compared to 
level I-III. A similar, correlation was seen for involvement of level VI-VII compared to level IV-V; with a 
higher risk metastatic for involvement of level VI-VII. Presence of retropharyngeal lymph node 
metastasis (level VII), is known to be a risk factor for both regional and distant recurrence 
[12,13,14,15]. We could validate this result in our patient group for distant recurrence. Based on our 
data, and previous publications on this subject, we can state that involvement of the lower neck as 
evaluated on CT  studies pretreatment entails a higher metastatic risk and represents more aggressive 
and advanced disease.  
A second goal was to investigate the prognostic value of size change as evaluated on CT studies of 
pathological lymph nodes after (C)RT. Therefore we considered both volume and largest axial diameter 
change. The latter only at individual nodal level, given the fact that after treatment, determination of 
the largest axial diameter does not necessarily involve the same lymph node.  Volume change was both 
at patient and individual nodal level of significant prognostic value. The less pronounced the volume 
reduction, the poorer the RC, DFS, MFS, OS and, at individual nodal level, and the more  LNR. Due to 
linear relationships between volume change and outcome no clinically useful cut-off values could be 
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selected. 
At individual nodal level the analysis was done both in- and excluding completely responding lymph 
nodes. Including these lymph nodes yields a theoretical predictive prognostic effect of size change of 
pathological lymph nodes after treatment. Excluding them delivers us more clinically useful 
information about the predictive effect of the size change of a residual lymph node after treatment. In 
the clinic, disappeared pathological lymph nodes on post-treatment CT is considered obviously as a 
favorable prognostic sign. However, even after excluding disappearing pathological lymph nodes, the 
relationship between volume change and LNR remained significant. Our results are in concordance 
with the data published by Clavel et al. In patients with node-positive head and neck cancer, a 
significant effect of volume change after CRT was reported [16]. In the light of adaptive RT, volume 
change of tumor and pathological lymph nodes during treatment has been studied extensively. 
However, data on the prognostic value of volume change after but also during RT are scarce. Mishra 
et al. failed to find a correlation between nodal volume change during (C)RT and neck control in 38 
patients with locoregionally advanced head and neck cancer [17]. Besides volume change, also the 
impact of change of largest nodal axial diameter on LNR was considered. Our data revealed, both in- 
and excluding completely responding pathological lymph nodes, a significant correlation between 
diameter change and outcome.  
Because of this linear relationship no cut-off value could be selected. Clavel et al. described a negative 
predictive value (NPV) of 100 % for a diameter decrease of > 80%. Hamilton et al. and Ojiri et al. 
proposed a cutoff value of >50% with NPV’s of 94 and 100 % respectively [16,18,19].  An extensive 
discussion of the role of other imaging modalities of the neck after (C)RT such as ultrasound, PET-CT, 
and MRI is beyond the scope of this article, but each of those are believed to be useful in assessing 
response and the need for salvage neck dissection. Ultrasound (US), in combination with fine needle 
aspiration cytology (FNAC), is an inexpensive and readily available tool. Yom et al. described a NPV of 
95% for US-FNAC [20,21]. Data on the role of post-treatment PET-CT are emerging rapidly, and results 
are promising. Loo et al. described a NPV of 100 % for PET-CT obtained 3 months after completion of 
radiotherapy [22]. This was further investigated in a multi-center study (PET-NECK), which recruited 
564 patients with N2 or N3 head and neck cancer treated with CRT and randomized between routine 
ND and a wait and see approach if PET-CT 9-13 weeks after treatment shows no abnormal FDGuptake 
in the neck [23]. This study reports similar results in patients who underwent PET-CT-guided 
surveillance and those who underwent planned neck dissection, but surveillance resulted in fewer 
operations and was more cost-effective. In the last few years advances in MRI, with development of 
diffusionweighted MR ( DW-MRI ) and dynamic contrast-enhanced MRI, have provided additional 
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information. Recently, Vandecaveye et al. evaluated response after RT in 29 patients with DW-MRI at 
three weeks after completion of treatment. He reported a NPV of 96% for adenopathies per neck side, 
and a sensitivity of 78% of DW-MRI versus 67% for conventional MRI for detecting sub centimeter 
lymph node metastasis [24].  
This was a monocentric retrospective study, with its inherent limitations, analyzing a heterogeneous 
patient population over a large period of time. Nevertheless, the strength of this study lies in the large 
number of analyzed data and the fact that all measurements on the CT scans were performed by the 
same observer, with cooperation of both a radiation oncologist and radiologist specialized in head and 
neck cancer. Moreover, sufficient follow-up was carried out in a uniform manner.  
Conclusion 
Our data show the prognostic value of both location as well as size change of pathological lymph nodes 
after (C)RT in locoregionally advanced head and neck cancer. Involvement of the lower neck entails a 
higher metastatic risk. In the follow-up of patients with lymph node involvement of the lower neck, 
the threshold to do radiological examinations should be lower. 
The less decrease of lymph node volume and largest axial diameter after treatment, the worse the 
outcome. Patients with less decrease in volume and largest axial diameter as evaluated on the post-
treatment CT scan might therefore benefit from a more closer radiological and clinical follow-up of the 
neck.  
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                              Part II 
TOXICITY AND PREDICTIVE  
MODELS FOR TOXICITY FOLLOWING RT  
IN HEAD AND NECK CANCER. 
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CHAPTER 6  
DEVELOPMENT OF A MULTIVARIATE MODEL FOR THE PREDICTION 
OF FIBROSIS GRADE ≥ 2 AT 6 MONTHS AFTER R(C)T. 
 
 
 
 
 
 
 
 
 
Elements in this chapter are published as: 
Nevens D,  Duprez F,  Daisne JF,  Laenen A, De Neve W, Nuyts S. Radiotherapy induced dermatitis is 
strong predictor for late fibrosis in head and neck cancer. The development of a predictive model for 
late fibrosis. Radiother Oncol. 2016 Sep 20.  
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Radiotherapy induced dermatitis is a strong predictor for late fibrosis in head and neck cancer.  
The development of a predictive model for late fibrosis. 
Purpose 
To determine if the severity of radiodermatitis at the end of radio(chemo)therapy (R(C)T) for head and 
neck cancer (HNC) is a predictive factor for late fibrosis of the neck and to find a model to predict neck 
fibrosis grade ≥ 2 (fibrosis RTOG2-4) at 6 months following R(C)T for HNC. 
Material/methods 
161 patients were prospectively included. We correlated radiodermatitis at the end of RCT, age, sex, 
T/N stage, tumor site, concomitant chemotherapy, upfront neck dissection, neo-adjuvant 
chemotherapy, accelerated RT, smoking, alcohol consumption, HPV status and the dose prescribed to 
the elective neck with fibrosis RTOG2-4 6 months after the end of treatment.  
Results 
Radiodermatitis at the end of R(C)T ≥ grade 3 proved to be associated with the incidence of fibrosis 
RTOG2-4 at 6 months (p<0.01). Furthermore, upfront neck dissection (p<0.01), increasing N stage 
(p<0.01) and tumor site (p=0.02) are significantly associated in univariate analysis with fibrosis RTOG2-
4 at 6 months of follow-up.  
Upfront neck dissection and radiodermatitis grade ≥3 at the end of R(C)T were identified by our 
multivariate model. Additionally, increasing N stage was selected as an independent predictor variable. 
The AUC for this model was 0.92.  
Conclusion 
A model for the prediction of fibrosis RTOG2-4 following R(C)T for head and neck cancer is presented 
with an AUC of 0.92. Interestingly, radiodermatitis grade ≥3 at the end of R(C)T is associated with 
RTOG2-4 fibrosis at 6 months. 
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Introduction 
Radiotherapy (RT) for head and neck cancer (HNC) has significantly changed over the past decades. 
Treatment intensification improved clinical outcome, but also increased both early and late toxicity, 
heavily compromising Quality of Life (QoL) of the surviving HNC patients [1-5]. Neck fibrosis by example 
is an important late complication following radio(chemo-)therapy (R(C)T) for HNC [6-8]. 
Several techniques have been used to treat fibrosis within the head and neck region, including 
lycopene, pentoxifylline, pirfenidone, vitamin E, aloe vera, corticosteroid injections, interferon gamma, 
hyperbaric oxygen, stretching exercises, prophylactic swallowing exercises, hyperthermia, impedance 
controlled microcurrent therapy and acupuncture [9]. However, none of these techniques have shown 
a clear benefit up to now [9]. Since the treatment options for fibrosis following RT for HNC are limited, 
we must currently focus on prevention. Therefore it is important to identify which patient and 
treatment related parameters are associated with late fibrosis to select patients at risk for fibrosis in 
order to apply prophylactic interventions. Furthermore, using these parameters, we might be able to 
select patients for studies that further investigate potential treatments for fibrosis following RT for 
HNC in the future. 
The purpose of this study was therefore to identify these parameters and to build a multivariate model 
to predict neck fibrosis grade ≥ 2 (fibrosis RTOG2-4) at 6 months following R(C)T for HNC. 
Material/methods 
Patient and treatment characteristics 
The current paper is a second analysis of a prospective randomized controlled trial on dose de-
escalation to the elective nodal volume in head and neck cancer. We collected prospectively gathered 
data from all 193 patients from this initial trial [10]. Inclusion criteria from the original trial were 
previously untreated, histologically proven squamous cell carcinoma of the oral cavity, oropharynx, 
hypopharynx, larynx or cervical lymph node metastases of unknown primary cancer (CUP). Patient 
work-up was done according to institutional guidelines. T1–T2N0 were allowed, if prophylactic neck 
irradiation was performed. Patients were older than 18 years with a Karnofsky performance status 
⩾70%. The decision for primary R(C)T with curative intent had to be made after a multidisciplinary 
meeting at each participating center. Concurrent chemotherapy was allowed, as well as pretreatment 
lymph node dissection. Local ethics committee approval was obtained before start of the study and all 
patients gave written informed consent. Patients were randomized to two treatment arms 
(experimental arm A and standard arm B). A total of 200 patients were included in the study (100 for 
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each arm). To minimize the influence of center-specific parameters randomization was performed per 
center. 
All macroscopically affected tumor sites were treated up to an equivalent dose at fractionation of 2 Gy 
(EQD2Gy) of 70 Gy. Fractionation schedule and total dose delivered to the primary tumor and affected 
lymph nodes were left to the discretion of each individual center. An overview of the different 
fractionation schedules and CTV-PTV margins can be found in the preliminary analysis of this study 
[10]. For the elective nodal volumes, patients randomized in arm A (experimental arm) were treated 
up to a EQD2Gy of 40 Gy. For arm B (control arm) the elective nodal volumes were treated up to a 
EQD2Gy of 50 Gy [10].  
The endpoint of the current study is fibrosis RTOG2-4 at 6 months of follow up. Patients from the original 
trial lacking toxicity scores at 6 months following the end of RT (32 patients) were excluded from the 
current analysis. A cohort of 161 patients (of the original 193 patients) remained available for further 
analysis.  
All patients were treated with intensity modulated radiotherapy (IMRT). For target volume definition, 
a planning CT scan was used. The Planning Target Volume (PTV) was cropped for the outer contours of 
the patient (body). Chemotherapy consisted of cisplatin 100 mg/m2 three weekly or cisplatin 
40 mg/m2 weekly. 
Toxicity scoring and statistical analysis.  
Early toxicity was scored prospectively using the CTCAE criteria (version 3.0), late toxicity was scored 
prospectively by the physician using the RTOG-EORTC late radiation morbidity scoring.  
We tested age, sex, T/N stage, tumor site, concomitant chemotherapy, upfront neck dissection, neo-
adjuvant chemotherapy, accelerated RT, HPV status, smoking (never-former-current), pack years, 
alcohol consumption (never-former-current), drinks/week the dose prescribed to the elective neck, 
HPV status and radiodermatitis (grade 0-2 versus grade 3-4) at the end of treatment for their potential 
to predict neck fibrosis RTOG2-4 6 months after the end of treatment. No patients underwent adjuvant 
surgery, besides the patients who underwent an upfront neck dissection. Since only 4 patients never 
smoked, we made a group of patients who never smoked or smoked in the past to use for the further 
statistical analysis. 
Fisher's exact test and Mann-Whitney U test were used for testing the association between fibrosis 
(grade 0-1 versus grade 2-4) with categorical or continuous variables, respectively. A stepwise selection 
   
 
129 
 
procedure was followed to determine the best combination of predictor variables for fibrosis RTOG2-4 
at 6 months. The Area under the ROC curve (AUC) was determined for the final model. Additionally a 
bootstrap-corrected AUC value was calculated. This AUC value corrects for over optimism resulting 
from the fact that model construction and model validation were performed on the same data set. All 
tests are two-sided, a 5% significance level is considered for all tests.  Analyses have been performed 
using SAS software (version 9.4 of the SAS System for Windows). 
Results 
The pre-treatment characteristics of these 161 patients are listed in Table 1. Different RT schedules 
were applied according to the policies of the individual treatment centres (Supplementary Data Table 
1). A hyperfractionated accelerated fractionation schedule was administered in 49 patients. A total 
dose of 72 Gy was delivered in an overall treatment time of 6 weeks. Concomitant CRT was used in 
113 patients. 
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PATIENTS AND TREATMENT CHARCTERISTICS 
Upfront neck dissection (ND) 
No ND 127/161 ( 78.9%) 
ND 34/161 ( 21.1%) 
Concomitant chemotherapy 
No chemotherapy 48/161 ( 29.8%) 
Cisplatinum 113/161 ( 70.2%) 
Neo-adjuvant chemotherapy 
No neo-adjuvant chemotherapy 155/161 ( 96.3%) 
Neo-adjuvant chemotherapy 6/161 (  3.7%) 
Smoking 
Never/former 88/160x ( 55.0%) 
Current 72/160x  ( 45.0%) 
Alcohol use of more than 3 units a day 
Never 13/160x  (  8.1%) 
Former 36/160x  ( 22.5%) 
Current 111/160x  ( 69.4%) 
T-stage 
1 3/161 (  1.9%) 
2 59/161 ( 36.7%) 
3 55/161 ( 34.2%) 
4 36/161 ( 22.4%) 
0 8/161 (5.0%) 
N-stage 
0 40/161 ( 24.8%) 
1 23/161 ( 14.3%) 
2a 6/161 (  3.7%) 
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PATIENTS AND TREATMENT CHARCTERISTICS 
2b 55/161 ( 34.2%) 
2c 34/161 ( 21.1%) 
3 3/161 (  1.9%) 
Primary tumor site 
Oral cavity 17/161 (  10.6%) 
                Oropharynx                                          72/161 ( 44.7%) 
HPV+                                      15/72 
HPV –                                    51/72 
                                     Unknown HPV status          6/72 
Hypopharynx 36/161 ( 22.4%) 
Larynx 28/161 ( 17.4%) 
CUP 8/161 (  5.0%) 
Gender 
Male 132/161 ( 82.0%) 
Female 29/161 ( 18.0%) 
Age at diagnosis 
Mean 59.5 
Median 58.0 
Range (39.0; 81.0) 
Drinks/week 
Mean 26.0 
Median 15.0 
Range (0.0; 300.0) 
Pack years 
Mean 34.3 
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PATIENTS AND TREATMENT CHARCTERISTICS 
Median 35.0 
Range (0.0; 104.0) 
UICC anatomical stage groups (7th edition) 
I 0 (0%) 
II 18 (11.2%) 
III 37 (23.0%) 
IV 105 (65.8%) 
Table 1. Pre-treatment characteristics of the patients cohort. ND=neck dissection, CUP=cancer of 
unknown primary, HPV=human papilloma virus. xFor one patient, no information regarding smoking 
and alcohol use could be obtained. 
 
The incidences of radiodermatitis at the end of treatment and fibrosis at 6 months of follow-up are 
presented in the supplementary data Table 2. Severe early and late skin toxicity are observed in about 
24.1% and 29.2% respectively. 
Upfront neck dissection (p<0.01), radiodermatitis at the end of R(C)T ≥ grade 3 (p<0.01), increasing N 
stage (p<0.01) and tumor subsite (p=0.02) are significantly associated with the incidence of fibrosis 
RTOG2-4 at 6 months in our patient population according to univariate analysis (Table 2). Figure 1 
presents the estimated probability (with 95% confidence intervals) of severe fibrosis for 3 levels of 
early skin toxicity.  
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Variable Fibrosis G0-1 Fibrosis G2-4 P value 
No upfront ND 104/127 (81.9%) 23/127 (18.1%) p<0.01 
Upfront ND 10/34 (29.4%) 24/34 (70.6%) 
 
Radiodermatitis G0-2 100/122 (82.0%) 22/122 (18.0%) p<0.01 
Radiodermatitis G3-4 14/39 (35.9%) 25/39 (64.1%) 
 
N0 38/40 (95.0%) 2/40 (5.0%) p<0.01 
N1 17/23 (73.9%) 6/23 (26.1%) 
N2a 4/6 (66.7%) 2/6 (33.3%) 
N2b 35/55 (63.6%) 20/55 (36.4%) 
N2c 19/34 (55.9%) 15/34 (44.1%) 
N3 1/3 (33.3%) 2/3 (66.7%) 
 
Oral cavity 11/17 (64.7%) 6/17 (35.3%) p=0.017 
Oropharynx 54/72 (75.0%) 18/72 (25.0%) 
Hypopharynx 23/36 (63.9%) 13/36 (36.1%) 
Larynx 24/28 (85.7%) 4/28 (14.3%) 
CUP 2/8 (25.0%) 6/8 (75.0%) 
Table 2. Statistically significant associations between the patient parameters and the incidence of 
fibrosis RTOG2-4 at 6 months, after univariate analysis. G=grade, CUP=cancer of unknown primary, 
ND=neck dissection. 
 
   
 
134 
 
 
Figure 1 presents the estimated probability (with 95% confidence intervals) of severe fibrosis for 3 
levels of early skin toxicity. There were only 4 patients with grade 0, who were excluded for this 
analysis. 
 
Concomitant chemotherapy (p=0.85), neo-adjuvant chemotherapy (p=0.36), hyperfractionated RT 
(p=1.00), smoking (p=1.00), pack years (p=0.23), alcohol consumption (p=0.88), drinks/week (p=0.39), 
T stage (p=0.59), HPV status (p=0.85), sex (p=0.50), age (p=0.13) and dose to the elective neck (40Gy 
vs 50Gy, p=0.86) were not associated with the incidence of fibrosis RTOG2-4. 
Upfront neck dissection (p<0.01) and radiodermatitis grade ≥3 (p<0.01) at the end of R(C)T were 
identified for the model. Additionally, increasing N stage was selected as an independent predictor 
variable (p=0.04) (Table 3). The AUC for this model containing upfront neck dissection, erythema at 
the end of treatment and increasing N stage was 0.92 (95% CI 0.87;0.96); the bootstrap-corrected AUC 
was 0.90 (95%CI 0.85;0.94).  
 
 
 
 
   
 
135 
 
Variable OR p-value 
LN dissection vs No LN dissection 159.06 (19.158;1320.7) <0.001 
Severe toxicity (≥3) vs No/mild toxicity (0-2) 129.18 (15.930;1047.6) <0.001 
N-stage (+1 level) 1.446 (1.012;2.068) 0.043 
 
Binary variables: 
OR>(<)1 means higher (lower) risk for first category. 
Continuous/ordinal variables: 
OR>(<)1 means higher (lower) risk for higher level. 
Table 3. Multivariable model with the selected variables and the corresponding odds ratios (OR) with 
95% confidence intervals. 
 
The risk for fibrosis RTOG2-4 at 6 months can be calculated using the following formula: 
𝐫𝐢𝐬𝐤 𝐟𝐨𝐫 𝐟𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐑𝐓𝐎𝐆𝟐 − 𝟒 𝐚𝐭 𝟔 𝐦𝐨𝐧𝐭𝐡𝐬 =  
𝒆𝝁
𝟏 + 𝒆𝝁
 
𝜇 =                      −5.3225 +  5.0693  (𝑜𝑛𝑙𝑦 𝑤ℎ𝑒𝑛 𝑢𝑝𝑓𝑟𝑜𝑛𝑡 𝑛𝑒𝑐𝑘 𝑑𝑖𝑠𝑠𝑒𝑐𝑡𝑖𝑜𝑛 𝑤𝑎𝑠 𝑝𝑒𝑟𝑓𝑜𝑟𝑚𝑒𝑑)
+  4.8612  (𝑤ℎ𝑒𝑛 𝑔𝑟𝑎𝑑𝑒 ≥ 3 𝑟𝑎𝑑𝑖𝑜𝑑𝑒𝑟𝑚𝑎𝑡𝑖𝑡𝑖𝑠 𝑎𝑡 𝑡ℎ𝑒 𝑒𝑛𝑑 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
+ 0.3691 𝑥 𝑁𝑠𝑡𝑎𝑔𝑒(𝑁0 = 0; 𝑁1 = 1; 𝑁2𝑎 = 2; 𝑁2𝑏 = 3; 𝑁2𝑐 = 4; 𝑁3 = 5) 
Furthermore, we investigated if the model performs better if the grade of dermatitis is included (0-1-
2-3-4), instead of only including a distinction between grade 0-2 or higher. The AUC for the model with 
the actual grade instead of the distinction between grade 0-2 or higher is 0.91. Changing the binary 
score with the grade of radiodermatitis does not make the model more performant. 
Table 4 presents the probability of fibrosis for the most common N-stages according to the 2 other 
variables of the model. 
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Neck dissection (ND) Radiodermatitis N-stage 
Predicted 
risk 
No ND Grade  (0-2) 
 
0 0.005 
1 0.007 
2b 0.015 
2c 0.021 
Grade (3) 
 
0 0.387 
1 0.477 
2b 0.656 
2c 0.734 
ND Grade (0-2) 
 
0 0.437 
1 0.529 
2b 0.701 
2c 0.773 
Grade (3) 
 
0 0.990 
1 0.993 
2b 0.997 
2c 0.998 
 
Table 4. Predicted severe fibrosis risk by patient characteristics. 
 
Discussion 
Neck fibrosis is a late complication following R(C)T for HNC that negatively affects QoL. Since the 
treatment options for fibrosis following RT for HNC are currently limited, the focus lies on prevention. 
A first step in searching for possibilities of prevention of mitigation resides in the identification of 
patient and treatment related parameters associated with late fibrosis. A previous model for fibrosis, 
based on retrospective data, selected a high dose to a 4.1-mm depth of the skin and upfront neck 
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dissection as risk factors for moderate to severe subcutaneous fibrosis after whole neck irradiation 
[11]. 
We hypothesized that early radiodermatitis was associated with late fibrosis either due to a different 
sensitivity to RT between patients for both early and late toxicity or due to consequential late toxicity 
caused by early toxicity. As a matter of principle, the relationship between increased early toxicity and 
late dysphagia has been demonstrated in the past [12].  
This hypothesis has been confirmed by our findings. Following univariate analysis, we detected upfront 
neck dissection, radiodermatitis at the end of R(C)T ≥ grade 3, increasing N stage and tumor subsite as 
being significantly associated with fibrosis RTOG2-4 at 6 months. Upfront neck dissection and 
radiodermatitis grade ≥3 at the end of R(C)T were identified by our multivariate model. Additionally, 
increasing N stage was selected. For example, using our model, a patient who received an upfront neck 
dissection for a nodal N2c stage head and neck tumor and suffered from radiodermatitis grade 2 at 
the end of radiotherapy, has a risk of developing fibrosis  RTOG2-4 at 6 months  of 77.26%.  
The fact that tumor location was not selected by our multivariable model can be explained by the 
observation that almost all patients with CUP received an upfront neck dissection. CUP was 
significantly associated with fibrosis RTOG2-4 at 6 months following univariate analysis.  
The question arises if we can prevent fibrosis by changing parameters that were selected by our 
multivariate model. Avoiding upfront neck dissections, the first factor of our model, seems a way to 
limit the incidence of fibrosis RTOG2-4 at 6 months. The influence of upfront neck dissection on late 
fibrosis was already described by Hirota et al [11]. The need for upfront ND in the treatment of HNC is 
still a matter of debate. Recently, a systematic review on the subject concluded that few comparative 
studies suggest possible benefits of upfront neck dissection in the RT organ-preserving setting in terms 
of early toxicity and oncological outcome, although the level of evidence is very low [13]. Most studies 
on this subject have a low number of patients, do not contain information on HPV status and date from 
an era before concomitant CT treatment was common. Larger comparative studies that include HPV 
status and concomitant CT and randomized controlled trials are needed in this setting to evaluate the 
necessity of upfront ND [12]. The effect of adjuvant neck dissection could not be assessed in the 
current study since none of the patients received a neck dissection following RT. 
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Another way to limit the incidence of  fibrosis RTOG2-4  might reside in the prevention of radiodermatitis 
at the end of R(C)T ≥ grade 3, the second factor of our model, as much as possible, since we clearly 
demonstrated that this early side effect has repercussions on the incidence of late fibrosis. The 
relationship between early and late side effects was recently demonstrated for dysphagia [12]. A 
recent review found no strong evidence of effect for any topical products in reducing radiodermatitis 
[14]. The MASCC Skin Toxicity Study Group developed radiodermatitis prevention and treatment 
guidelines based on evidence from randomized, controlled trials. The adoption of washing with water, 
with or without a mild soap, and allowing the use of antiperspirants is supported by randomized trials. 
There is some evidence that silver sulfadiazine cream can reduce dermatitis score [15]. 
Another possibility to limit the incidence of early radiodermatitis besides topical products is the use of 
new RT techniques such as proton RT [16] or adaptation of the treatment, in order to limit the dose to 
the neck as much as possible, when patients experience more than average early symptoms [12]. This 
can be done by using adaptive replanning or by changing to other treatment modalities such as proton 
planning where available in case of more than average early toxicity [12]. These kind of tailored 
treatment adjustments based on early symptom profiles may be worthwhile to investigate in future 
clinical studies [12]. Furthermore, in the future, genetic analysis could help us to select patients who 
are more at risk for early toxicity like radiodermatitis. Selection of these patients before treatment 
harbors the potential to adapt and individiualize their treatment in order to limit early dermatitis and 
late fibrosis. Polymorphism near the LIG3 gene, for example, is associated with early skin toxicity 
following RT [17]. 
The selection of the third factor of our multivariate model, increasing N stage, might be due to the fact 
that in more advanced nodal stages the surrounding soft tissues and skin receive a higher RT dose, 
since the pathological lymph nodes are larger and are more likely to be in close contact with the skin. 
However we cannot confirm this interaction with our current data. We found no difference between 
administering a EQD2Gy of 40 Gy versus 50 Gy to the elective neck in terms of late fibrosis. This could 
be explained by the theory that the curative doses to pathological lymph nodes have more impact on 
radiodermatitis and late fibrosis than the dose to the elective nodal volume. This theory originates out 
of the observation that increased N stage is selected for our model but administering a EQD2Gy of 40 
Gy versus 50 Gy to the elective neck was not. 
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Apart from avoiding the factors that were selected for our model as much as possible in order to limit 
late fibrosis, our model could be of use for future studies looking at treatment options for patients 
facing fibrosis. For these studies, it is important to be able to select potential patients in an early stage. 
Treatment options like stretching exercises and prophylactic swallowing exercises are very time-
consuming and less likely to be used on the long term in a less than average compliant population [9].   
With our model we achieved an AUC of 0.92. The AUC is also referred to as Concordance index and 
bears the following interpretation: a model with perfect discrimination would have an index of 1, 
whereas a value of 0.5 indicates that a coin toss would provide information as accurate as that given 
by the model. Because we have no external validation of our model, additionally a bootstrap-corrected 
AUC value is presented. This AUC value corrects for overoptimism resulting from model construction 
and model validation that were performed on the same data set. The corrected AUC gives an honest 
estimate of predictive accuracy of the model if it would be applied to an independent sample [18].  
The fact that diabetes and skin diseases (such as sclerodermia) was not assessed in our patient 
population is a limitation. We did not take this into account in the analysis of this study because we 
did not screen for these factors at inclusion of the randomized trial [10]. On the other hand, the 
strength of this paper lies in the fact that all data were prospectively gathered and that this is the first 
paper to demonstrate a link between radiodermatitis and late fibrosis.  
A model for the prediction of fibrosis RTOG2-4 following R(C)T for HNC is presented with an AUC of 0.92. 
A bootstrap-correction was performed because we were not able to externally validate our results. 
Interestingly radiodermatitis at the end of R(C)T is associated with RTOG2-4 fibrosis at 6 months in our 
patient population. Attempts should be undertaken to decrease radiodermatitis in order to decrease 
late fibrosis. 
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Supplementary data 
 
 
 
Table 1 supplementary data. Different RT schemes of our study population. 
 
Radiodermatitis G0-2 at the end of treatment 122/161 (75.8%) 
Radiodermatitis G3-4 at the end of treatment 39/161 (24.2%) 
Fibrosis G0-1 at 6 months of follow-up 114/161 (70.8%) 
Fibrosis G2-4 at 6 months of follow-up 47/161 (29.2%) 
Table 2 supplementary data. Incidences of radiodermatitis at the end of treatment and fibrosis at 6 
months of follow-up. 
 
 
 
 
 
 
Conventional fractionation 
70 Gy/2 Gy 21 patients 
69.12 Gy/2.16 Gy 71 patients 
66 Gy/2.2 Gy 20 patients 
Hyperfractionation schedule 
40 Gy/2 Gy (once 
daily) + 32 Gy/1.6 Gy (twice daily) 
49 patients 
PTV elective nodal volume EQD2 
50 Gy 76 patients 
40 Gy 85 patients 
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CHAPTER 7 
VALIDATION OF THE TOTAL DYSPHAGIA RISK SCORE (TDRS) IN HEAD 
AND NECK CANCER PATIENTS AND COMPARISON OF PATIENT AND 
PHYSICIAN SCORED DYSPHAGIA. 
 
 
 
 
 
 
 
Elements in this chapter are published as: 
Nevens D, Deschuymer S, Langendijk JA, Daisne JF, Duprez F, De Neve W, Nuyts S. Validation of the 
total dysphagia risk score (TDRS) in head and neck cancer patients in a conventional and a partially 
accelerated radiotherapy scheme. Radiother Oncol. 2016 Feb;118:293-7. 
 
Elements in this chapter are resubmitted to Dysphagia after major revision: 
Nevens D, Goeleven A, Duprez F, Braeken R, Decabooter E, De Smet M, Lutters L, Laenen A, Dejaeger 
E, De Neve W, Nuyts S. Does the total dysphagia risk score correlate with swallowing function examined 
by video fluoroscopy? 
 
Elements in this chapter are submitted to Oral Oncology: 
Nevens D, Goeleven A, Duprez F, Laenen A, Braeken R, Decabooter E, De Smet M, Lutters L, Dejaeger 
E, De Neve W, Nuyts S. Correlation of patient and physician scored dysphagia with videofluoroscopies 
in patients treated with radiotherapy for head and neck cancer.  
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Validation of the total dysphagia risk score (TDRS) in head and neck cancer patients in a 
conventional and a partially accelerated radiotherapy scheme. 
 
Background and purpose 
A risk model, the total dysphagia risk score (TDRS), was developed to predict which patients are most 
at risk to develop grade ⩾2 dysphagia at 6 months following radiotherapy (RT) for head and neck 
cancer. The purpose of this study was to validate this model at 6 months and to investigate the power 
at earlier and later time-points. A second aim was to see if this model can be used in a partially 
accelerated RT regimen. 
 
Materials and methods 
164 patients from 3 different centres treated with RT between 2008 and 2014 were included in the 
current study. Both physician-scored dysphagia and QoL data were prospectively obtained. The TDRS 
of all patients was correlated with the physician-scored dysphagia and the QoL data. To validate this 
prediction model, we tested the validity in terms of calibration and discrimination. 
 
Results 
Partial acceleration had no influence on the TDRS. Regarding physician-scored dysphagia, there was a 
significant correlation with dysphagia grade ⩾2 at 1, 3, 6 and 9 months. The area-under-the-curve at 
1 month was 0.85; at 3 months 0.80; at 6 months 0.85; at 9 months 0.86 and 0.79 at 12 months. 
Regarding QoL, TDRS correlates with PEG-tube usage at 6 and 12 months. 
 
Conclusion 
We found significant correlations between TDRS and dysphagia grade ⩾2 and PEG-tube usage. 
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 Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world. 
Radiation therapy (RT) with or without concurrent chemotherapy (CT) has emerged as the treatment 
of choice for patients with locally advanced HNSCC. 
 
The use of altered RT fractionation schedules and the addition of concurrent CT to the management 
of HNSCC have significantly increased both loco regional control and overall survival [1] and [2]. 
However this came at the cost of more treatment related toxicity, especially xerostomia and dysphagia 
[3], [4] and [5]. Dysphagia has a strong negative impact on health-related quality of life (QoL) during 
and after treatment [3]. 
 
Predicting which patients are at risk for developing severe dysphagia can help to select patients who 
might benefit from a preventive percutaneous endoscopic gastrostomy (PEG)-tube placement before 
the start of treatment [3], [4], [5], [6] and [7]. 
 
In 2009, the total dysphagia risk score (TDRS), a risk model for assessing the risk to develop dysphagia 
after RT for HNSCC, was created. The following independent prognostic factors for swallowing 
dysfunction at 6 months were found and incorporated into this model: (1) T3–T4, (2) bilateral neck 
irradiation, (3) weight loss prior to radiation, (4) oropharyngeal and nasopharyngeal tumours, (5) 
treatment modality: accelerated RT and concomitant chemoradiation (CRT). The aim of the authors 
was to find a risk model to predict dysphagia at 6 months (SWALL6months). Based on the TDRS, 3 risk 
groups to develop dysphagia could be defined (low-, intermediate- and high-risk patients). Until now, 
this risk model was only validated retrospectively by one research group for acute dysphagia, in a small 
patient cohort (47 patients) [8]. 
 
The aim of this study was to prospectively validate this risk model as a predictive measure for 
physician-scored and patient-scored (QoL) dysphagia at 6 months. Since in one of the participating 
centres a partially accelerated RT schedule was used, we also investigated how partial acceleration 
needs to be scored in the TDRS. Furthermore, we wanted to investigate the predictive power of this 
model at 1, 3, 9 and 12 months of follow-up. 
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 Material and methods 
 
Patient data 
We collected data from 270 patients from 3 different centres treated between 2008 and 2014. All 
patients were diagnosed with HNSCC originating from the oral cavity, oropharynx, larynx or 
hypopharynx and were included in prospective randomized trials on de-escalation in the elective neck. 
Patient work-up was done according to institutional guidelines. The decision for primary (C)RT or 
surgery followed by postoperative (C)RT with curative intent had to be made by the multidisciplinary 
board meeting at each participating centre. All patients gave written informed consent. Patients were 
excluded according to the same criteria as used in the original paper (Fig. 1) [3]. Patients who received 
concurrent cetuximab were excluded from the present study. The most important pre-treatment 
characteristics are listed in Table 1. 
 
 
Figure 1. Inclusion and exclusion of patients according to the criteria of the original article [1]. 
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 Average age 59.9year 
Median age 59year (range 38–83year) 
Male 134 (81.7%) 
Female 30 (28.3%) 
T1 6 (3.7%) 
T2 57 (34.8%) 
T3 55 (33.5%) 
T4 46 (28.0%) 
N0 43 (26.2%) 
N1 22 (11.3%) 
N2 95 (57.9%) 
N3 4 (2.4%) 
Baseline swallowing 
Grade 0 106 (64.6%) 
Grade 1 58 (35.4%) 
Weight loss at baseline 
No weight loss 108 (65.8%) 
1–10% 50 (30.5%) 
>10% 6 (3.7%) 
Tumour subsites 
Larynx 35 (21.3%) 
Oropharynx 77 (47.0%) 
Oral Cavity 24 (14.6%) 
Hypopharynx 28 (17.1%) 
Bilateral neck irradiation 164 (100%) 
 
Table 1. Patient characteristics. 
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 Treatment 
All patients were treated with intensity modulated RT (IMRT). For target volume definition, a 
planning-CT scan was used. The overall treatment time ranged between 40 days and 51 days. Different 
RT schedules were applied according to the habits of the individual treatment centres (Table 2). RT 
was delivered 5 days a week. 
 
A hyperfractionated accelerated fractionation schedule was given to 75 patients. A total dose of 72 Gy 
was delivered in an overall treatment time of 6 weeks: twenty daily fractions of 2 Gy (40 Gy), 5 times 
a week, followed by 20 fractions of 1.6 Gy twice daily (32 Gy). 
Nine patients underwent a tumour resection prior to RT. 30 patients were included in a study with 
adaptation of the treatment after 2 and 4 weeks into treatment. 
 
Concomitant CRT was given in 110 patients. CRT consisted of cisplatin 100 mg/m2 three weekly or 
cisplatin 40 mg/m2 weekly. 
Table 2. Different RT schemes of our study population. 
Scoring 
Dysphagia was scored prospectively according to the RTOG/EORTC Acute and Late radiation morbidity 
scoring. QoL was assessed with the EORTC QLQ-C30 and the head and neck cancer module, the EORTC 
QLQ-H&N35 questionnaire at 6 months and at 12 months. We chose to correlate global health status, 
appetite loss, pain, swallowing, trouble with social eating, the use of nutritional supplements, feeding 
tube usage and weight loss with the TDRS risk groups. 
 
Since all patients were included in a study protocol, follow-up after radiotherapy was done uniformly 
every two months for the first 2 years. 
 
CONVENTIONAL FRACTIONATION 
70 Gy/2 Gy, 
69.12 Gy/2.16 Gy, 
66 Gy/2.20 Gy, 
69 Gy/2.30 Gy 
 
11 patients 
41 patients 
25 patients 
3 patients 
HYPERFRACTIONATION SCHEDULE 
40 Gy/2 Gy (once daily)+ 32 Gy/ 1.6 Gy (twice daily) 
 
75 patients 
POSTOPERATIVE RADIOTHERAPY 
66 Gy/2 Gy 
69.12 Gy/2.16 Gy 
 
3 patients 
6 patients 
ADAPTIVE RADIOTHERAPY using 2 treatment adaptations  30 patients 
PTV elective nodal  volume EQD2 
50 Gy 
40 Gy 
 
48 patients 
116 patients 
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 Statistics 
To validate the TDRS, we tested model performance in terms of calibration and discrimination. 
As a first step, we calculated the TDRS for every patient. We defined the weight loss as the percentage 
of total body weight lost during the 6 months prior to RT. The TDRS was scored as described in the 
original paper [3]. 
 
In the original manuscript, there were however no patients who were treated with a combination of 
partially accelerated radiotherapy and chemotherapy. To decide which scoring we had to give to these 
patients, we searched for the best fit testing calibration-in-the-large. In the original article 
chemotherapy was scored as 5 points, and accelerated radiotherapy was scored as 6 points. Therefore 
we chose to calculate the TDRS of patients who received accelerated RT combined with CT first as 5 
(no added effect of the partially accelerated RT) and later on as 6. One previous article scored 
concomitant partial accelerated RT and CT as 5 points; however without mentioning why [8]. 
 
Afterwards, we calculated the expected risk for every patient individually using the original article [3]. 
The mean expected risks were later on compared with the observed prevalence of RTOG 2–4 dysphagia 
in our patient population. We tested the calibration-in-the-large first using 5 points to score partially 
accelerated RT and CT, and later on using 6 points to score partially accelerated RT and CT in order to 
define the best fit and the best scoring method. 
 
Furthermore, the Hosmer–Lemeshow goodness of fit test was used to assess whether or not the 
observed event rates match the expected event rates in consecutive subgroups of the model 
population. 
 
Finally, the prediction capability of the TDRS was assessed. Using a logistic regression model, receiver 
operator characteristic curves (ROC) were plotted to test discrimination in terms of area under the 
curve (AUC) to evaluate the predictive capability of the model. A p-value of less than 0.05 was taken 
to indicate statistical significance. These analyses were performed using STATISTICA. Quality of Life 
data were handled as described by the EORTC guidelines. 
 
Results 
The prevalence of grade 2–4 RTOG swallowing dysfunction (RTOGG2-4) decreased over time. The 
prevalence of RTOGG2-4 was 55.2% (90 of 163 patients at risk) at 1 month (SWALL1month), 31.3% (51 
of 164 patients at risk) at 3 months (SWALL3months), 20,1% at 6 months (33 of 164 patients), 11% (17 
of 154 patients at risk) at 9 months (SWALL9months) and 6.3% (7 of 112 patients at risk) at 12 months 
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 (SWALL12months). There was no prospectively scored RTOG swallowing dysfunction for one patient 
at 1 month, for 10 patients at 9 months and for 42 patients at 12 months. The relationship between 
the three risk groups and the prevalence of RTOGG2-4 at 1 and 6 months are listed in the Appendix. 
 
After calculation of the TDRS, five patients were classified in the low-risk group (TDRS 0–9); 54 patients 
in the intermediate-risk group (TDRS10–18) and 105 patients in the high-risk group (TDRS > 18). 
 
Firstly, we used 5 points to score partially accelerated RT combined with CT, this would mean that 
there is no effect of partial acceleration. We found an expected risk to develop RTOG 2–4 dysphagia 
at 6 months of 32% (95% CI 17–43%). The observed RTOG 2–4 dysphagia at 6 months in our patient 
group was 20.1%, thus within this 95% CI. 
 
When we used 6 to score partially accelerated RCT, our results were not within this 95% CI. Therefore, 
we used 5 points for the scoring in the second part of our study for partially accelerated RT with 
concomitant CT. 
 
Our population was divided into 10 groups using the Hosmer–Lemeshow test. The mean risks and the 
observed prevalence were correlated at all 5 time points. We found a non-significant p-value at all 5 
time points, indicating no evidence of poor fit of the TDRS (i.e. no significant difference between 
predicted and observed prevalences). 
 
At 1 month, there was a significant correlation between the TDRS and RTOGG2-4 (p = 0.001). This was 
also observed at 3 (p = 0.001) and 6 months (p = 0.001). At 9 months we saw a borderline significant 
correlation (p = 0.05). At 12 months the correlation was not significant. The AUC at 1 month was 0.85 
(95% confidence interval: 0.78–0.89); at 3 months 0.80 (95% confidence interval: 0.77–0.84); at 6 
months 0.85 (95% confidence interval: 0.79–0.90) (Fig. 2); at 9 months 0.86 (95% confidence interval: 
0.80–0.91) and 0.79 (95% confidence interval: 0.72–0.84) at 12 months. 
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Figure 2. ROC (receiver operator characteristic) curve to evaluate the prediction capability of the 
TDRS for grade 2 or higher late swallowing dysfunction at 6 months. 
 
Global health status, appetite loss, pain, swallowing problems, trouble with social eating, the use of 
nutritional supplements and weight loss at 6 and 12 months were not significantly correlated with the 
risk groups of the TDRS. The use of a feeding tube was significantly correlated with the risk groups of 
the TDRS at 6 months (p = 0.017). At 12 months, the correlation was borderline significant (p = 0.050). 
 
Discussion 
Dysphagia remains a major problem for patients treated witch (C)RT for locally advanced HNSCC. 
Dysphagia leads to longer eating times, inability to eat different types of food, and fear or inability to 
eat in public which in turn results in social isolation and depression. The TDRS is a way to predict 
dysphagia at 6 months [9]. 
 
In the original TDRS paper, a conventional fractionation and accelerated fractionation schedule was 
applied [3]. In our study 75 patients received a hyperfractionated partially accelerated fractionation 
schedule [10]. For patients who received partially accelerated RT with concurrent CT and the score of 
0 for partially accelerated RT without concurrent CT, proved to be the best fit. This is in line with the 
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 study of Konwai et al. In that study, six patients who underwent partially accelerated RT, were also 
allocated to 5 points when concurrent CT was given [8]. However in this study the authors do not 
clarify why 5 points were given. 
 
Besides the problem of the scoring of partial acceleration, we observed a second problem in our 
patient cohort; the scoring of the administration of cetuximab. In the original TDRS paper, no patients 
were treated with cetuximab [3]. Although the RCT suggested that the addition of cetuximab to RT 
does not increase dysphagia, we excluded this subgroup of patients because of a possible negative bias 
[11] and [12]. Patients who received cetuximab in the participating centres could not receive CT 
because of morbidity and general health status. These morbidities might influence the dysphagia 
scoring. 
 
A third problem that we encountered using TDRS score, was weight loss prior to RT. In the original 
paper, there was no definition of the time period of weight loss, neither how weight loss due to surgery 
should be handled [3]. We chose to compare the weight at the start of RT with the weight 6 months 
prior to start. This definition can however have repercussions on the scoring. A small difference in 
measured weight (0 or 1% loss) makes a difference of 5 points on the total TDRS score (Appendix). 
Those 5 points can lead to a different category (low, intermediate, high risk to develop dysphagia). 
 
Our observed dysphagia rates are in line with the ones described by Konwai et al. and Langendijk et al. 
[3] and [8]. However, we only identified 5 patients in the low risk group. A possible explanation is that 
all our patients received a bilateral neck irradiation (scored 9 points). At 12 months we did not observe 
a significant correlation, whereas at the other time points the correlation is significant. A possible 
explanation is that there were only 7 patients out of 112 patients with a RTOG2-4 at 12 months. The 
TDRS model was developed to predict RTOG2-4 at 6 months of follow-up. The authors of the original 
paper did not develop nor test the model for later or earlier time points, but showed that there was a 
correlation between RTOG2-4 at 6 months and at later time points. This is the first paper to test this 
model at 1, 3, 9 and 12 months in a prospective way. Since our population consists of only 164 patients, 
it is important to say that these results at other time-points than 6 months are only exploratory and 
should be further validated. 
 
To appreciate if the observed significant correlations were not a coincidence we performed a ROC 
analysis. AUC’s at the different time points ranged between 0.79 and 0.86, indicating a good predictive 
value of the model. Whether this means that the TDRS can be used to take predictive measures is 
however not clear. 
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Firstly it remains unclear from which preventive measurements patients would benefit the most. The 
impact of PEG use on swallowing and swallowing-related outcomes remains unclear. Some researchers 
have suggested that PEG use may negatively affect the swallowing physiology, function and/or quality 
of life. A recent published review of twenty studies could not clarify this either [13]. On the other hand, 
recently, a prospective randomized trial was set up to evaluate the impact of prophylactic swallowing 
exercises on swallowing-related outcomes in HNSCC patients treated with curative RT [14]. There was 
no difference between the two groups (standard care versus home swallowing exercises) on the 
dysphagia outcomes during and after treatment. The authors of the paper blame this on poor 
adherence to exercises and dropouts. The best intervention method to lower dysphagia is thus 
currently unknown. 
 
Secondly, using the TDRS, we would still take preventive measures in patients who do not necessarily 
need it. Our ROC-analysis resulted in 70% specificity for 80% sensitivity indicating a reasonable rate of 
detecting patients that would benefit from an intervention, but also a substantial group of patients 
that will not need such an intervention. Therefore we do not recommend to use this model to select 
patients who might benefit from PEG-tube placement before the start of treatment, since PEG tube 
dependency was not the endpoint of the TDRS model. Recently, however, 2 models were published by 
Wopken et al. to predict PEG tube dependency at 6 months. Interestingly the first model uses 
comparable parameters as the TDRS score does (T, weight loss at baseline, bilateral neck irradiation 
and treatment modality). A difference is that also nodal stage is taken into consideration in this model 
[15]. The second model, however, also included radiotherapy plus cetuximab and the mean dose to 
the superior and inferior pharyngeal constrictor muscle, to the contralateral parotid gland and to the 
cricopharyngeal muscle [16]. 
 
Regarding QoL, only PEG-usage correlated with TDRS at 6 months and borderline at 12 months. Other 
QoL items were not significantly correlated. In the past, studies on the correlation between patient-
rated dysphagia and objective assessments of dysphagia showed conflicting results [1] and [3]. A 
possible explanation can be that QoL scoring in HNSCC patients, who are known to be frail and often 
have a low socio-economic status, can be challenging. 
 
The strength of this article is that all scores (physician- as well as patient rated by QoL) were 
prospectively gathered, in contrast to the previous validation study were the morbidity was 
retrospectively scored based on the medical records [8]. 
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 We are aware that the RT schemes of our study population are very diverse. However our results 
indicate that TDRS can be used with different RT schemes. Above all, the TDRS is easy to use in daily 
clinical practice and might guide clinicians in identifying patients who might benefit from additional 
attention to swallowing problems during (C)RT and follow-up. 
 
The TDRS has been validated for predicting physician-scored swallowing dysfunction induced by (C)RT 
at 6 months. Moreover, we found significant correlations between TDRS and RTOGG2-4 at 1, 3, 6 and 
9 months, with acceptable AUC’s. 
 
We found that this predictive model can also be used with a partially accelerated RT scheme; the 
partial acceleration does not have to be taken into account. Regarding QoL, we found a correlation 
between PEG-tube usage at 6 and 12 months. 
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 Supplementary data 
 
- TDRS = T classification (T3-T4 = 4 points) + Bilateral neck irradiation (= 9 points) + weight loss 
at baseline (1-10 % = 5 points; > 10% = 7 points) + primary tumor site (oropharynx = 7 points; 
nasopharynx  = 9 points) + treatment modality (accelerated radiotherapy = 6 points; 
concomitant chemotherapy = 5 points). 
 
- Relationship between the three risk groups and grading of swallowing dysfunction in RTOG 
Acute Radiation Morbidity Scoring Criteria at 1 month. 
 RTOG 0-1 RTOG 2-4 Total 
Low risk group 5 0 5 
Intermediate risk group 42 12 54 
High risk group 26 78 104 
Total 73 90 163 
 
- Relationship between the three risk groups and grading of swallowing dysfunction in RTOG 
Acute Radiation Morbidity Scoring Criteria at 6 months. 
 RTOG 0-1 RTOG 2-4 Total 
Low risk group 5 0 5 
Intermediate risk group 52 2 54 
High risk group 74 31 105 
Total 131 33 164 
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 Does the total dysphagia risk score correlate with swallowing function examined by video 
fluoroscopy? 
 
Background and purpose 
The purpose of this study was to correlate the total dysphagia risk score (TDRS) with swallowing 
function as measured by videofluoroscopy of swallowing using the swallowing performance scale 
(SPSS) and the penetration aspiration scale (PAS). 
 
Materials and methods 
Sixty-three patients from 2 different centers treated with radiotherapy for head and neck cancer were 
evaluated in the current study. Swallowing videofluoroscopies at baseline, 6 and 12 months following 
radiotherapy were evaluated by 2 observers. The TDRS of all patients was calculated and correlated 
with the consensus PAS and SPSS scores of the 2 observers. 
 
Results 
Regarding the PAS scale, we did not observe a significant correlation with the TDRS. Regarding SPSS 
we found a significant correlation at 6 months (p=0.01) and a borderline significant correlation at 12 
months (p=0.05). We observed a statistically significant lower risk for patients in the intermediate risk 
category when compared to the high risk category. When we compared low versus high we did not 
observe a significant difference. When comparing low versus intermediate risk patients, we observed 
higher SPSS scores in the low risk group (p=0.01). When the low and intermediate risk patients were 
grouped together, we observed less swallowing problems as measured by SPSS and PAS in the low and 
intermediate group when compared to the high risk group (p=0.05) at 6 months. 
 
Conclusion 
Patients with high risk TDRS scores correlated with higher SPSS scores when compared to the 
intermediate group and the intermediate and low risk group together. However, low risk patients in 
our patient cohort could not be distinguished from high or intermediate risk patients. 
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 Introduction 
 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world. 
Radiation therapy (RT) with or without concurrent chemotherapy (CT) has emerged as the treatment 
of choice for patients with locally advanced HNSCC. The use of altered RT fractionation schedules and 
the addition of concurrent CT to the management of HNSCC have significantly increased both 
locoregional control and overall survival [1, 2]. However this came at the cost of more treatment 
related toxicity, especially dysphagia [3 -6]. Dysphagia has a strong negative impact on health-related 
quality of life (QoL) during and after treatment [3, 5]. 
In 2009, the total dysphagia risk score (TDRS), a risk model for assessing the risk to develop dysphagia 
after RT for HNSCC, was created [3]. The following independent prognostic factors for swallowing 
dysfunction at 6 months were found and incorporated into this model: (1) T3–T4, (2) bilateral neck 
irradiation, (3) weight loss prior to radiation, (4) oropharyngeal and nasopharyngeal tumours, (5) 
treatment modality: accelerated RT and concomitant chemoradiation (CRT). The aim of the authors 
was to find a risk model to predict dysphagia at 6 months. Based on the TDRS, 3 risk groups to develop 
dysphagia could be defined: low- (TDRS 0-9), intermediate- (TDRS 10-18) and high-risk patients (TDRS 
>18). This risk model was validated retrospectively by one research group for acute dysphagia [7] and 
for acute and late dysphagia (1, 3, 6 and 9 months following CRT) by our research group in a prospective 
manner [8]. The aim of this study was to correlate the TDRS with swallowing function as measured by 
videofluroscopies (using the swallowing performance scale (SPSS) and the penetration aspiration scale 
(PAS) - scales can be found in the supplementary data). The TDRS is known to correlate with physician 
scored dysphagia but the relation to objective measurements like videofluoroscopy is unknown. 
 
Material and methods 
 
Patient data 
 
The current paper is a secondary analysis of a prospective randomized controlled trial on dose de-
escalation to the elective nodal volume in head and neck cancer [9]. Inclusion criteria of the original 
trial were previously untreated, histologically proven squamous cell carcinoma of the oral cavity, 
oropharynx, hypopharynx, larynx or cervical lymph node metastases of unknown primary cancer 
(CUP). Patient work-up was done according to institutional guidelines. T1–T2N0 were allowed, if 
prophylactic neck irradiation was performed. Patients were older than 18 years with a Karnofsky 
performance status ⩾70%. The decision for primary (chemo-)RT with curative intent had to be made 
after a multidisciplinary meeting at each participating center. Concurrent chemotherapy was allowed, 
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 as well as pretreatment lymph node dissection. Local ethics committee approval was obtained before 
start of the study and all patients gave written informed consent. Patients were randomized to two 
treatment arms (experimental arm A and standard arm B). A total of 200 patients were included in the 
study (100 for each arm). To minimize the influence of center-specific parameters randomization was 
performed per center. 
All macroscopically affected tumor sites were treated up to a normalized iso-effective dose in 2 Gy 
fractions (NID2Gy) of 70 Gy. Fractionation schedule and total dose delivered to the primary tumor and 
affected lymph nodes were left to the discretion of each individual center. An overview of the different 
fractionation schedules and CTV-PTV margins can be found in the preliminary analysis of this study 
[10]. For the elective nodal volumes, patients randomized in arm A (experimental arm) were treated 
up to a NID2Gy of 40 Gy. For arm B (control arm) the elective nodal volumes were treated up to a 
NID2Gy of 50 Gy [9]. 
In 2 centers of this study, patients received a videofluoroscopy at baseline and at 6 and 12 months 
following the end of treatment. The endpoint of the current study is swallowing problems evaluated 
on PAS and SPSS at 6 and 12 months of follow up in this patient population. Patients from the original 
trial lacking pretreatment videofluoroscopy and videofluoroscopy at 6 or 12 months following the end 
of RT were excluded from the current analysis. After exclusion of patients who did not meet the 
inclusion criteria, 63 patients could be further analyzed. 
 
Scoring and VFS protocol 
 
Videofluoroscopies were done at baseline and at 6 and/or 12 months following the end of therapy. 
They were digitalized and scored blindly by 2 trained supervisors with at least 20 years of experience 
in the evaluation of videofluoroscopy (authors AG and ED). Afterwards we calculated the inter-rater 
agreement between the 2 observers and made a consensus scoring for the PAS and SPSS based on the 
highest score of the 2 observers for every patient at every time-point (baseline-6months-12months). 
During videofluoroscopy, patients were given a standard amount of 10 cc liquid bolus. This bolus 
consisted of a contrast agent (Micropaque ® Barii Sulfas Guebert, France). When there was risk for 
aspiration, a low osmotic iodine agent was used (Ultravist ®). 
 
Statistics 
 
As a first step, we calculated the TDRS for every patient. We defined the weight loss as the percentage 
of total body weight lost during the 6 months prior to RT, as we did in a previous paper [8]. The TDRS 
was scored as described in the original paper [3]. 
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 To determine the inter-rater agreement between both observers, the intraclass correlation 
coefficient (ICC) was calculated. The ICC takes values between 0 and 1 with higher values indicating 
higher levels of agreement. Proportional odds models were used to look at the link between TDRS and 
videofluoroscopies. The interaction with time was tested. A significant interaction with time means 
that the association between the variables is different between the 3 time points (baseline, 6 months, 
12 months). In such case, results are reported per time point. In absence of an interaction effect, the 
main effect is presented. All tests are two-sided, a 5% significance level is assumed for all tests. 
Analyses have been performed using SAS software (version 9.4 of the SAS System for Windows). 
 
Results 
 
Patient characteristics of the 63 patients who were included in this study are listed in Table 1.  
PATIENT AND TREATMENT 
CHARACTERISTICS 
SEX  
Female 12/63 ( 19.05%) 
Male 51/63 ( 80.95%) 
AGE  
Mean 61.4 
Median 61.0 
IQR (55.0; 68.0) 
Range (38.0; 80.0) 
DOSE TO THE ELECTIVE 
NECK 
 
40 46/63 ( 73.02%) 
50 17/63 ( 26.98%) 
NECK DISSECTION  
No 42/63 ( 66.67%) 
Yes 21/63 ( 33.33%) 
LOCATION  
CUP 4/63 (  6.35%) 
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 PATIENT AND TREATMENT 
CHARACTERISTICS 
Hypopharynx 15/63 ( 23.81%) 
Larynx 11/63 ( 17.46%) 
Oropharynx 33/63 ( 52.38%) 
T  
CUP 4/63 (  6.35%) 
1 4/63 (  6.35%) 
2 24/63 ( 38.10%) 
3 19/63 ( 30.16%) 
4 12/63 ( 19.05%) 
N  
0 10/63 ( 15.87%) 
1 10/63 ( 15.87%) 
2a 3/63 (  4.76%) 
2b 22/63 ( 34.92%) 
2c 18/63 ( 28.57%) 
CHEMOTHERAPY  
No 25/63 ( 39.68%) 
Yes 38/63 ( 60.32%) 
Table 1. Patient and treatment characteristics. 
 
All patients (n=63) received a baseline videofluoroscopy, 54 patients received an additional 
videofluoroscopy at 6 months of follow-up, 39 patients received an additional videofluoroscopy at 12 
months of follow-up.  
The ICC values for the agreement regarding the PAS and SPSS scoring between both observers 
demonstrated a fair level of inter-rater agreement for SPSS (range 0.56-0.75) and a good level of 
agreement for PAS (range 0.64-0.94). Agreement seemed to be better for pre-measurements than at 
6 or 12 months (Table 2).The different TDRS groups were rather unbalanced in our patient population. 
Forty nine percent of the study population belonged to the high risk group according to the TDRS. 
Thirty eight percent belonged to the intermediate risk group and 12.70 % to the low risk group (Table 
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 3). Regarding the PAS scale, we did not observe a significant p-value regarding interaction (p=0.14), 
meaning that the interaction was the same at all time points (baseline, 6 and 12 months). This 
interaction was not significant (p=0.15) when we removed interaction from the model, meaning that 
we did not observe a significant correlation between TDRS and PAS scored at baseline, 6 and 12 months 
of follow-up. 
 
Intraclass Correlation Coefficient (95% CI) 
Score pre 6m 12m Overall 
PAS 0.937 (0.899;0.962) 0.763 (0.625;0.855) 0.639 (0.411;0.792) 0.803 (0.740;0.853) 
SPSS 0.747 (0.614;0.838) 0.555 (0.341;0.715) 0.577 (0.326;0.753) 0.648 (0.547;0.730) 
CI: Confidence Interval 
Table 2. The Intraclass Correlation Coefficient values for the agreement regarding the PAS and SPSS 
scoring between both observers. 
Regarding SPSS, we found a p-value of p<0.01 for interaction, indicating that the interaction was 
different at all time-points. We observed no correlation between the TDRS and baseline SPSS values; 
a significant correlation was however observed between the TDRS and SPSS score at 6 months (p=0.01) 
and a borderline significant effect at 12 months (p=0.05) (Table 4). 
We observed a statistically significant lower risk for patients in the intermediate risk category when 
compared to the high risk category at 6 months of follow-up (p=0.02; OR -0.804 (-1.506;-0.103)). When 
we compared low versus high we did not observe a significant difference (p=0.08; OR 0.981 (- 
0.107;2.069)). When comparing low versus intermediate risk patients, we observed significantly higher 
SPSS scores in the low risk group (p=0.01; OR 1.786 (0.670;2.902)) (Table 5). 
Since we only had 8 patients in the low risk group, we repeated the analysis where we combined the 
low (n=8) and intermediate risk patients (n=24) together in one group to compare to the high risk 
group (n=31). Regarding PAS, we did not observe statistically significant differences. We found a 
significant p-value for interaction p<0.01 regarding the SPSS. We found again no correlation at baseline 
and a significant correlation at 6 months (p=0.01) but not at 12 months (p=0.08). When we looked at 
6 months to the low + intermediate risk group versus the high risk group, we observed a borderline 
significant correlation (p=0.05; OR -0.406(-1.207;-0.082), where the low and intermediate risk group 
together have less swallowing problems as evaluated on the SPSS when compared to the high risk 
group (Table 5). 
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 TDRS 
High risk group 31/63 ( 49.21%) 
Intermediate risk group 24/63 ( 38.10%) 
Low risk group 8/63 ( 12.70%) 
Table 3. The TDRS groups in our patient population. 
 
TDRS (global test) <0.01 
baseline: TDRS (global test) 0.76 
6 months: TDRS (global test) <0.01 
12 months: TDRS (global test) 0.05 
Table 4. Correlation of the TDRS with the SPSS at all time points. 
 
 
Comparison Estimate (95% CI) P-value 
low vs intermediate 1.786 (0.670;2.902) <0.01 
low vs high 0.981 (-0.107;2.069) 0.08 
intermediate vs high -0.804 (-1.506;-0.103) 0.03 
Low+intermediate vs high -0.406(-1.207;-0.082) 0.05 
CI: Confidence Interval 
Estimate>(<)0 means higher (lower) SPSS score for first level 
Table 5. Comparison of the different risk groups with SPSS at all time points. 
 
Discussion 
 
Dysphagia remains a major problem for patients treated witch (C)RT for locally advanced HNSCC. 
Dysphagia leads to longer eating times, inability to eat different types of food, and fear or inability to 
eat in public which in turn results in social isolation and depression. The TDRS is a way to predict 
dysphagia at 6 months. The purpose of this study was to correlate TDRS with videofluoroscopy 
evaluation. This is the first paper to correlate this model with videofluoroscopies. We chose to use the 
PAS and SPSS since these scales have been used extensively and have been validated [10-15]. The 
hypothesis of this paper was to see if the TDRS could guide us to see which patients are at risk for high 
scores on SPSS and PAS and might need a videofluoroscopic examination in the follow up. Since our 
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 population consists of only 63 patients, and not all patients received a videfluoroscopy at all time 
points, it is important to say that these results are only exploratory. We did not observe a correlation 
between the TDRS and PAS. Regarding the SPSS we observed a better correlation with the TDRS. 
However, we could not distinguish the low risk group from the high risk group and more importantly 
it seemed that the low risk group was more at risk when compared to the intermediate risk group. This 
might be partially explained by the imbalances in our patient population when we look at the division 
in the different TDRS risk categories. Fifty percent of the patients were T3–T4, all patients received a 
bilateral neck irradiation, 52% of the patients had an oropharyngeal tumor, and 60% received 
concomitant chemoradiation. These factors are highly scored in the TDRS, leaving almost no patients 
with low scores in our patient population (n=8). 
Therefore, we repeated the analysis combining the low and intermediate risk group. This way we 
obtained more balanced groups (n=31 in the high risk group and n=32 in the low/intermediate risk 
group). We found significant higher SPSS scores in the high risk group when compared to the low risk 
group. Therefore, based on our study we cannot recommend the use of the TDRS to select patients 
who might benefit from the additional information provided by videofluoroscopies following RT for 
head and neck cancer. Nonetheless, the TDRS has been validated in the past to predict acute and late 
physician scored dysphagia. Therefore it can have its use in selecting suitable candidates for preventive 
strategies for dysphagia [3]. However the best intervention method to lower dysphagia is currently 
unknown [8]. The strength of this paper is that this paper is the first to correlate TDRS with 
videofluoroscopies, the fact that all data were prospectively gathered and that the scoring was done 
by 2 experienced blinded observers. Furthermore, our research group has experience with research 
concerning the TDRS [8]. Limitations of the current study are the relatively small patient population 
and the imbalances between the different risk groups of the TDRS. 
 
Conclusions 
 
High risk TDRS patients had higher SPSS scores when compared to the intermediate group and the 
intermediate and low risk group together. However, low risk patients in our patient cohort could not 
be distinguished from high or intermediate risk patients. 
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 Supplementary data 
Penetration Aspiration Scale 
No penetration/aspiration 1 Contrast does not enter the airway. 
Penetration 2 Contrast enters the airway-remains above the vocal cords-no 
residu. 
3 Contrast remains above vocal folds-visible residu remains. 
4 Contrast contacts vocal folds-no residu. 
5 Contrast contacts vocal folds-visible residu remains. 
Aspiration 6 Contrast passes glottis-no subglottic residu. 
7 Contrast passes glottis-visible subglottic resdiu despite patients 
response. 
8 Contrast passes glottis-visible subglottic residu-absent patient 
response. 
 
Swallowing Performance Status Scale 
1 Normal. 
2 Abnormal oral or pharyngeal stage but able to eat regular diet without modifications or 
swallowing precautions. 
3 Mild impairment-mild dysfunction in oral or pharyngeal stage. Requires modified diet or 
therapeutic swallowing precautions. 
4 Mild-moderate impairment-need for therapeutic precautions-mild dysfunction in oral or 
pharyngeal stage. Requires modified diet and therapeutic precautions to minimize aspiration 
risk. 
5 Moderate impairment-moderate dysfunction in oral or pharyngeal stage, aspiration noted on 
exam. Requires modified diet and swallowing precautions to minimize risk of aspiration. 
6 Moderate-severe dysfunction-requires supplemental central feeding support-moderate 
dysfunction in oral or pharyngeal stage, aspiration noted on exam. Requires modified diet and 
swallowing precaution to minimize riks of aspiration. 
7 Severe impairment-severe dysfunction with significant apiration or inadequate oropharyngeal 
transit to esophagus, NPO, requires primary enteral feeding support. 
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 Correlation of patient and physician scored dysphagia with videofluoroscopies in patients treated 
with radiotherapy for head and neck cancer. 
 
Background and purpose 
The aim of this study was firstly to investigate the association between  patient scored dysphagia and 
physician scored dysphagia in head and neck cancer patients treated with radiotherapy. Furthermore 
we wanted to evaluate which of both correlated best with swallowing problems and swallowing 
changes  as evaluated by swallowing videofluoroscopies. 
 
Materials and methods  
Sixty-three patients from 2 different centers treated with radiotherapy for head and neck cancer were 
evaluated in the current study. Swallowing videofluoroscopies at baseline, 6 and 12 months following 
radiotherapy were evaluated by 2 observers using the Penetration Aspiration Scale (PAS) and 
Swallowing Performance Status Scale (SPSS) and correlated with patient and physician scored 
dysphagia. 
 
Results 
We observed a significant association between physician and patient scored dysphagia (p<0.01) both 
pre-treatment and post-treatment. 
Furthermore, the risk of a worse score on the PAS and SPSS increased significantly with increasing 
scores of both physician as well as patient scored dysphagia, and this at all assessed time-points. 
Regarding the detection of changes in the PAS and SPSS scores, patients could detect changes in the 
PAS score better, but both correlated well with the PAS and SPSS score. 
 
Conclusion  
Both physician and patient scored dysphagia correlate well with swallowing videofluoroscopies. Since 
patient scored dysphagia correlates better with PAS and changes in the PAS score, and physician scored 
dysphagia correlates better with SPSS, we advocate to use both patient and physician scored dysphagia 
in future trials. 
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 Introduction 
Head and neck cancer is the fifth most common cancer worldwide [1]. Radiation therapy (RT) with or 
without concurrent chemotherapy (CT) has emerged as the treatment of choice for patients with 
locally advanced head and neck cancer [2,3]. The use of altered RT fractionation schedules and the 
addition of concurrent CT to the management of head and neck cancer have significantly increased 
both locoregional control and overall survival [4]. However this came at the cost of more treatment 
related toxicity, especially dysphagia [5-7]. 
In the past, studies showed conflicting results regarding the associations of patient scored dysphagia 
and physician scored dysphagia [8-13]. A possible explanation can be that scoring by head and neck 
cancer patients, who are known to be frail and often have a low socio-economic status, can be 
challenging. However, the relationship between observer and patient scored toxicity has received little 
attention in oncology. The aim of this study was therefore firstly to investigate the association between  
patient scored dysphagia and physician scored dysphagia in head and neck cancer patients treated 
with RT or a combination of RT and CT. Secondly, we wanted to evaluate which of both correlated  best 
with objective swallowing  and changes in swallowing as evaluated on swallowing videofluoroscopies. 
Material and methods 
 
Patient data 
 
The current paper is an analysis of a sub-population of patients who were included in a prospective 
randomized controlled trial on dose de-escalation to the elective nodal volume in head and neck 
cancer  [14, 15]. Inclusion criteria of the original trial were previously untreated, histologically proven 
squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx or cervical lymph node 
metastases of unknown primary cancer (CUP). Patient work-up was done according to institutional 
guidelines. T1–T2N0 were allowed, if prophylactic neck irradiation was performed. Patients were older 
than 18 years with a Karnofsky performance status ⩾70%. The decision for primary (chemo-)RT with 
curative intent had to be made after a multidisciplinary meeting at each participating center. 
Concurrent chemotherapy was allowed, as well as pretreatment lymph node dissection. Local ethics 
committee approval was obtained before start of the study and all patients gave written informed 
consent. Patients were randomized between two treatment arms (experimental arm A and standard 
arm B). A total of 200 patients were included in the study (100 for each arm). To minimize the influence 
of center-specific parameters randomization was performed per center.  
All macroscopically affected tumor sites were treated up to a normalized iso-effective dose in 2 Gy 
fractions of 70 Gy. Fractionation schedule and total dose delivered to the primary tumor and affected 
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 lymph nodes were left to the discretion of each individual center. For the elective nodal volumes, 
patients randomized in arm A (experimental arm) were treated up to an EQD 2Gy of 40 Gy. For arm 
B (control arm) the elective nodal volumes were treated up to an EQD 2Gy of 50 Gy.  
In 2 participating centers, patients received a videofluoroscopy at baseline and at 6 and 12 months 
following the end of treatment. Sixty-tree patients could be further analyzed.  
 
Scoring and VFS protocol 
 
Videofluoroscopies were performed at baseline and at 6 and/or 12 months following the end of 
therapy. They were digitalized and scored blindly by 2 trained supervisors with at least 20 years of 
experience in the evaluation of videofluoroscopy (authors Ann Goeleven and Eddy Dejaeger). 
Afterwards we calculated the inter-rater agreement between the 2 observers and made a consensus 
scoring for the PAS (Penetration Aspiration Scale) and SPSS (swallowing performance status scale) 
based on the highest score of the 2 observers for every patient at every time-point (baseline-6months-
12months).  
During videofluoroscopy, patients were given a standard amount of 10 cc liquid bolus. This bolus 
consisted of a contrast agent (Micropaque ® Barii Sulfas Guebert, France). When there was risk for 
aspiration, a low osmotic iodine agent was used (Ultravist ®).  
Physicians scored dysphagia pretreatment using CTCAE version 2 acute toxicity scoring and post-
treatment using the RTOG/EORTC late toxicity scoring. Patient reported dysphagia was scored using 
the EORTC H&N35 quality of life questionnaire. 
 
Statistics 
 
To determine the inter-rater agreement between both observers, the intraclass correlation coefficient 
(ICC) was calculated. The ICC takes values between 0 and 1 with higher values indicating higher levels 
of agreement.  
For the first aim of the study, the patients’ dysphagia score was modeled as response variable and the 
physicians’ dysphagia score as covariate. For the second aim, RX values were modeled as a function of 
either patients’ or physicians’ dysphagia scores. For this analysis, the Akaike information criterion (AIC) 
is presented to compare model fit between both non-nested models. For both analyses, linear models 
were used including random effects to deal with longitudinal measurements. Interactions between 
covariates and time were tested to study differential effects of the covariates between time points. In 
absence of interaction effects (p-value interaction ≥ 0.05), the main effects of the covariates were 
reported as estimated slopes with 95% confidence intervals. Change of the scores were equally 
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 calculated for all measures so that a lower value indicates improvement and a higher value indicates 
worsening of dysphagia. Then, interactions with time interval are tested, related to the question 
whether associations between change scores are different between intervals. 
 
PATIENT AND TREATMENT 
CHARACTERISTICS 
GENDER  
Female 12/63 ( 19.0%) 
Male 51/63 ( 80.9%) 
AGE  
Mean 61.4 
Median 61.0 
IQR (55.0; 68.0) 
Range (38.0; 80.0) 
DOSE TO THE ELECTIVE 
NECK 
 
40 46/63 ( 73.0%) 
50 17/63 ( 27.0%) 
NECK DISSECTION  
No 42/63 ( 66.7%) 
Yes 21/63 ( 33.3%) 
LOCATION  
CUP 4/63 (  6.3%) 
Hypopharynx 15/63 ( 23.8%) 
Larynx 11/63 ( 17.5%) 
Oropharynx 33/63 ( 52.4%) 
T  
CUP 4/63 (  6.3%) 
1 4/63 (  6.3%) 
2 24/63 ( 38.1%) 
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 PATIENT AND TREATMENT 
CHARACTERISTICS 
3 19/63 ( 30.2%) 
4 12/63 ( 19.0%) 
N  
0 10/63 ( 15.9%) 
1 10/63 ( 15.9%) 
2a 3/63 (  4.8%) 
2b 22/63 ( 34.9%) 
2c 18/63 ( 28.6%) 
CHEMOTHERAPY  
No 25/63 ( 39.7%) 
Yes 38/63 ( 60.3%) 
Table 1. Patient and treatment characteristics 
Results 
Patient characteristics of the 63 patients included in this study are listed in Table 1.  
All patients (n=63) received a baseline videofluoroscopy, 54 patients received an additional 
videofluoroscopy at 6 months of follow-up and 39 patients received an additional videofluoroscopy at 
12 months of follow-up. The ICC values for the agreement regarding the PAS and SPSS that were scored 
on the swallowing videofluoroscopies on all 3 time-points demonstrated a fair level of inter-rater 
agreement for SPSS (range 0.56-0.75) and a good level of agreement for PAS (range 0.64-0.94) between 
both observers. Agreement seemed to be better for pre-therapy measurements when compared to 6 
or 12 months after the end of treatment (Table 2).   
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Intraclass Correlation Coefficient (95% CI) 
Score baseline 6 months 12 months Overall 
PAS 0.937 (0.899;0.962) 0.763 (0.625;0.855) 0.639 (0.411;0.792) 0.803 (0.740;0.853) 
SPSS 0.747 (0.614;0.838) 0.555 (0.341;0.715) 0.577 (0.326;0.753) 0.648 (0.547;0.730) 
CI: Confidence Interval 
Table 2. The Intraclass Correlation Coefficient values for the agreement regarding the PAS and SPSS 
scoring between both observers. 
 
The incidence of patient and physician scored dysphagia is presented in the supplementary material. 
Firstly, we investigated the correlation between physician and patient dysphagia scores. There was no 
evidence that this association would differ between time-points (pre-treatment and at 6/12 months 
of follow-up) (interaction p=0.1). Over all time-points we observed a significant association between 
physician and patient scored dysphagia (p<0.01). With every 1-level increase of the physician scored 
dysphagia, there is an average increase of 5.3 points on the patients dysphagia score (95% CI 
(4.077;6.594)).  
Secondly, we investigated the correlations between patient and physician scored dysphagia and 
videofluoroscopies. In none of the analyses, statistically significant interactions with time were 
observed (Table 3 a). We found a statistically significant association between both the physician and 
patient scored dysphagia and PAS score (p<0.01). The risk of a worse score on the PAS increased 
significantly with the increase of both physician and patient dysphagia scores. Furthermore, we found 
a  large difference in AIC values (585 versus 504, respectively). Although both scores are thus 
significantly positively correlated with dysfunction on videofluoroscopies, the patient dysphagia scores 
correlate better in comparison to the physician dysphagia scores. Similarly, we found that both 
dysphagia scores are significantly associated with SPSS (p<0.01). Although, this time, the physician 
dysphagia scores are more accurate when compared to the patient  scoring (AIC 462 vs 470, 
respectively) (Table 3 b).  
Also the analysis on change in scores revealed positive associations between both patient and 
physician scored dysphagia and the PAS as well as the SPSS (p<0.01).  Patients’ scores associate better 
with changes in the PAS score (AIC 308 vs 346, respectively). For the SPSS, the AIC values were very 
similar, so both physicians and patients change scores correlate equally to changes in the SPSS (table 
4 a and 4b). 
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PAS 
P-value 
interaction Estimate (95% CI) P-value AIC 
Physicians score: +1 level 0.051 1.650 (1.315;1.985) <.0001 585.53 
Patients score: +1 unit 0.325 0.219 (0.193;0.245) <.0001 504.35 
 
SPSS 
P-value 
interaction Estimate (95% CI) P-value AIC 
Physician s score: +1 level 0.491 1.378 (1.155;1.602) <.0001 462.29 
Patients score: +1 unit 0.293 0.141 (0.117;0.164) <.0001 470.22 
CI: Confidence Interval; AIC: Akaike Information Criterion (smaller=better) 
P-value interaction: tests interaction between the variable and time. 
P-value: main effect variable (over time points) or effect per time point (if significant interaction) 
Estimate>(<)0 means increased (decreased) SPSS score with increased dysphagia level 
Table 3a and 3b. Correlation of physician and patient scored dysphagia with PAS (table a) and SPSS 
(table  b) 
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Table 4a and 4b. Correlation of changes in physician and patient scored dysphagia with changes in 
PAS (table a) and SPSS (table b). 
 
Discussion 
The aim of this study was to investigate the association between patient scored dysphagia and 
physician scored dysphagia in head and neck cancer patients treated with RT. Furthermore we wanted 
to see which of both correlated best with swallowing videofluoroscopies and changes in swallowing 
during follow-up. 
The incidence of dysphagia in our patient group was comparable to recent literature [5-8]. 
Furthermore, the incidence of patient scored dysphagia was comparable to the reference data 
regarding quality of life in head and neck cancer patients [16]. 
Our study showed that there is a good association between patient and physician scored dysphagia 
scores, in the pre-treatment as well as in the post-treatment setting (6 and 12 months following 
treatment). We correlated physician and  patients scoring with swallowing videofluoroscopies, since 
this gives us a more objective evaluation of the dysphagia of each patient. The swallowing 
videofluoroscopies were scored blindly by 2 trained supervisors with at least 20 years of experience in 
the evaluation of videofluoroscopy. On the swallowing videofluoroscopies, we chose to use the PAS 
PAS 
P-value 
interaction Estimate (95% CI) P-value AIC 
Physicians change score: +1 level 0.703 1.517 (1.031;2.003) <.0001 346.10 
Patients change score: +1 unit 0.516 0.168 (0.135;0.200) <.0001 308.88 
 
SPSS 
P-value 
interaction Estimate (95% CI) P-value AIC 
Physician s score: +1 level 0.853 1.044 (0.683;1.404) <.0001 295.80 
Patients score: +1 unit 0.604 0.089 (0.059;0.119) <.0001 294.54 
CI: Confidence Interval; AIC: Akaike Information Criterion (smaller=better) 
P-value interaction: tests interaction between the variable and time. 
P-value: main effect variable (over time points) or effect per time point (if significant interaction) 
Estimate>(<)0 means increased (decreased) SPSS score with increased dysphagia level 
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and SPSS since these scales have been used extensively and have been validated [17-22]. Levels of 
agreement between both observers were good for both scales. 
The risk of a worse score on the PAS and SPSS increases significantly with increasing scores of both 
physician as well as patient scoring at all assessed time-points. Although both scores are thus 
significantly positively correlated with dysfunction on videofluoroscopies, the patient dysphagia scores 
correlate better with the PAS in comparison to the physician dysphagia scores. Regarding the SPSS, the 
physician scored dysphagia score explains better the risk than the patient dysphagia scores. Regarding 
the detection of changes in the PAS and SPSS scores, patients could detect changes in the PAS score 
better, but both correlated well with the PAS and SPSS change score. These observations indicate, that, 
if feasible we have to include both patient and physician dysphagia scores in future trials that assess 
dysphagia following radiotherapy for head and neck cancer. 
In recent publications, the association between patient scored dysphagia (using the MDADI 
questionnaire) and videofluroscopies was examined [11, 12]. Patient perception of swallowing 
function did not correlate well with actual physiologic functioning [11, 12]. On the other hand, other 
studies found statistically significant associations between videofluoroscopies and patient scored 
dysphagia [9,13]. A study that compared physician and patient scored dysphagia found that physician 
scoring correlated with patient scored quality of life endpoints to a very low degree [10]. 
This study is the first study to correlate both patient and physician scored dysphagia with 
videofluoroscopies and also assessed changes in dysphagia in the follow-up. In this study we found 
overall good correlations between patient and physician scored dysphagia, however, we have to bear 
in mind that this patient group is probably a very motivated subgroup of head and neck cancer patients 
since they  firstly agreed to be included in a randomised trial. Furthermore, the patients were also 
willing to undergo several videofluoroscopies during follow-up. This selection of more motivated 
patients might influence the results of the quality of life scoring and might explain the conflicting 
results when compared to past studies.  
Limitations of the study are the relatively small patient population and large proportion of dropouts. 
This might be due to the fact that videofluoroscopies are stressful procedures. Advantages of this study 
are the uniform and prospective scoring of patient and physician assessed dysphagia and the 
experience of the observers scoring the videofluoroscopies.  
Conclusion 
Both patient and physician scored dysphagia correlate well with PAS an SPSS scores as evaluated on 
swallowing videofluoroscopies, with no evidence of differences between the pre-treatment setting 
and the post-treatment setting. 
  
178 
 
Since patient scored dysphagia correlates better with PAS and changes in the PAS score, and physician 
scored dysphagia correlates better with SPSS, we advocate to use both patient and physician scored 
dysphagia in future trials. 
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Supplementary material 
The incidence of patient and physician scored dysphagia in our patient cohort: 
 
 
 Baseline 6 months 12 months 
Physician dysphagia  
Grade 0 n/N (%) 31/63 ( 49.2%) 22/54 ( 40.7%) 16/39 ( 41.0%) 
Grade 1 n/N (%) 18/63 ( 28.6%) 23/54 ( 42.6%) 16/39 ( 41.0%) 
Grade 2 n/N (%) 14/63 ( 22.2%) 9/54 ( 16.7%) 7/39 ( 17.9%) 
 
  Baseline 6 months 12 months 
Patient dysphagia 
 Median 22.0 22.0 10.0 
IQR (20.0; 24.0) (22.0; 26.0) (8.0; 14.0) 
Range (14.0; 52.0) (16.0; 50.0) (6.0; 34.0) 
Baseline phyciscian scoring was done according to the CTCAE scoring system for acute toxicity.  
Patient scoring was done according to the EORTC/RTOG scoring system for late toxicity. 
Patient dysphagia was scored according to the EORTC H&N35 quality of life questionnaire (number 
between 0 and 100). 
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CHAPTER 8 
THE ROLE OF PAROTID STEM CELLS IN RADIATION-INDUCED 
XEROSTOMIA AND SPARING OF THE SUPERFICIAL PAROTID LOBE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Elements in this chapter are published as: 
Nevens D, Nuyts S. The role of stem cells in the prevention and treatment of radiation-induced 
xerostomia in patients with head and neck cancer. Cancer Med. 2016 Jun;5(6):1147-53. 
Elements in this chapter are submitted to Oral Oncology as: 
Nevens D, Nuyts S. Can sparing of the superficial contralateral parotid lobe reduce xerostomia 
following radiotherapy for head and neck cancer? 
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The role of stem cells in the prevention and treatment of radiation-induced xerostomia in patients 
with head and neck cancer. 
Xerostomia is an important complication following radiotherapy (RT) for head and neck cancer. Current 
treatment approaches are insufficient and can only temporarily relieve symptoms. New insights into 
the physiopathology of radiation-induced xerostomia might help us in this regard. This review 
discusses the current knowledge of salivary gland stem cells in radiation-induced xerostomia and their 
value in the prevention and treatment of this complication. Salivary gland stem cell transplantation, 
bone marrow-derived cell mobilization, molecular regulation of parotid stem cells, stem cell sparing 
RT, and adaptive RT are promising techniques that are discussed in this study. 
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1 Introduction 
Radiotherapy (RT) is an important treatment modality in the management of head and neck cancer 
(HNC). RT can be used as a single modality or in combination with surgery and/or chemotherapy (CT). 
One of the most frequently reported side effects following RT in patients with HNC is hyposalivation 
and subsequent xerostomia due to co-irradiation of the salivary glands [1, 2]. Xerostomia significantly 
impairs the patient's quality of life due to the many secondary effects such as impairment of taste, 
swallowing, and speech [2-6]. Furthermore, the oral mucosa can become dry and atrophic, leading to 
frequent ulceration [6]. 
Approximately 40% of patients with HNC will experience xerostomia to some degree after treatment 
with RT [7-11]. The introduction of new techniques such as parotid-sparing intensity-modulated RT 
(IMRT) has resulted in less xerostomia; however, toxicity outcome is still far from perfect [12]. The 
Oncology and Radiotherapy Group for Head and Neck Cancer (GORTEC) proposed to evaluate 
prospectively acute and late toxicities, locoregional control, and overall survival for patients treated 
for head and neck cancer (HNC) with IMRT and bilateral neck irradiation in the GORTEC 2004–03 study. 
It was reported that 16.1% of patients treated with parotid-sparing IMRT experienced severe 
xerostomia 18 months after the completion of treatment [13]. 
Xerostomia can occur early during RT treatment. Depending on the localization of the tumor and the 
radiation portals, a rapid decrease of the salivary flow rate is observed during the first week of RT, 
after which there is a continuing gradual decrease to less than 10% of the initial flow rate. This early 
reaction is unforeseen because the excretory, acinar cells in the salivary glands have a slow mitotic 
rate; a fast response to RT is therefore not expected [6, 14]. It is suggested that early damage may be 
due to damage to the plasma membrane of acinar cells, compromising the receptor-mediated signaling 
pathways of water excretion. No immediate cell death takes place. Late damage, on the other hand, 
may be explained by (DNA) damage to the salivary gland stem cells (SCs) and subsequent lack of proper 
cell renewal [15, 16]. 
A review of published studies suggested that severe xerostomia can be avoided if either the mean dose 
to both parotid glands is less than 25 Gy or one parotid gland is spared to a mean dose of less than 20 
Gy [17]. GORTEC 2004-03 showed that a mean dose administered to the spared parotid below 28 Gy 
led to significantly less severe xerostomia [13]. 
Following RT, salivary gland recovery is dependent on the radiation dose and on the number of 
remaining viable SCs [6]. Increasing the regenerative potential of salivary glands by SC therapy after 
irradiation should be able to restore tissue homeostasis [6]. Gaining knowledge in the field of salivary 
gland SCs may thus provide means of preventing late xerostomia or could lead to new treatment 
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strategies to improve regeneration of these cells after RT. These new treatment approaches are in 
demand because the current clinical management of xerostomia is often difficult and brings in many 
cases no substantial relief for the patient [18]. 
In 2006, our research group published a literature review on radiation-induced xerostomia in patients 
with head and neck cancer [2]. Since this review was published, there has been extensive research in 
the field of xerostomia prevention and treatment after RT in head and neck cancer. A substantial 
proportion of this research focused on the link between salivary gland SCs and xerostomia. Research 
on salivary gland SCs and treatment strategies regarding these cells is scattered in literature. 
Therefore, we present in this review an overview of new findings in this field, with emphasis on 
possible therapeutic applications. 
A systematic literature search was performed in the MEDLINE/PubMed database for articles published 
between January 1990 and September 2015. The objective was to trace all literature containing 
original data on new findings and potential treatment strategies in the field of salivary gland SCs. 
The literature search was performed in October 2015 using combinations of Mesh terms of 
“xerostomia”, “radiotherapy”, “salivary gland,” and “stem cell”. Furthermore, extensive cross-
referencing of the selected articles was performed. Case reports were eliminated from this review. 
Furthermore, the search was limited to English language. Gender and age were not limited. 
2 Prevention and treatment of radiation-induced xerostomia 
 
2.1 Stem cell transplantation and bone marrow-derived cell mobilization 
2.1.1 Stem cell transplantation 
Before transplantation of SCs is possible, surgical removal of salivary gland tissue before the start of 
the oncologic treatment is needed. Later on, SCs need to be collected. The ultimate goal of SC 
transplantation is regeneration of the function of the salivary gland by differentiation of these 
transplanted SCs into functional salivary gland cells [19-25]. 
Since 2004, several studies were performed in which submandibular and parotid gland SCs were 
transplanted in animal models after RT [19-25]. The best marker, however, to select SCs for 
transplantation, still remains unclear. The most studied marker is c-Kit. [15, 20-22, 25, 26] 
Transplantation of c-Kit-positive cells in mice submandibular glands can restore function and 
morphology [25, 26]. Interestingly, these c-Kit-positive cells are also found in human salivary glands 
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[26]. Whether these c-Kit-positive cells in humans have the same regenerative potential needs to be 
investigated. 
On the other hand, it is suggested that CD 49f, CD 29, CD 24, and CD 133 might be used as markers for 
salivary gland SCs in mice [15, 27-30]. The finding of these other markers is important because some 
of the cells of the c-Kit-negative population may also have regenerative potential, indicating that c-Kit 
is inadequate as a marker and that a combination of markers is needed, especially when a low amount 
of donor material is available [25]. 
Side population cells have been identified in various organs as putative SCs; their precise function, 
however, remains unclear. In mice salivary glands, side population cells did not seem to have SC activity 
[27]. However, a side population cell-derived protein—clusterin—was identified as a factor to recover 
from hypofunction of the salivary glands. It is believed that clusterin scavenges reactive oxygen species 
after irradiation [27]. This means that this protein might have an additional benefit when stem cell 
transplantation is performed. 
2.1.2 Bone marrow-derived cell mobilization 
Mesenchymal SCs from the bone marrow can be mobilized [31, 32]. After migration, they secrete 
growth and survival factors that enhance the regeneration of tissue by stimulating the proliferation 
and differentiation of remaining salivary gland SCs and by decreasing inflammation and modifying the 
immune response [31]. Importantly, this effect can be mimicked by adding keratinocyte growth factor, 
prophylactic pilocarpine (a nonselective muscarinic receptor agonist) or hyperbaric oxygen [23, 33, 
34]. 
Selection of patients for this treatment will be very important. When the damage to the salivary gland 
is expected to be low, this technique using bone marrow-derived cells could be enough to limit 
xerostomia after RT. When the damage is expected to be high, bone marrow-derived cell mobilization 
could be insufficient, so SC transplantation may be necessary [31]. 
 
2.2 Molecular regulation of salivary gland stem cells 
Until recent, little was known about the molecular regulators of SCs in human salivary glands. 
Nowadays, there is growing evidence that the Wnt/β-catenin signaling pathway is essential for 
maintenance and activation of different types of SCs, including these of the salivary glands [35-37]. 
Regeneration of SCs is impaired by Wnt inhibition and enhanced by Wnt activation in epithelial organs 
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such as the liver, airways, and intestines [38, 39]. The central mediator of Wnt signaling is β catenin, 
which acts as an activator of gene transcription. 
There is increasing data that activation of this pathway may also have a radioprotective effect and 
might decrease xerostomia numbers in irradiated patients [36, 40]. Forced activation of the Wnt/β-
catenin pathway in mice during RT prevents both acute and chronic hyposalivation through inhibition 
of apoptosis and preservation of functional salivary stem/progenitor cells [36]. 
Wnt activation is also known to promote angiogenesis and innervation during development. In this 
regard, it is speculated that Wnt activation can help in the regeneration of the damage to blood supply 
and innervation after irradiation. This can play an additional role in the prevention of hyposalivation 
after RT [41]. 
These findings are promising; however, further research is mandatory to confirm the results and to 
investigate whether activation of this pathway is sufficient to prevent xerostomia in humans after RT. 
Regarding the introduction of this technique, a major concern that needs further clarification is that 
overexpression of the Wnt/β-catenin pathway has been linked to carcinogenesis [42]. 
Furthermore, there is emerging evidence that transient activation of the Hedgehog pathway and 
modulation of the GDNF pathway might play a role in preserving salivary gland SCs after RT [30, 43-
45]. An overview of all the cross talking intercellular signaling pathways involved in the development 
and regeneration of salivary gland SCs is beyond the scope of this study but can be found in a recent 
review by Liu et al. [43]. 
 
2.3 Bath and shower principle in RT 
Intensity-modulated RT (IMRT) is the modality of choice to reduce xerostomia numbers following RT 
for HNC [12]. Minimization of the mean dose to the parotid glands is the preferred technique to 
achieve parotid gland function sparing [13, 17]. In spite of technical improvements, xerostomia after 
IMRT remains a serious problem [12]. 
A first possible explanation for this higher-than-expected incidence of xerostomia is the hypothesis 
that radiation of the parotid gland has a “bath and shower effect”. Photon-based IMRT gives an overall 
low dose to the entire parotid gland [46]. There is evidence that the tolerance to a high dose of RT to 
a small subvolume (“shower”) is strongly reduced by giving a subtolerance dose to the surrounding 
volume (“bath”) [46]. Van Luijk et al. demonstrated this in the parotid gland in a rat model [46]. The 
parotid glands were irradiated up to a dose of 10 Gy, which did not result in late loss of function. 
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Addition of a bath of 1–10 Gy to the caudal 50% of the glands resulted in enhanced function loss. This 
indicates that avoiding an overall low dose to the parotid gland in rats could lead to less parotid gland 
hypofunction and subsequently to less xerostomia. Recovery after RT appears to be dependent on the 
number of remaining SCs after treatment [25]. Currently, we have no good idea about the 
radiosensitivity of parotid gland SCs; however, the results above are suggesting that these SCs are very 
radiosensitive. High-precision RT, avoiding low doses to the entire parotid gland, can possibly 
counteract this problem. Proton RT, for example, has a steeper dose gradient, and could therefore 
avoid a low dose to the surrounding tissues more easily. 
 
2.4 Sparing of SC-rich regions in the parotid gland during RT 
Sparing of SC-rich regions within the parotid gland could help in preventing xerostomia following RT 
[47]. The specific location of these SCs and therefore the region to spare has been the subject of 
debate. Several research groups found that (c-Kit positive) stem/progenitor cells in the salivary gland 
are located in the larger excretory ducts [47, 48]. Van Luijk et al. investigated the relationship between 
the localization of parotid SCs and late parotid gland dysfunction after irradiation in a rat model [46, 
47]. They found a correlation in the rat model where high-precision irradiation to the center of the 
parotid gland resulted in excessive reduction of saliva production, indicating that this zone contains a 
large population of SCs. The dose to specific volumes of the parotid gland was also correlated by this 
research group to saliva production 1 year after RT. This research group showed in a cohort of patients 
with HNC that the RT dose to the region of the salivary gland containing stem/progenitor cells 
predicted the function of the salivary glands 1 year after RT [47]. Miah et al. found that sparing the 
superficial lobe of both parotid glands may offer a higher incidence of recovery of salivary function 
compared to whole contralateral parotid gland sparing alone in oropharyngeal cancers [48]. Buettner 
et al. found similar results [49]. In our department, we conducted a study in which we included 28 
patients who were treated with chemoradiotherapy (CRT) for HNC. We looked at the mean radiation 
dose to the superficial and deep ipsilateral parotid lobe and correlated this with patient- and physician-
scored xerostomia. In this small patient group, we observed a significant correlation between 
physician-scored xerostomia ≥2 and the mean dose to the ipsilateral superficial parotid lobe. Sparing 
of the superficial ipsilateral parotid lobe, while sparing the whole contralateral parotid gland, could 
mean a step forward toward decreasing xerostomia after RT for HNC (unpublished data). We will 
investigate this hypothesis further in a larger patient cohort. 
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2.5 Sparing of the submandibular gland and oral cavity during RT 
Dijkema et al. stated that sparing of the contralateral submandibular gland, in addition to parotid gland 
sparing, might result in improved patient-reported xerostomia [50]. Little et al. found that mean doses 
to the parotid glands, submandibular glands, and oral cavity are significant predictors of both patient-
reported and observer-rated xerostomia after chemo-IMRT, with oral cavity doses remaining 
significant after adjusting for the parotid gland and submandibular gland doses [51]. Jellema et al. 
found that the mean dose to the parotid and submandibular glands could influence the risk of 
xerostomia at 6 months; no significant differences were found when xerostomia was correlated with 
the oral cavity dose [9]. These results, however, support efforts to spare all the salivary glands as much 
as possible [51]. Mean RT doses to the submandibular gland exceeding 39 Gy cause permanent 
ablation of both stimulated and unstimulated flow [52]. These findings are promising. It might be 
interesting to combine research on sparing of the submandibular gland and oral cavity with sparing of 
SC-rich regions in the parotid gland during RT. 
 
2.6 Adaptive RT 
One of the unique aspects of RT to the head and neck region is that noticeable changes in the anatomy 
occur during treatment. These changes include shrinkage of the tumor, but also of the surrounding 
organs at risk (such as the parotid and submandibular glands) [53]. Furthermore, a medial shift of the 
parotid glands is often described during RT [54]. A small study of our research group including five 
patients showed a median relative volume loss of the parotid glands of 41.5% during RT (range 20.0–
48.4%). The parotid glands generally shifted medially due to tumor shrinkage and weight loss. 
Therefore, the plan created on the initial planning computed tomography may no longer be optimal 
for the changed anatomy during treatment. Moreover, the actual RT dose delivered to the patients 
may be significantly different from what was planned. Computed tomographies taken during the 
course of RT could be used to evaluate at what point in time the target volume, organs at risk and dose 
distribution have changed to such an extent that replanning is necessary [53]. This adaptive approach 
could result in less irradiation of the organs at risk and thus less irradiation of the parotid SCs. 
We recently closed a multicenter randomized adaptive radiotherapy trial including 100 patients with 
HNC. All patients received a computed tomography at 2 and 4 weeks after start of treatment, 
replanning was performed at these time-points. Further follow-up of these patients will give us more 
insights into whether this adaptive RT technique results in less xerostomia. 
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3 Conclusions 
To date, none of the described techniques concerning SCs to treat xerostomia are ready for clinical 
implementation, although most of them seem very promising in animal models. 
It will become clear in future trials which technique or combination of techniques will be the most 
beneficial, cost-effective, and easy to implement. The emphasis, nevertheless, has to be on avoiding 
xerostomia as much as possible. If both the shower and bath assumption, the role of the contralateral 
submandibular gland and the importance of SC sparing RT are confirmed in future trials, high-specific 
proton RT could be a way to counteract these problems at the same time. 
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Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy 
for head and neck cancer? 
Purpose 
The purpose of this study is to see whether sparing the superficial contralateral parotid lobe can help 
limiting xerostomia following radiotherapy for head and neck cancer. 
Material and methods 
Eighty-eight patients that were included in 2 prospective randomized studies, were analysed in the 
current study. Using the dosimetry of both the parotid glands, we divided our patients in 4 groups. 
Group 1 includes patients where we were able to reduce the radiation dose below the threshold in 
order to spare both the ipsilateral and contralateral parotid glands, group 2 consist of patients where 
only the contralateral parotid gland could be spared. Group 3 consists of patients where only the 
contralateral superficial parotid lobe could be spared, while in group 4 not even the contralateral 
superficial lobe could be spared. 
Results 
When we compare group 1 and group 2, we did not observe a significant difference between both 
groups in terms of xerostomia scores at 6 or 12 months. When we compared these groups with group 
3, we observed significant differences with more xerostomia in group 3 where only the contralateral 
superficial lobe was spared. A significant difference was also observed between group 3 and group 4 
with more xerostomia in group 4. 
Conclusion 
When sparing of the whole contralateral parotid gland is not possible, delineating both the superficial  
parotid glands and trying to spare at least one of them can mean a way forward in limiting xerostomia 
in head and neck cancer patients treated with radiotherapy. 
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Introduction 
Radiotherapy (RT) is an important treatment modality in the management of head and neck cancer 
(HNC). RT can be used as a single modality or in combination with surgery and/or chemotherapy (CT). 
One of the most frequently reported side effects following RT in patients with HNC is hyposalivation 
and subsequent xerostomia due to co-irradiation of the salivary glands [1, 2]. Xerostomia significantly 
impairs the patient's quality of life due to the many secondary effects such as impairment of taste, 
swallowing, and speech [2-6]. Approximately 40% of patients with HNC will experience xerostomia to 
some degree after treatment with RT [7-11]. The introduction of new techniques such as parotid-
sparing intensity-modulated RT (IMRT) has resulted in less xerostomia; however, toxicity outcome is 
still far from perfect [12]. The consensus has been reached that xerostomia can be substantially 
reduced by limiting the mean parotid gland dose to <26–30 Gy as a planning criterion [13].  
Xerostomia can occur early during RT treatment. It is suggested that early damage may be due to 
damage to the plasma membrane of acinar cells, compromising the receptor-mediated signaling 
pathways of water excretion. Late damage, on the other hand, may be explained by (DNA) damage to 
the salivary gland stem cells (SCs) and subsequent lack of proper cell renewal [15, 16]. Sparing of SC-
rich regions within the parotid gland could thus theoretically help in preventing xerostomia following 
RT [17]. The specific location of these SCs and therefore the region to spare has been the subject of 
debate. The data from the group in Groningen suggest that SCs are located in the vicinity of the major 
ducts residing in the superficial lobe [14]. Miah et al. found that sparing the superficial lobe of both 
parotid glands may offer a higher incidence of recovery of salivary function compared to whole 
contralateral parotid gland sparing alone in oropharyngeal cancers [18]. 
The purpose of this study is to see whether sparing the superficial contralateral parotid lobe can help 
limiting xerostomia following radiotherapy for head and neck cancer. 
Materials and methods 
Patients 
Eighty-eight patients that were included in 2 prospective randomized studies, were analysed in the 
current study [19, 20, ClinicalTrials.gov Identifier:NCT01287390]. The inclusion criteria were previously 
untreated, histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, 
larynx or cervical lymph node metastases of unknown primary cancer (CUP). All patients were treated 
with definitive RT or chemoradiotherapy for head and neck cancer between 2009 and 2015. In all 
patients, the intention was to limit the irradiation to at least one parotid gland to a mean dose less 
than 26 Gy and doses to the submandibular glands were kept as low as possible.  
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The delineation of the parotid lobe, and superficial and deep lobes were done retrospectively by 1 
observer after the planning. The planning was thus performed without optimization for these 
structures.  Parotid tissue lateral to the retromandibular vein was defined as the superficial lobe (Figure 
1) [23]. All patients were treated with IMRT using a commercially available treatment planning system 
(Eclipse®). The following dose-volume parameters were extracted from the treatment plans: Dmean 
ipsilateral parotid gland, Dmean contralateral parotid gland, Dmean of the superficial contralateral and 
deep parotid lobe and the Dmean of the superficial ipsilateral and deep parotid lobe. These structures 
were considered to be spared when the mean dose was less than 26 Gy. Using the dosimetrical 
information, we divided our patients in 4 groups. Group 1 includes patients where we achieved to 
spare both the ipsilateral and contralateral parotid gland, group 2 consists of patients where only the 
contralateral parotid gland could be spared. Group 3 consists of the patients where only the 
contralateral superficial parotid lobe could be spared (Figure 1), while in group 4 not even one 
superficial lobe could be spared. Xerostomia was scored by physicians using the RTOG/EORTC scoring 
system for late toxicity at 6 and 12 months of follow-up. Proportional odds models were used to look 
at the link between the different groups and xerostomia at 6 and 12 months. The interaction with time 
was tested. A significant interaction with time means that the association between the variables is 
different between the 2 time points (6 months, 12 months). All tests are two-sided, a 5% significance 
level is assumed for all tests. Analyses have been performed using SAS software (version 9.4 of the SAS 
System for Windows). 
 
Figure 1. Example of a patient of group 3 where only the contralateral superficial parotid lobe could 
be spared (arrow). 
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Results 
Patient characteristics can be found in Table 1. 
 
PATIENT AND TREATMENT 
CHARACTERISTICS 
SEX  
Female 17/88 ( 19.3%) 
Male 71/88 ( 80.7%) 
AGE  
Mean 63.4 
Median 62.1 
Range (38.0; 80.0) 
LOCATION  
CUP 5/88 (5.7%) 
Hypopharynx 22/88 (25.0%) 
Larynx 15/88 (17.0%) 
Oropharynx 46/88 (52.3%) 
T  
CUP 5/88 (5.7%) 
1 6/88 (6.8%) 
2 36/88 (40.9%) 
3 29/63 (33.0%) 
4 12/63 ( 13.6%) 
N  
0 13/88 ( 14.8%) 
1 14/88(15.9%) 
2a 5/88 ( 5.7%) 
2b 31/63 ( 35.2%) 
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PATIENT AND TREATMENT 
CHARACTERISTICS 
2c 25/63 ( 28.4%) 
CHEMOTHERAPY  
No 30/88 (34.1%) 
Yes 58/88 ( 65.9%) 
Table 1. Patient and treatment characteristics. 
We included a total of 88 patients in our study and divided these patients in 4 groups (Table 2). In 21 
patients, both the ipsilateral and contralateral parotid glands could be spared (group 1). In 41 patients 
the contralateral parotid gland could be spared, but the ipsilateral could not be spared (group 2). Thus, 
in 62 patients at least the contralateral lobe could be spared, meaning that in the remaining 26 patients 
the contralateral parotid gland could not be spared entirely. In 14 of these patients the superficial 
contralateral parotid lobe could be spared (group 3), while in 12 patients not even the superficial lobes 
could be spared (group 4). 
Incidences of xerostomia at 6 and 12 months are presented in table 3. 
Xerostomia 
6 months 
n=88 
12 months 
n=84 
Grade 0 21 (24 %) 24 (27%) 
Grade 1 40 (45%) 38 (45%) 
Grade 2 21 (24%) 19 (22%) 
Grade 3 6 (7%) 3 (4%) 
Grade 4 0 0 
Table 3. Incidences of xerostomia (RTOG/EORTC scoring) at 6 and 12 months. 
 
We observed a statistically significant global effect between the 4 groups and the xerostomia scores 
with a p value of 0.02. Therefore, we performed a subsequent pairwise comparison between the 4 
groups. We observed a p value for interaction of p=0.11; meaning that the observed effect between 
the 4 groups and xerostomia was the same at 6 and 12 months of follow-up.   
The pairwise comparison is presented in Table 3. When we compare group 1 and group 2 (sparing of 
both parotid glands versus sparing of the contralateral parotid gland), we did not observe a significant 
difference between both groups in xerostomia at 6 or 12 months. When we compared group 1 and 
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group 2 with group 3, we observed significant differences with more xerostomia in group 3 where only 
the contralateral superficial lobe was spared. When we correlated group 1 and group 2 with group 4, 
we observed a similar result with more xerostomia in group 4 when compared to group 1 and group 
2. Furthermore a significant difference was observed between group 3 and group 4 with more 
xerostomia in group 4. 
 
Comparison Estimate (95% CI) P-value 
Group 1 vs Group 2 -1.033 (-2.693;0.626) 0.22 
Group 1 vs Group 3 -1.250 (-2.405;-0.096) 0.04 
Group 1 vs Group 4 -1.473 (-2.391;-0.555) 0.01 
Group 2 vs Group 3 -7.467 (-14.90;-0.034) 0.05 
Group 2 vs Group 4 -0.804 (-1.506;-0.103) 0.02 
Group 3 vs Group 4 -1.167 (-2.249;-0.085) 0.04 
CI: Confidence Interval 
Estimate < 0 means lower score of xerostomia for first level 
Table 4. Pairwise comparison of the different groups of the study. Group 1: Both the ipsilateral and 
contralateral parotid lobes could be spared; Group 2: Contralateral parotid gland could be spared, 
but the ipsilateral could not be spared; Group 3: Only contralateral superficial parotid lobe could be 
spared; Group 4: Both parotid lobes, and both superficial lobes could not be spared. 
 
Discussion 
Severe xerostomia following radiotherapy in head and neck cancer can be avoided by sparing one 
parotid gland [13,14]. The patient cohort of this study was therefore planned trying to spare at least 
one parotid gland. However, in 26 patients (29% of the patients) the contralateral parotid gland could 
not be spared entirely. In these patients we need to find other ways to limit xerostomia. Therefore, 
the purpose of this study is to see whether sparing the superficial contralateral parotid lobe can help 
limiting xerostomia following radiotherapy for head and neck cancer. 
When we compared group 1 and group 2 (sparing of both parotid gland versus sparing of the 
contralateral parotid gland), we did not observe a significant difference between both groups in 
xerostomia at 6 or 12 months. Sparing of both the parotid glands versus only one entire parotid gland 
did not result in less xerostomia at 6 and 12 months of follow-up in our patient population. However 
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sparing both parotid glands or just one proved to be better in terms of xerostomia outcome when 
compared to just sparing one superficial parotid gland or not being able to spare a superficial parotid 
gland at all. Interestingly, a significant difference was also observed when we compared group 3 and 
group 4. These data suggest that when we cannot spare both or one parotid gland from high dose 
irradiation, sparing of the contralateral superficial parotid gland results in less xerostomia after 6 and 
12 months of follow-up. Delineating both the superficial  parotid glands and trying to spare them can 
thus mean a way forward in limiting xerostomia in head and neck cancer patients treated with 
radiotherapy in patients where an entire parotid gland cannot be spared. 
Data on superficial parotid lobe sparing in literature are scarce. In a recent study, contralateral parotid 
sparing was compared to bilateral superficial lobe parotid sparing. The results of this study showed 
that bilateral superficial parotid lobe sparing results in less high-grade xerostomia [18,23]. In this study 
they advocate delineation of the superficial parotid lobes, a suggestion that we, based on our results, 
agree upon. 
A strong point of this paper is the prospective scoring of toxicity, and the uniform delineation by one 
observer. Possible limitations are the fact that we did not take the dose to the submandibular glands 
and oral cavity into account. Dijkema et al stated that sparing of the contralateral submandibular gland, 
in addition to parotid gland sparing might result in less xerostomia [24]. Little et al found that mean 
doses to the parotid glands, submandibular glands and oral cavity are significant predictors of 
xerostomia, with oral cavity doses remaining significant after adjusting for the parotid gland and 
submandibular gland doses [25].  Jellema et al found that the mean dose to the parotid and 
submandibular glands could influence the risk of xerostomia at 6 months; no significant differences 
were found when xerostomia was correlated with the oral cavity dose [9]. These results support efforts 
to spare all the salivary glands as much as possible, as was done for the patients in our study. Given 
the relatively small patient population and the fact that we had already 4 groups when we took the 
dose to the parotid glands into account, we were not able to further subgroup the patients taking into 
account dose to other relevant organs in the current study. 
Conclusion 
When sparing of the whole contralateral parotid gland is not possible, delineating the superficial  
parotid glands and trying to spare at least one of them can mean a way forward in limiting xerostomia 
in head and neck cancer patients treated with radiotherapy. 
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Chapter 9 
GENERAL DISCUSSION AND FUTURE PERSPECTIVES. 
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The main focus of this PhD project was to investigate different approaches to improve the therapeutic 
ratio for HNC patients undergoing R(C)T. Firstly, we wanted to determine the best treatment and 
follow-up strategy for the neck nodes (PART I of this project). We assessed if upfront neck dissection 
and radiotherapy dose de-escalation to the elective lymph nodes could help us improve the 
therapeutic ratio for HNC. Furthermore we assessed the safety of a CT-based follow-up approach of 
the neck nodes. Secondly, in PART II of this project, we aimed to validate and create predictive models 
for toxicity following R(C)T.  These models can give us more insights how to avoid treatment related 
toxicity and help us to further individualize the treatment of HNC patients. 
 
PART I DETERMINING THE BEST TREATMENT AND FOLLOW-UP STRATEGY FOR THE NECK NODES 
The results we obtained from a comparative multicentric retrospective study (chapter 3) that assessed 
the potential benefit of an upfront neckdissection (ND), suggest that such ND before CRT brings no 
benefit in terms of oncological outcome for HNC patients. We observed no statistically significant 
differences between upfront ND versus no upfront ND regarding LC, RC, DC and DFS. DFS was similar 
in both groups; around 60% in both treatment arms after 3 years of follow up. Comparison of our 
results with literature is difficult since most patient cohorts are small and originate from the era before 
IMRT or 3DCRT or concomitant chemotherapy was used. Three studies reported no statistically 
significant differences regarding oncological outcome [1-3]. Two studies showed a significant impact 
on RC [4,5], however one of these studies was published in 1991 [4] and the question arises if these 
results still stand after the many advances in RT and the addition of concomitant systemic treatment 
for HNSCC of the last decade [6-8]. The study by Liu et al dates from 2012, however RT was performed 
using 2D techniques and none of the patients received chemotherapy [9]. Comparison with today’s 
R(C)T is therefore difficult. One study used 3-DCRT and IMRT and reported better OS and DFS following 
upfront ND when compared to CRT alone. However, this was a relatively small study, in which only 32 
patients of the study population of 135 patients received an upfront ND and only 9 patients were 
treated with (C)RT [10]. Furthermore, the reason why patients received upfront ND was not explained. 
Regarding toxicity, we found more moderate to severe late fibrosis following upfront ND. This was 
confirmed prospectively in chapter 6 where upfront ND was incorporated as a key factor in our model 
to predict fibrosis ≥grade 2.   
A prospective randomized trial regarding the need for upfront ND could once and for all end the 
debate whether upfront ND is beneficial in locally advanced head and neck cancer. It remains unlikely 
however that such a study will be undertaken, since the evidence of a benefit in terms of oncological 
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outcome following ND is so scarce and given the findings of our retrospective study regarding outcome 
and prospective studies regarding toxicity.  
In chapter 4, we discussed the results of a multicentric randomized trial on dose de-escalation to the 
elective lymph nodes in head and neck cancer in terms of In late toxicity, oncological outcome and 
quality of life.  The primary endpoint of this study was late dysphagia as this is the most important 
quality of life compromising toxicity after curative treatment of HNC [11]. A preliminary analysis of our 
study demonstrated that a dose de-escalation to the elective lymph nodes, significantly reduced the 
volume of the swallowing apparatus irradiated up to a high dose without compromising target 
coverage and dose homogeneity. Clinically this dose reduction resulted into significantly less grade ⩾3 
dysphagia in the de-escalated arm 3 months after treatment with similar LRC and DFS rates [12]. 
Regarding late toxicity, we observed a trend towards less late dysphagia, however not confirmed 
following longitudinal analysis [13]. Furthermore, we observed significantly less moderate salivary 
gland toxicity in the 40 Gy arm at 6 and 18 months, confirmed after longitudinal analysis.  Regarding 
QoL, the results of the study are in favor of the 40 Gy arm [14]. Outcome in terms of local, regional and 
distant control and survival did not differ significantly between the groups after two years of follow 
up. In the 40 Gy arm however, we observed a higher absolute number of all regional recurrences (i.e. 
in the elective neck as well as in pre-existing pathological lymph nodes). It was reassuring that there 
were only 2 regional recurrences in the elective neck outside the high-dose PTV in the 40 Gy arm and 
1 in the 50 Gy arm. Because these numbers were too small to conclude that more elective neck 
recurrences would occur when lowering the dose in the elective neck from 50 to 40 Gy EQD2Gy, we 
have set up an extra study combining the data of 3 prospective studies using dose de-escalation to 
the elective lymph nodes. Two hundred thirty-three patients included in 3 prospective randomized 
studies were analysed. This number of patients is comparable to a recent publication that looked at 
the pattern of nodal recurrence in head and neck cancer patients following a dose of 50 Gy to the 
elective nodal volume (n=264)  [15]. The actuarial rate of recurrence in the electively irradiated lymph 
node regions was 3.9% (95% CI 1.8-6.0) at 2 years. There is extensive data on the rate of recurrences 
in the elective nodal volume following a dose of 50 Gy (EQD2Gy) [15-23]. Observed rates of recurrence 
in electively irradiated lymph node regions varied from 2% to 11%. Our results are thus comparable 
to literature following 50 Gy (EQD2Gy), and more importantly are in line with the latest studies [15, 
23]. We only found 5 recurrences outside the elective volume of which 2 recurrences were located in 
an ipsilateral intraparotid lymph node. Furthermore, we found 1 recurrence in level VI, 1 in level IB and 
1 in the retropharyngeal lymph nodes. These results confirm previous observations that recurrences 
in the retropharyngeal lymph nodes and in level IB are rare [23]. It could be hypothesized that lowering 
the dose for subclinical disease could result in less disease control and thereby in higher numbers of 
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distant metastases [24]. In this study we observed a 2 year distant control of 83.2% (95% CI 76.3-90.1). 
This is comparable to recent literature following a dose of 50 Gy [15, 23]. This is reassuring with respect 
to the risk of enhancing the occurrence of distant metastases when lowering the dose to the elective 
neck. To conclude the discussion on chapter 4, we can advocate the further use of 40 Gy (EQD2Gy) to 
the elective lymph nodes in future clinical study protocols, since we demonstrated that this is a safe 
treatment approach that deserves further exploration since it reduces acute and late toxicity and has 
a positive effect on quality of life. 
In chapter 5, we assessed the safety of a CT-based follow-up approach of the neck nodes following 
CRT. Furthermore, we tried to identify predictive factors that we incorporated into a model to predict 
regional recurrences following CRT using CT-derived parameters and clinical parameters. The role of 
planned neck dissection after CRT for locoregionally advanced HNC has weakened over the past decade 
but is still a matter of debate. Data from mostly retrospective series support a conservative approach 
with ND only carried out in those patients with residual disease on a clinical or radiological basis [25-
31]. Some centers still perform planned ND in all patients with N2 or N3 disease, irrespective of their 
response to initial treatment [32]. Robust data from randomized trials addressing this issue are lacking. 
In our center we advocate a conservative approach, thereby avoiding ND and its complications in a 
large amount of patients. Outcome using this approach in our patient cohort is comparable to that 
described by other authors [28, 29]. In our dataset we could only confirm a negative relation between 
the presence of necrosis and MFS, and between total nodal volume and DFS. Furthermore, a higher T 
stage was statistically significant associated with a poorer outcome. In the post-treatment setting, 
scoring nodal CT characteristics does have more prognostic significance. We  confirmed the value of 
necrosis and ECS, as well as measuring lymph node diameter and total nodal volume on CT studies 
after CRT. Using the results of our study, a model was constructed to estimate the risk for RR in a 
given patient. This model reached a good AUC of 0.78.  
Furthermore, we investigated the prognostic impact of the location of pathological lymph nodes. We 
analyzed the distribution of affected lymph node levels, clustered adjacent levels and compared them 
to each other. As described for overall survival by Jones et al. in a large cohort of 947 patients, one 
would expect a worse prognosis with pathological involvement of the lower neck [33]. We could 
establish a significant correlation between location and metastatic risk, without significant impact on 
the DFS. Involvement of level IV-V entails a higher risk to develop metastasis compared to level I-III. A 
similar correlation was seen for involvement of level VI-VII compared to level IV-V; with a higher 
metastatic risk for involvement of level VI-VII. Presence of retropharyngeal lymph node metastasis 
(level VII), is known to be a risk factor for both regional and distant recurrence [34-37]. We could 
validate this result in our patient group for distant recurrence. Based on our data, and previous 
publications on this subject, we can state that involvement of the lower neck as evaluated on CT  
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studies pretreatment entails a higher metastatic risk and represents more aggressive and advanced 
disease. We also investigated the prognostic value of size change as evaluated on CT studies of 
pathological lymph nodes after (C)RT. The less pronounced the volume  reduction, the poorer the RC, 
DFS, MFS, OS and, at individual nodal level, the more nodal recurrences. Our results are in concordance  
with the data published by Clavel et al. In patients with node-positive head and neck cancer, a  
significant effect of volume change after CRT was reported [38]. In the light of adaptive RT, volume 
change of tumor and pathological lymph nodes during treatment has been studied extensively. 
However, data on the prognostic value of volume change after but also during RT are scarce. Mishra 
et al. failed to find a correlation between nodal volume change during (C)RT and neck control in 38 
patients with locoregionally advanced head and neck cancer [39]. Besides volume change, also the 
impact of change of largest nodal axial diameter on LNR was considered. Our data revealed, both in- 
and excluding completely responding pathological lymph nodes, a significant correlation between 
diameter change and outcome.  Because of this linear relationship no cut-off value could be selected. 
Clavel et al. described a negative predictive value (NPV) of 100 % for a diameter decrease of > 80%. 
Hamilton et al. and Ojiri et al. proposed a cutoff value of >50% with NPV’s of 94 and 100 % respectively 
[40, 41].  Patients with less decrease in volume and largest axial diameter as evaluated on the post-
treatment CT scan might therefore benefit from a more closer radiological and clinical follow-up of 
the neck.  
 
To conclude the discussion on part I of this PhD thesis, we can state that our data suggest that we can 
improve the therapeutic ratio in head and neck cancer by omitting upfront neck dissections. 
Furthermore, we showed that a CT-based follow-up is safe and present a model to calculate the risk of 
regional relapses in a given patient. We also demonstrated that dose de-escalation to the elective 
lymph nodes bears the potential to limit toxicity and improve quality of life with the same oncological 
outcome. 
PART II PREDICTIVE MODELS FOR LATE TOXICITY IN HNC 
 
In chapter 6, we have built a predictive model for fibrosis. A first step in searching for possibilities of 
prevention of fibrosis following R(C)T in head and neck cancer resides in the identification of patient 
and treatment related parameters associated with late fibrosis. A previous model for fibrosis,  based 
on retrospective data, selected a high dose to a 4.1-mm depth of the skin and upfront neck  dissection 
as risk factors for moderate to severe subcutaneous fibrosis after whole neck irradiation [42]. We 
hypothesized that acute radiodermatitis was associated with late fibrosis either due to a different 
sensitivity to RT between patients for both acute and late toxicity or due to consequential late toxicity 
caused by acute toxicity. As a matter of principle, the relationship between increased acute toxicity 
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and late dysphagia has been demonstrated in the past [43]. This hypothesis has been confirmed by our 
findings. Upfront neck dissection, radiodermatitis grade ≥3 at the end of R(C)T and increasing N stage 
were identified by our multivariate model. The question arises if we can prevent fibrosis by changing 
parameters that were selected by our  multivariate model. Avoiding upfront neck dissections, the first 
factor of our model, seems a way to limit the incidence of fibrosis RTOG2-4 at 6 months. The influence 
of upfront neck dissection on late fibrosis was already described by Hirota et al [42]. Furthermore, we 
demonstrated in chapter 3 that upfront neck dissections is associated with more late fibrosis. Limiting 
upfront ND can thus limit late fibrosis. Another way to limit the incidence of  fibrosis RTOG2-4  might 
reside in the prevention of radiodermatitis at the end of R(C)T ≥ grade 3, the second factor of our 
model, as much as possible, since we clearly demonstrated that this acute side effect has repercussions 
on the incidence of late fibrosis. A recent review found  however no strong evidence of effect for any 
topical products in reducing radiodermatitis [44]. Another possibility to limit the incidence of acute 
radiodermatitis besides  topical products is the use of new RT techniques such as proton RT [45] or 
adaptation of the  treatment, in order to limit the dose to the neck as much as possible, when patients 
experience more than average acute symptoms [43]. These kind of tailored treatment adjustments 
based on acute symptom profiles may be worthwhile to investigate in future clinical studies. 
Furthermore, in the future, genetic analysis could help us to select patients who are more at risk for 
acute toxicity like radiodermatitis. Selection of these patients before treatment harbors the potential 
to adapt and individualize their treatment in order to limit acute dermatitis and late fibrosis. The 
selection of the third factor of our multivariate model, increasing N stage, might be due to the fact that 
in more advanced nodal stages the surrounding soft tissues and skin receive a higher RT  dose, since 
the pathological lymph nodes are larger and are more likely to be in close contact with  the skin. 
However we cannot confirm this interaction with our current data. We found no difference between 
administering an EQD 2Gy of 40 Gy versus 50 Gy to the elective neck in terms of late fibrosis (Chapter 
4). This could be explained by the theory that the curative doses to pathological lymph nodes have 
more  impact on radiodermatitis and late fibrosis than the dose to the elective nodal volume. This 
theory originates out of the observation that increased N stage is selected for our model but 
administering a NID2Gy of 40 Gy versus 50 Gy to the elective neck was not. Apart from avoiding the 
factors that were selected for our model as much as possible in order to limit late fibrosis, our model 
could be of use for future studies looking at treatment options for patients facing fibrosis. For these 
studies, it is important to be able to select potential patients in an early stage.  
 
Dysphagia remains a major problem for patients treated witch (C)RT for locally advanced head and 
neck cancer [46-49]. Since a good model already exists to predict dysphagia, namely the Total 
Dysphagia Risk Score (TDRS), we chose to validate this externally in collaboration with the original 
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research group that created the model in chapter 7 of this PhD thesis. The TDRS model was developed 
to predict RTOG Grade 2-4 at 6 months of follow-up [46]. The authors of the original paper did not 
develop nor test the model for later or earlier time points nor correlated this with patient scored 
dysphagia. We tested this model at 1, 3, 9 and 12 months in a prospective way, in physician scored 
dysphagia but also in patient scored dysphagia. Patient scored dysphagia was not significantly 
correlated with the TDRS. Physician scored dysphagia correlated well with the TDRS at all time-points. 
Area Under the Curves at the different time points ranged between 0.79 and 0.86, indicating a good 
predictive value of the model. Whether this means that the TDRS can be used to take predictive 
measures is however not clear. Firstly it remains unclear from which preventive measurements 
patients would benefit the most. The impact of PEG use on swallowing and swallowing-related 
outcomes remains unclear. Some researchers have suggested that PEG use may negatively affect the 
swallowing physiology, function and/or quality of life. A recent published review of twenty studies 
could not clarify this either [50]. On the other hand, recently, a prospective randomized trial was set 
up to evaluate the impact of prophylactic swallowing exercises on swallowing-related outcomes in 
HNSCC patients treated with curative RT [51]. There was no difference between the two groups 
(standard care versus home swallowing exercises) on the dysphagia outcomes during and after 
treatment. The authors of the paper blame this on poor adherence to exercises and dropouts. The best 
intervention method to decrease the risk of dysphagia is thus currently unknown. Secondly, using the 
TDRS, we would still take preventive measures in patients who do not necessarily need it. Our ROC-
analysis resulted in 70% specificity for 80% sensitivity indicating a reasonable rate of detecting patients 
that would benefit from an intervention, but also a substantial group of patients that will not need 
such an intervention. Therefore we do not recommend to use this model to select patients who might 
benefit from PEG-tube placement before the start of treatment. In a subsequent paper, we tested if 
the TDRS could guide us to see which patients might need a videofluoroscopic examination in the 
follow up after CRT for head and neck cancer by correlating the TDRS with swallowing problems 
observed on videofluoroscopies. We failed to distinguish the low risk TDRS group from the high risk 
group using videofluoroscopies. Therefore, based on our study we cannot recommend the use of the 
TDRS to select patients who might benefit from the additional information provided by 
videofluoroscopies following RT for head and neck cancer. Currently, we can use the TDRS in studies 
looking at preventive treatment options for patients treated with CRT for head and neck cancer since 
it is important to be able to select potential patients in an early stage.  The use of the TDRS in current 
clinical practice seems however limited. 
Since we found conflicting results in our TDRS validation paper (patient reported dysphagia did not 
correlate with the TDRS, but physician scored dysphagia did), we decided to further investigate this. 
Our study showed that there is a good association between patient and doctor scored dysphagia 
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scores, as well in the pre-treatment as in the post-treatment setting. To investigate which of both is to 
use in following studies addressing dysphagia in the head and neck cancer patients, we correlated 
physician and  patients scoring with swallowing videofluoroscopies, since this gives us a more objective 
evaluation of the dysphagia of each patient. Both physician and patient scored dysphagia correlate 
well with swallowing videofluoroscopies. Since patient scored dysphagia correlates better with PAS 
and changes in the PAS score, and physician scored dysphagia correlates better with SPSS, we advocate 
to use both patient and physician scored dysphagia in future trials. 
 
In chapter 8 an overview of the current knowledge of salivary gland stem cells in radiation-induced 
xerostomia and their value in the prevention and treatment of this complication was given. Salivary 
gland stem cell transplantation, bone marrow-derived cell mobilization, molecular regulation of 
parotid stem cells, stem cell sparing RT, and adaptive RT are techniques that were discussed.  
To date, none of these techniques concerning stem cells to treat xerostomia are ready for clinical 
implementation, although most of them seem very promising in animal models. Therefore, we have 
set up a study to compare see whether sparing the superficial contralateral parotid lobe can help 
limiting xerostomia following radiotherapy for head and neck cancer. Severe xerostomia following 
radiotherapy in head and neck cancer can be avoided by sparing one parotid gland [52,53]. The patient 
cohort of this study was therefore planned trying to spare at least one parotid gland. However, 29% of 
the patients of the study we performed the contralateral parotid gland could not be spared entirely. 
We found that when we cannot spare both or one parotid gland, sparing of the contralateral superficial 
parotid gland results in less xerostomia after 6 and 12 months of follow-up. Delineating both the 
superficial  parotid glands and trying to spare them can thus mean a way forward in limiting xerostomia 
in head and neck cancer patients treated with radiotherapy in patients where an entire parotid gland 
cannot be spared. Data on superficial parotid lobe sparing in literature are scarce. In a recent study, 
contralateral parotid sparing was compared to bilateral superficial lobe parotid sparing. The results of 
this study showed that bilateral superficial parotid lobe sparing results in less high-grade xerostomia 
[54,55]. In this study they advocate delineation of the superficial parotid lobes, a suggestion that we, 
based on our results, agree upon. 
 
To conclude the discussion on part II of this PhD thesis, we can state that we created a prediction 
model for late fibrosis and validated an existing model regarding dysphagia. We can use these 
models in studies looking at preventive treatment options for toxicity in patients treated with CRT 
for head and neck cancer to select patients who are most at risk. Regarding xerostomia, we showed 
that when sparing of the whole contralateral parotid gland is not possible, delineating both the 
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superficial  parotid glands and trying to spare at least one of them can mean a way forward in limiting 
xerostomia in head and neck cancer patients treated with radiotherapy. 
Future prospects 
The goal of our research group is to further increase the therapeutic index in head and neck cancer. 
To reach this goal, we want to:  
1) tailor treatment intensity to every patient individually based on validated prognostic and 
predictive parameters incorporated in a model,  
2) optimize quality of RT by improving tumor volume definition and identifying radioresistant 
subvolumes within the tumor using functional imaging.  
We have set up 2 studies to achieve these goals. 
 
TO CREATE A PROGNOSTIC AND PREDICTIVE MODEL 
 
We want to to develop a prognostic model, which will be instrumental in the individualization of 
treatment. We have set up a study wherein outcome of head and neck cancer patients will be 
correlated to molecular and functional imaging variables in 120 patients diagnosed with HNSCC. Many 
potential factors influencing prognosis have been identified in the past. We chose for a combination 
of molecular, genetic and functional imaging parameters. Functional imaging parameters will be 
included in our model as a first parameter. Hypoxia is known to be an important negative prognostic 
factor. Therefore this will be the second parameter of our model. The third parameter we want to 
include in our model is the association of the tumor with HPV. 
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TO IMPROVE QUALITY OF RT USING FUNCTIONAL IMAGING. 
 
The main objective of this study is to correlate tumor volume and parameters derived from DWI, DCE-
MRI and FDG-PET with pathological tumor volume and different pathological tumor characteristics in 
head and neck cancer. Doing so, we will investigate the role of these imaging modalities in tumor 
volume definition and in the identification of radioresistant subvolumes.  
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None of the currently used imaging techniques can adequately identify the exact tumor volume in 
HNSCC, let alone define radioresistant subvolumes.  Preliminary results using functional imaging 
techniques show however promising results in this respect by giving us information amongst others 
on glucose metabolism, vascularisation and cellularity. Pathologic validation of the different functional 
imaging parameters is however essential, since we do not know the true meaning of these parameters 
at the moment. Therefore we will compare the tumor volume as delineated on the functional imaging 
techniques with the pathological tumor volume in resection specimens of 20 patients diagnosed with 
HNSCC. This way we will investigate if these imaging techniques are accurate in tumor volume 
definition. 
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Summary 
Head and neck cancer (HNC) is a broad term that encompasses a large number of tumour entities that 
originate from different subsites, such as the nasal cavity, nasopharynx, oral cavity, oropharynx, larynx, 
hypopharynx and salivary glands. In Belgium, in the year 2013, more than 2500 patients were 
diagnosed with head and neck cancer. By far, head and neck squamous cell carcinoma (HNSCC) is the 
most common histological subtype. Exposures to tobacco and/or alcohol are well-known, important 
risk factors for developing HNSCC. Human papilloma virus (HPV) infections, on the other hand, is 
another important risk factor for the development of HNSCC. The main treatment options for loco-
regionally advanced HNSCC are (chemo-) radiotherapy (RT) and surgery. 
 
In Chapter 1 some general concepts regarding head and neck cancer and the treatment of these 
tumors were elucidated. Furthermore, an overview of some inportant technological advances was 
provided and the most important side efffects following radiotherapy for head and neck cancer were 
highlighted.  
 
In Chapter 2, we provided an overview of the aims of this work. The main focus of this PhD project was 
to investigate different methods to improve the therapeutic ratio for patients diagnosed with HNC who 
are treated with (C)RT. We want to achieve this by determining the best treatment and follow-up 
strategy for the neck (PART I of this project).The best treatment strategy for the neck is still a matter 
of debate in HNC.  We want to assess if upfront neck dissection, dose de-escalation of the elective neck 
or volumetric dose reduction can help us improve the therapeutic ratio for HNC. Furthermore we want 
to assess the safety of a CT-based follow-up approach of the neck. 
Furthermore, we want to validate and create  predictive models for toxicity following RCT (PART II of 
this project). Using these models, can give us more insights how to avoid treatment related toxicity 
and help us further individualize the treatment of HNC patients. 
 
In chapter 3 the benefit of upfront neck dissection in locally advanced head and neck cancer (HNC) 
treated with primary (chemo-) radiotherapy (CRT) was evaluated. Therefore, we retrospectively 
compared outcome and toxicity between patients with and without upfront ND followed by CRT. Two-
hundred sixty-four consecutive patients with HNC without metastases at diagnosis and with lymph 
node stage N2-N3 were included in 2 centers. Both treatment regimens have a comparable local, 
regional and distant control. However, fibrosis and more specifically fibrosis grade ≥2 is more 
prominent following upfront ND and CRT when compared to CRT alone. 
 
  
224 
 
In chapter 4, we discussed the results of a multicentric randomized trial on dose de-escalation to the 
elective lymph nodes in head and neck cancer in terms of In late toxicity, oncological outcome and 
quality of life.  Regarding late toxicity, we observed a trend towards less late dysphagia, however not 
confirmed following longitudinal analysis. Furthermore, we observed significantly less moderate 
salivary gland toxicity in the 40 Gy arm at 6 and 18 months, confirmed after longitudinal analysis.  QoL 
following RT for head and neck cancer is less impaired when a 40 Gy-equivalent dose is given to the 
elective lymph nodes. For physical functioning, emotional functioning and speech problems we 
observed statistically significant and clinically relevant differences between both treatment arms in 
favor of the 40 Gy-equivalent dose arm. Outcome in terms of local, regional and distant control and 
survival did not differ significantly between the groups after two years of follow up. It was reassuring 
that there were only 2 regional recurrences in the elective neck outside the high-dose PTV in the 40 
Gy arm and 1 in the 50 Gy arm. Because these numbers were too small to conclude that more elective 
neck recurrences would occur when lowering the dose in the elective neck from 50 to 40 Gy EQD2Gy, 
we have set up an extra study combining the data of 3 prospective studies using dose de-escalation to 
the elective lymph nodes. Two hundred thirty-three patients included in 3 prospective randomized 
studies were analysed. The actuarial rate of recurrence in the electively irradiated lymph node regions 
was 3.9% (95% CI 1.8-6.0) at 2 years. Our results are comparable to literature following 50 Gy 
(EQD2Gy).  
In chapter 5, we assessed the safety of a CT-based follow-up approach of the neck nodes following 
CRT. Furthermore, we tried to identify predictive factors that we incorporated into a model to predict 
regional recurrences following CRT using CT-derived parameters and clinical parameters. In our dataset 
we could only confirm a negative relation between the presence of necrosis and MFS, and between 
total nodal volume and DFS. Furthermore, a higher T stage was statistically significant associated with 
a poorer outcome. In the post-treatment setting, scoring nodal CT characteristics does have more 
prognostic significance. We  confirmed the value of necrosis and ECS, as well as measuring lymph node 
diameter and total nodal volume on CT studies after CRT. Using the results of our study, a model was 
constructed to estimate the risk for a regional recurrence in a given patient.  
Furthermore, we investigated the prognostic impact of the location of pathological lymph nodes. 
Involvement of level IV-V entails a higher risk to develop metastasis compared to level I-III. A similar 
correlation was seen for involvement of level VI-VII compared to level IV-V; with a higher metastatic 
risk for involvement of level VI-VII. Based on our data, and previous publications on this subject, we 
can state that involvement of the lower neck as evaluated on CT  studies pretreatment entails a higher 
metastatic risk and represents more aggressive and advanced disease. We also investigated the 
prognostic value of size change as evaluated on CT studies of pathological lymph nodes after (C)RT. 
The less pronounced the volume  reduction, the poorer the RC, DFS, MFS, OS and, at individual nodal 
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level, the more nodal recurrences. Patients with less decrease in volume and largest axial diameter as 
evaluated on the post-treatment CT scan might therefore benefit from a more closer radiological and 
clinical follow-up of the neck.  
 
In chapter 6, we made a model to predict moderate-severe fibrosis at 6months following RT.  
161 patients were prospectively included. Radiodermatitis at the end of R(C)T ≥ grade 3 proved to be 
associated with the incidence of fibrosis RTOG2-4 at 6 months (p<0.01). Furthermore, upfront neck 
dissection (p<0.01), increasing N stage (p<0.01) and tumor site (p=0.02) are significantly associated in 
univariate analysis with the incidence of fibrosis RTOG2-4 at 6 months of follow-up in our patient 
population following univariate analysis. Upfront neck dissection and radiodermatitis grade ≥3 at the 
end of R(C)T were identified for our multivariate model. Additionally, increasing N stage was selected 
as an independent predictor variable. The AUC for this model was 0.92.  
 
In chapter 7, a risk model, the total dysphagia risk score (TDRS), was developed to predict which 
patients are most at risk to develop grade ⩾2 dysphagia at 6months following radiotherapy (RT) for 
head and neck cancer. The purpose of this study was to validate this model at 6months and to 
investigate the power at earlier and later time-points. A second aim was to see if this model can be 
used in a partially accelerated RT regimen. 164 patients from 3 different centres treated with RT 
between 2008 and 2014 were included. To validate this prediction model, we tested the validity in 
terms of calibration and discrimination. Partial acceleration had no influence on the TDRS. Regarding 
physician-scored dysphagia, there was a significant correlation with dysphagia grade ⩾2 at 1, 3, 6 and 
9months. The area-under-the-curve at 1month was 0.85; at 3months 0.80; at 6months 0.85; at 
9months 0.86 and 0.79 at 12months. Regarding QoL, TDRS correlates with PEG-tube usage at 6 and 
12months. Furthermore, we correlated the TDRS with the SPSS scale and the PAS scale as eveluated 
on videofluoroscopies. Patients with high risk TDRS scores correlated with higher SPSS scores when 
compared to the intermediate group and the intermediate and low risk group together. However, low 
risk patients in our patient cohort could not be distinguished from high or intermediate risk patients. 
 
In chapter 8 an overview of the current knowledge of salivary gland stem cells in radiation-induced 
xerostomia and their value in the prevention and treatment of this complication was given. Salivary 
gland stem cell transplantation, bone marrow-derived cell mobilization, molecular regulation of 
parotid stem cells, stem cell sparing RT, and adaptive RT are promising techniques that are discussed. 
Furthermore, we investigated superficial parotid gland sparing in radiotherapy for head and neck 
cancer. When we cannot spare both or one parotid gland, sparing of the contralateral superficial 
parotid gland results in less xerostomia after 6 and 12 months of follow-up. Delineating both the 
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superficial  parotid glands and trying to spare them can thus mean a way forward in limiting xerostomia 
in head and neck cancer patients treated with radiotherapy in patients where an entire parotid gland 
cannot be spared. 
Chapter 9 consists of a general discussion and an overview of future prospects related to this PhD 
project. 
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Samenvatting 
 
Hoofd- en halstumoren vormen een heterogene groep van maligniteiten die ontstaan uit de mucosale 
aflijning van de bovenste aerodigestieve tractus. Meer dan 90% van deze tumoren zijn 
plaveiselcelcarcinomen. Ze zijn wereldwijd de zesde meest voorkomende maligne tumoren. In België 
werden meer dan 2.500 nieuwe diagnosen gesteld in 2013. Tot voor kort werden als oorzakelijke 
factoren voornamelijk alcoholmisbruik en/of roken naar voren geschoven. Sinds enkele jaren zijn er 
echter ook meer en meer aanwijzingen voor een virale etiologie, met name het humaan papillomavirus 
(HPV).  
Radiotherapie al dan niet in combinatie met chemotherapie is een belangrijke behandelingsmodaliteit 
voor lokaal gevorderde hoofd-en halstumoren.  
 
In hoofdstuk 1 werden enkele algemene aspecten over hoofd- en halstumoren en de behandeling 
aangehaald. Daarnaast werd een overzicht gegeven van een aantal belangrijke innovaties in de 
bestralingsbehandeling van hoofd-en halstumoren en van de belangrijkste nevenwerkingen na een 
bestralingsbehandeling voor hoofd-en halskanker. Bovendien werd de huidige kennis omtrent de 
behandeling van de hals bij hoofd-en halstumoren verder toegelicht. 
 
In hoofdstuk 2 werd het opzet van dit doctoraal proefschrift verder verduidelijkt. Dit onderzoek wil de 
radiotherapeutische behandeling van hoofd- en halstumoren verbeteren door de behandeling van de 
hals te optimaliseren en voorspellende modellen voor nevenwerkingen volgend op een 
bestralingsbehandeling te valideren en te creëren.  
Over de beste behandelingsstrategie voor de hals bij lokaal gevorderde hoofd- en halstumoren is 
momenteel weinig consensus. In deel I van dit project willen we daarom de waarde van een 
nekdissectie voor een bestralingsbehandeling bekijken, en bekijken of een reductie van de dosis op de 
electieve nek resulteert in behoud van tumorcontrole met minder nevenwerkingen. Bovendien willen 
we evalueren of opvolging doormiddel van een CT scan een goede strategie is na een behandeling met 
radiotherapie voor hoofd- en halstumoren.  
 
In hoofdstuk 3 werd het effect van een nekdissectie voor radiochemotherapie bij lokaal gevorderde 
hoofd- en halstumoren nagegaan. We analyseerden de gegevens van 264 patiënten van 2 centra met 
een verschillende aanpak voor lokaal gevorderde hoofd-en halstumoren. In het 1e centrum worden 
patiënten behandeld met definitieve radiochemotherapie, in het 2e centrum wordt geopteerd om voor 
de radiochemotherapie een nekdissectie uit te voeren.  Uit onze resultaten bleek deze laatste aanpak 
niet resulteert in een betere lokale controle, regionale controle, of metastase-vrije-overleving. Ook 
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ziekte-vrije-overleving was gelijk in beide groepen. Wat de toxiciteit betreft, bemerkten we significant 
meer fibrose ≥ graad 2 bij de patiënten die behandeld werden met een nekdissectie voor de 
radiochemotherapie. 
 
In hoofdstuk 4 rapporteerden we de late oncologische controle, toxiciteit en levenskwaliteit voor 
patiënten die behandeld werden in een dosis de-escalatie studie van de electieve hals. We 
includeerden 200 patiënten in een gerandomiseerde multi-centrische studie. 100 patiënten werden 
behandeld met een dosis van 40Gy, 100 patiënten werden behandeld met een dosis van 50Gy. Na een 
follow-up van gemiddeld meer dan 2 jaar, observeerden we geen verschil in lokale controle, regionale 
controle, het optreden van metastasen, overleving en ziekte-vrije-overleving tussen beide 
patiëntengroepen. Qua late toxiciteit merkten we een trend tot minder slikproblemen in de 40Gy arm, 
evenals een significant verschil betreffende minder speekselklier-problemen.  
Op het vlak van levenskwaliteit zien we algemeen een beter resultaat in de de-escalatie arm. We 
bemerken een statistisch significant verschil voor algemene gezondheid, fysisch functioneren, 
emotioneel functioneren, misselijkheid en vomitus, pijn, slikproblemen, spraakproblemen, problemen 
met eten in het openbaar en sputa in het voordeel van de de-escalatie arm. Klinisch relevante 
verschillen werden gezien tussen beide groepen voor fysisch functioneren, emotioneel functioneren 
en spraakproblemen. Deze verschillen waren allemaal in het voordeel van de de-escalatie arm. 
 
In hoofdstuk 5 hebben we de opvolging van de hals via CTscans bekeken. We hebben hiervoor de CT’s 
voor de behandeling en na de behandeling van 183 patiënten geanalyseerd. Op deze CT’s hebben we 
de grootte van de klieren, de aanwezigheid van necrose, extracapsulaire uitbreiding en de 
aanwezigheid van calcificaties gecorreleerd met regionale controle. Op deze manier hebben we een 
model gecreëerd dat de kans op regionaal herval kan berekenen. In het model werd T stadium voor de 
behandeling, necrose aanwezig na de behandeling en de grootste axiale diameter voor de behandeling 
van de pathologische lymfeklier geselecteerd.  
Bovendien hebben we in dit hoofdstuk gekeken of volume- en diameter-verandering en localisatie van 
de pathologische lymfeklieren voorspellend zijn voor ziekte-controle in hoofd en halskanker. Onze data 
tonen dat er een hoger risico is op metastasen wanneer er pathologische lymfeklieren zijn in de lage 
hals. Bovendien zagen we bij beperkte vermindering van volume en diameter een slechtere 
tumorcontrole. Deze patiënten zouden baat kunnen hebben bij een meer nabije opvolging.  
 
In deel II van dit project willen we predictieve modellen voor toxiciteit valideren en creëren. Deze 
modellen kunnen ons helpen om nevenwerkingen volgend op een bestralingsbehandeling te 
vermijden en de behandeling van patiënten met hoofd- en halskanker te individualiseren. 
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In hoofdstuk 6 werd een model ontwikkeld om gemiddelde tot ernstige fibrose op 6 maand volgend 
op een radiochemotherapie te voorspellen. 161 patiënten met prospectief gescoorde fibrose tijdens 
en na de radiochemotherapie werden geïncludeerd. We correleerden radiodermatitis aan het einde 
van de behandeling, leeftijd, geslacht, T/N stadium, tumor localisatie, concomitante chemotherapie, 
nekdissectie voor de behandeling, geaccelereerde radiotherapie, roken, alcohol-gebruik, HPV status 
en de radiotherapie dosis op de electieve lymfeklieren met fibrose graad 2-4 een half jaar na 
behandeling. Radiodermatitis graad 3 of meer aan het einde van de behandeling was geassocieerd met 
fibrose graad 2-4 (p<0.01). Nekdissecties voor de behandeling (p<0.01), een hoger N stadium (p<0.01) 
en tumor localisatie (p=0.02) zijn gecorreleerd met fibrose na univariate analyse. In het multivariaat 
model werd een nekdissectie voor de bestralingsbehandeling opgenomen, alsook ernstige 
radiodermatitis en meer gevorderd N stadium. Met dit model bereikten we een AUC van 0.92. 
In hoofdstuk 7 hebben we de “totale dysfagie risico score (TDRS)” extern gevalideerd en bekeken of 
dit model ook kan gebruikt worden in een partieel geaccelereerd radiotherapie schema.  
We valideerden de TDRS voor de predictive van arts-gescoorde dysfagie op 6 maand volgend op een 
radiochemotherapie behandeling voor hoofd-en halskanker. Bovendien vonden we significante 
correlaties tussen de TDRS score en dysfagie op 1, 3, 6 en 9 maanden. De TDRS kan ook gebruikt 
worden in een gedeeltelijk geaccelereerd radiotherapie schema. We vonden ook correlaties tussen 
PEG-gebruik op 6 en 12 maand en de TDRS. Bovendien hebben we de totale dysfagie risico score 
gecorreleerd met videofluoroscopies. De TDRS correleerde met de SPSS schaal op 6 maand en er was 
een trend op 12 maand. Correlaties met de PAS schaal konden niet worden aangetoond. 
 
In hoofdstuk 8 werd een overzicht gegeven van de huidige kennis omtrent stamcellen in de 
parotisklieren en hun potentieel in de preventie en behandeling van xerostomie volgend op een 
bestralingsbehandeling. Transplantatie van speekselklierstamcellen werd besproken, alsook 
mobilisatie van stamcellen afkomstig uit het ruggenmerg, moleculaire regulatie van 
speekselklierstamcellen en stamcel sparende radiotherapie. Verder in dit hoofdstuk werd er verder 
ingegaan op het sparen van de oppervlakkige parotislob bij radiotherapie voor hoofd-en halstumoren. 
Als een volledige lob niet kan gespaard worden, kan het sparen van een oppervlakkige lob helpen in 
het vermijden van xerostomie na radiotherapie. 
 
Hoofdstuk 9 tenslotte, bevat een algemene discussie en een overzicht van de resultaten van dit 
onderzoeksproject. Bovendien worden ook de toekomstige onderzoeksprojecten aangehaald. 
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